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Abstract 
 
Adipose tissue secreted proteins (adipokines) have been proposed to form a link 
between obesity and type 2 diabetes (T2D). Resistin and visfatin are two adipokines 
which have been previously suggested as having roles in the pancreatic islet. The aim 
of this study was therefore to investigate the regulatory role of the adipokines resistin 
and visfatin in the pancreatic beta-cell. In order to do this, pancreatic β-cell lines from 
rat (BRIN-BD11) and mouse (βTC-6) were used to study the effect of exogenous 
incubation with physiological and pathological concentrations of resistin and visfatin 
on diverse elements of beta-cell biology including cell viability, gene expression and 
insulin secretion. In addition to this the expression levels of these two adipokines was 
also measured in the beta-cell. PCR array analysis showed that resistin and visfatin 
treatment resulted in significant changes in the expression of key beta-cell specific 
genes. Interestingly, both resistin and visfatin are highly expressed in the beta-cells. 
This suggests that the roles of these adipokines are not confined to adipose tissue but 
also in other endocrine organs. Resistin treatment significantly increased viability of 
the beta-cells at physiological concentrations however there was no increase with the 
elevated pathological concentrations. Resistin at elevated concentrations decreased 
insulin receptor expression in the beta-cells however there was no significant effect at 
lower concentrations. Both physiological and elevated resistin concentrations did not 
have any effect on glucose stimulated insulin secretion. Incubation of visfatin induced 
phosphorylation of insulin receptor and the intracellular signalling MAPK, ERK1/2. 
Visfatin treatment at 200ng/ml also significantly increased insulin secretion. These 
effects were replicated by incubation of beta-cells with the product of visfatin’s 
enzymatic action, nicotinamide mononucleotide and were reversed by visfatin 
inhibitor FK866. Visfatin treatment at low concentrations did not have any effect on 
cell viability however the elevated concentrations resulted in a decline. These data 
indicate that both resistin and visfatin potentially play  important roles in beta-cell 
function and viability and that they form a significant link between adipose tissue and 
the pancreatic islet in type 2 diabetes.  
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1.1. Diabetes: pathology and epidemiology 
 
Diabetes mellitus (commonly referred to as diabetes) describes a group of metabolic 
diseases of multiple aetiology characterized by high blood glucose levels resulting 
from defects in insulin secretion, action or both. The most easily recognized 
symptoms of diabetes are thirst, polyuria, blurring of vision, hyperglycaemia, 
glycosuria, and ketoacidosis (Mayfield, 1998).  
 
The two common forms of diabetes are type 1 diabetes (T1D) and type 2 diabetes 
(T2D) which are both caused by a combination of genetic and environmental risk 
factors. T1D is an autoimmune disease resulting from selective destruction of insulin-
producing pancreatic β-cells by autoreactive T helper 1 (Th1) cells and their 
mediators and is often characterised by absolute insulin deficiency (Atkinson and 
Maclaren, 1994). The process leading to T1D appears to start when the immune 
system recognizes and attacks proteins on the surface of the β-cells, possibly 
mistaking them for antigenic matter belonging to an invading organism. The immune 
response results in the T-lymphocytes flooding into the pancreatic islets and causing 
an inflammation known as insulitis. Once enough β-cells have been destroyed, the 
symptoms of diabetes begin to appear. 
 
Patients suffering from T1D have to inject insulin to compensate for the absolute 
insulin deficiency caused by this aberrant autoimmune response. Currently available 
therapies do not closely mimic the normal function of the β-cell, which precisely 
adjusts the rate of insulin secretion in response to biological needs. Type 1 diabetics 
thus have to constantly monitor their glucose levels and inject insulin whenever 
required. Lack of proper control can result in either hypoglycaemia which can cause a 
coma or hyperglycaemia which increases the risk of developing diabetic 
complications such as blindness, kidney failure and amputations (Cowie et al., 1989; 
Icks et al., 1997).  
 
In comparison, T2D is a more complex metabolic disorder characterized by obesity, 
impaired β-cell function, increased endogenous hepatic glucose output and insulin 
resistance in target tissues (Leahy, 2005). T2D is the most common metabolic disease 
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worldwide (Zimmet et al., 2001). The incidence of T2D is increasing worldwide 
primarily due to increases in the prevalence of a sedentary lifestyle, consumption of 
high-calorie diets and obesity (Tuomilehto et al., 2001). Between 2000 and 2010 the 
prevalence of T2D is projected to rise by 47% to over 215 million affected world-
wide (Amos et al., 1997). Furthermore, the problem is no longer restricted to the 
ageing population with increasing number of children and young adults developing 
diabetes (Fagot-Campagna et al., 2001). The Asian / Pacific region is projected to 
have the largest population of people diagnosed with diabetes in the world accounting 
for 46 percent of the global burden of diabetes (Coughlan et al., 1997). 
 
About 90% of cases of T2D are associated with obesity. In relation to this, 
approximately 197 million people worldwide are thought to have impaired glucose 
tolerance (IGT), most commonly due to obesity and the associated metabolic 
syndrome (Dunstan et al., 2002). This number is expected to increase significantly to 
420 million by 2025. (Hossain et al., 2007). Various measures of being overweight, 
such as relative weight, body mass index, and body fat distribution, have repeatedly 
been shown to be risk factors for T2D (Colditz et al., 1995). Not only does this trend 
have significant implications for the individuals concerned in terms of developing 
complications associated with the disease, but there are also significant health cost for 
society and governments at large. Lifestyle changes, while desirable, have proven 
difficult to achieve. Thus, a better understanding of the molecular mechanisms 
underlying insulin resistance will be required to combat the epidemics of T2D and 
cardiovascular disease that are fuelled by obesity-associated insulin resistance.  
 
Although T2D is thought of as a polygenic disease, most of the progress in treatment 
to date has been in identifying genes that cause several uncommon forms of diabetes 
with monogenic inheritance. The most common form of monogenic diabetes is 
maturity-onset diabetes of the young (MODY) syndrome, causing autosomal 
dominant non–insulin dependent diabetes appearing before the age of 25 years and 
diabetes due to mutations in mitochondrial DNA (Vaxillaire et al., 2006). Neonatal 
diabetes mellitus (NDM) is another form of monogenic diabetes, usually defined as 
overt diabetes diagnosed during the first 6 months of life (Hamilton-Shield, 2007).  
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In humans, mutations in specific genes lead to the various forms of MODY. 
Mutations of the glucokinase (GCK) gene lead to the manifestation of MODY-2 
(Hattersley et al., 1992), with the remaining five types of MODY resulting from 
defects in genes encoding for transcription factors: Hnf-4α (MODY-1), Hnf-1α 
(MODY-3), Pdx-1 (MODY-4), Hnf-1ß (MODY-5), and NeuroD1 (MODY-6) 
(Yamagata et al., 1996; Horikawa et al., 1997; Stoffers et al., 1997). Many novel 
mutations found in the MODY genes are constantly being reported in different 
population groups. Despite an impressive number of landmark achievements and 
breakthroughs in diabetic research, many questions about the causes of diabetes and 
its chronic complications remain unanswered. 
 
Previous studies have also implicated cytokines as important mediators in the 
destruction of pancreatic beta-cells and impaired function leading to both T1D and 
T2D (Arnush et al., 1998, Oshima et al., 2006). The proinflammatory cytokines 
interleukin (IL)-1β, either alone or in combination with tumour necrosis factor-alpha 
(TNF-α) or interferon-gamma (IFN)-γ have been shown to elicit dramatic negative 
effects on pancreatic beta (β) cells in vitro (Alba et al., 2004; Ou et al., 2002). 
 
1.2. Factors influencing the prevalence of T2D  
 
It is now well established that T2D results from the interaction between a genetic 
predisposition and behavioural and environmental risk factors (Gerich, 1998). 
Previous studies have shown that first degree relatives of individuals with T2D are 
about 3 times more likely to develop the disease than individuals without a positive 
family history of the disease (Flores et al., 2003; Gloyn et al., 2003, Hansen, 2003). 
This together with other studies provide compelling evidence that genetic factors 
make a major contribution to the development of T2D and helps to illustrate that the 
disease is in part inherited. Environmental factors, especially diet, physical activity, 
and age, interact with genetic predisposition to affect disease prevalence. However 
despite their major role, the genetic causes of the most common forms of T2D remain 
elusive and the genetic basis of the disease has yet to be identified. 
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The growing prevalence of T2D and cardiovascular disease in Western societies is 
known to be linked to excess adiposity (Kahn et al., 2000, Porte et al., 1998)  with the 
past decade witnessing a parallel rise in the incidence of obesity and T2D among both 
children and adults (Flegal et al., 2002). Evidence from several studies indicates that 
obesity and weight gain are linked to an increased risk of T2D (Ford et al., 1997, 
Resnick et al., 2000) and intentional weight loss associated with a reduction in the 
risk and rate of developing T2D (Will et al., 2002). Perhaps the most sobering 
observation regarding the obesity epidemic is the fact that obesity generally confers a 
significantly increased rate of mortality when compared with individuals of normal 
body weight (Jazet et al., 2003).  
 
It has now been demonstrated that T2D can be prevented, or at least delayed, by both 
pharmacological and non-pharmacological interventions, such as lifestyle 
modification including diet, exercise and therapeutic agents including metformin and 
pioglitazone (Pax et al., 1997, Tuomilehto et al., 2001, Knowler et al., 2002, Chiasson 
et al., 2002, Buchanan et al., 2000). Metformin is a mild insulin-sensitizing agent 
which improves hyperglycemia primarily through its suppression of hepatic glucose 
production via AMPK activation (Kirpichnikov et al., 2002) while pioglitazone works 
by activating peroxisome proliferator-activated receptors-gamma (PPAR-γ) (Krentz 
AJ and Friedmann PS, 2006). Diet has also long been believed to be an important risk 
factor for T2D. Some randomised trials have consistently shown, increased physical 
activity and weight loss are efficient approaches for the control and prevention of 
T2D (Alberti et al., 2007, Hu et al., 2001).  
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1.3. The beta cell function: insulin secretion, 
signalling and glucose homeostasis 
 
1.3.1. Beta cell biology 
 
Pancreatic islet ß-cells function mainly to secrete insulin in response to changes in 
circulating levels of glucose and amino acids in the blood (Weyer et al., 1999). 
Normal glucose homeostasis requires the finely tuned orchestration of insulin 
secretion by pancreatic β cells in response to subtle changes in blood glucose levels. 
Glucose tolerance is determined by the balance of insulin secretion and insulin action 
(Lillioja et al., 1988). Any alteration in β-cell function has profound impact on 
glucose homeostasis with excessive secretion of insulin liable to cause 
hypoglycaemia, and insufficient insulin secretion ordinarily resulting in 
hyperglycaemia. 
 
Insulin is a small protein hormone, with a molecular weight of about 6000 Daltons 
composed of two chains held together by disulfide bonds and synthesized in 
significant quantities only in beta-cells in the pancreas. Since the discovery of the 
insulin gene sequence (Bell et al., 1980), several patients with insulin gene mutations 
have been identified. Some of the mutations have been shown to affect insulin 
processing by inhibiting conversion of proinsulin to insulin (Chan et al., 1987; 
Warren-Perry et al., 1997) while others produce normally processed insulin with 
subnormal biological activity e.g. reduced affinity of insulin for its receptor (Nanjo et 
al., 1986). 
 
1.3.2. Insulin secretion 
 
Insulin is secreted primarily in response to elevated blood glucose concentrations after 
which it causes reduction of hepatic glucose output (via decreased gluconeogenesis 
and glycogenolysis) and increases the rate of glucose uptake, primarily into striated 
muscle and adipose tissue (Hedeskov, 1980; Straub et al., 2002). Glucokinase is the 
key rate-limiting enzyme in glucose metabolism in β-cells and has been convincingly 
shown to be the glucose sensor for glucose-stimulated insulin secretion (Matschinsky 
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et al., 1993). In addition to glycaemic control, insulin is a pleiotropic hormone that 
also influences all aspects of carbohydrate, protein, and lipid metabolism where it 
exerts its effects by increasing lipid synthesis in liver and fat cells, and attenuating 
fatty acid release from triglycerides in fat and muscle (Vernon et al., 1991; Kersten, 
2001; Hansmannel et al., 2006). Because muscle lacks glucose 6-phosphatase, 
glycogenolysis in muscle does not provide glucose for release into the blood (Bresolin 
et al., 1989). However, when insulin levels are low, muscle exports amino acids and 
other substrates to the liver for gluconeogenesis.  
 
Glucose stimulates insulin secretion by generating, triggering and amplifying signals 
in the beta-cells (Henquin, 2000). Glucose-stimulated biphasic insulin secretion 
involves at least two signalling pathways: the KATP channel-dependent (Thams et al., 
2005) and KATP channel-independent pathways (Westerlund et al., 2001). In the first 
instance, insulin secretion is induced by glucose entry into ß-cells, and its metabolism 
leads to the generation of metabolic coupling factors including ATP (Doliba et al., 
2007). Enhanced glucose metabolism increases the cellular adenosine triphosphate / 
adenosine diphosphate (ATP/ADP) ratio. This induces closure of ATP-dependent 
potassium ion channels and membrane depolarization which, in turn, leads to 
activation and opening of voltage-dependant calcium ion (Ca2+) channels. This 
resultant increase in Ca2+ entry and intracellular Ca2+as well as the increase in ATP 
induces the movement of insulin-containing large dense core vesicles to the plasma 
membrane, their docking and their fusion to release the peptide hormone. The KATP 
channel-independent pathways augment the response to increased intracellular Ca2+ 
by mechanisms that are currently unknown. 
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Figure 1.0 Schematic representation of glucose stimulated insulin 
secretion in the pancreatic β cells. Glucose enters the β-cells by GLUT-2 
glucose transporter and the intracellular glucose is subsequently metabolized to 
produce ATP. Elevation of ATP/ADP ratio induces closure of cell surface K+ 
channels resulting in depolarization and opening of voltage-gated calcium channels. 
This facilitates extracellular Ca2+ influx into the β-cell.  A rise in free cytosolic Ca2+ 
triggers the exocytosis of insulin. Key: + = stimulation; - = inhibition; ADP = 
adenosine diphosphate; ATP = adenosine triphosphate; Glut-2 = glucose transporter 2 
Figure adapted from Henquin, 2000. 
 
The cells work in a feedback loop in maintaining a narrow range of blood glucose 
levels. In the first instance; as previously illustrated, hyperglycaemia signals the β-
cells to produce insulin and suppress glucagon, which switches off glucose production 
from the liver and increases glucose uptake in muscle, fat, and liver. This results in 
 23 
normoglycaemia. Conversely, hypoglycaemia signals the β-cells to decrease insulin 
secretion and increase glucagon, which stimulates glucose production from the liver. 
In non-diabetics where β-cell function is intact, the rate of hepatic glucose production 
equals the rate of glucose disposal, however in the presence of β-cell dysfunction 
resulting in inadequate insulin secretion, hepatic glucose production exceeds glucose 
disposal, and fasting hyperglycaemia ensues (Porte, 1991) 
 
1.3.3 Insulin signalling and transduction pathways 
 
Insulin rapidly elicits its biological response by inhibiting hepatic glucose production 
and stimulating peripheral glucose utilization. Various signalling pathways and 
feedback mechanisms are involved in regulating β-cell function and insulin’s ability 
to maintain whole-body glucose homeostasis. Insulin action is initiated at the point 
when it binds to the extracellular domain of the insulin receptor resulting in a cascade 
of signalling events which culminate in translocation of the major insulin responsive 
glucose transporter 4 (GLUT-4) from intracellular vesicles to the plasma membrane 
(Olefsky et al. 1990). The critical function of the insulin receptor in glucose 
homeostasis has been confirmed in insulin-receptor knockout mice which have a 
defect in glucose sensing and die shortly after birth with severe hyperglycaemia, 
ketosis and reduced beta cell mass, despite hyperinsulinemia (Kulkarni et al.1999). In 
addition to this, individuals have been identified with rare genetic defects in the 
insulin receptor that influence expression, insulin binding, and tyrosine kinase activity 
which result in severe insulin resistance (Krook et al., 1996; Taylor et al., 1998) 
 
The insulin receptor is a heterotetrameric transmembrane protein composed of two 
extracellular α subunits and two β subunits linked together by disulphide bonds and a 
member of the tyrosine kinase receptor family. The insulin receptor is expressed in 
almost all mammalian tissues, with the highest concentration found in target tissues of 
insulin: skeletal muscle, adipose tissue and liver (Cheatham et al., 1995). Skeletal 
muscle is the largest tissue by mass regulated by insulin, and is responsible for over 
80% of insulin-stimulated glucose disposal (Zurlo et al., 1990; Zierath et al., 2000). 
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Insulin binds to the extracellular α subunits of the receptor, transmitting a signal 
across the plasma membrane. The α-subunits contain the insulin binding sites whereas 
the β-subunits are transmembrane proteins containing the tyrosine kinase domains. 
 
 
            
Figure 1.1 The insulin signalling system responsible for the action of 
insulin in glucose homeostasis. This is achieved through binding of insulin to 
its receptor and subsequent interaction of the insulin receptor with IRS-1/2 and other 
substrate molecules. This leads to eventual GLUT-4 translocation and glucose uptake 
into the cells. Key: Cbl=c-Cbl proto-oncogene, GS=glycogen synthase, Glut-
4=glucose transporter-4, GRB2= growth factor receptor bound protein 2, IR=insulin 
receptor, IRS=insulin receptor substrate, PI3K=phosphatidylinositol 3-kinase, PDK= 
PIP3-dependent kinase, PIP= phosphatidylinositol triphosphate, PKC=protein kinase 
C, SH2= Src homology 2 
 
 
The critical initial steps in insulin signalling include phosphorylation of scaffolding 
proteins and activation of phosphatidylinositol 3-kinase (PI3). PI3 kinase forms a 
complex with various growth factor receptors hence it has been implicated in the 
signalling mechanism of growth receptors that act through tyrosine kinase. The 
 25 
presence of PI3 kinase in non-proliferating cells such as platelets and neutrophils 
suggests it has an additional role (Traynor-Kaplan et al., 1989; Kucera and 
Rittenhouse, 1990; Parker and Waterfield, 1992).  
 
The tyrosine kinase domain of the insulin receptor located on the cytoplasmic portion 
of the β-subunit once activated undergoes conformational change resulting in rapid 
auto-phosphorylation and docking of insulin receptor substrate (IRS) proteins such as 
IRS-1, IRS-2, IRS-3 and IRS-4 (Kaburagi et al., 1999). Other substrates include 
growth factor receptor bound protein 2 (Grb-2) - associated binder-1 (Gab1), p60dok, 
the c-Cbl proto-oncogene (Cbl), adaptor protein with pleckstrin homology (PH) and 
Src homology 2 (SH2) domains (APS) and 3 isoforms of SH2 domain-containing 
alpha-2 collagen-related protein (Shc) (Virkamäki et al., 1999). Tyrosine 
phosphorylation of these proteins creates recognition sites for both Src homology 
(SH2) binding and phosphotyrosine binding (PTB) domains of several downstream 
effector proteins.  
 
Tyrosine phosphorylation of IRS-1 leads to recruitment and activation of 
phosphatidylinositol-3-kinase (PI3K) through the SH2 domain of the p85 subunit of 
PI3 kinase (Baker et al., 1992). This then generates intracellular lipids such as 
phosphatidylinositol triphosphate PI(3,4,5)P3, that activate PIP3-dependent kinase 
(PDK) that, in turn, phosphorylate and activate Akt / protein kinase B (PKB), which is 
necessary for stimulation of glucose transporter molecules. Akt is a proto-oncogene 
encoding a serine-threonine kinase (also known as PKB or RAC-PK) (Bos, 1995). 
Activated Akt phosphorylates and regulates components of the glucose transporter 4 
(GLUT-4) complex, protein kinase C (PKC) isoforms, and GSK3, all of which are 
critical in insulin-mediated metabolic effects (Czech et al., 1999, Ueki et al., 1998). 
The best understood mechanism of IRS-protein-mediated signalling is the binding of 
SH2 domain-containing signaling molecule PI3-kinase by tyrosine phosphorylation 
sites on IRS proteins.  
 
The ability of insulin to recruit the insulin-responsive glucose transporter GLUT-4 
from an intracellular compartment to the cell surface in muscle and adipose tissue 
accounts for the majority of insulin’s effect to stimulate glucose uptake in the body 
(Kainulainen et al., 1994; Dombrowski et al., 1998). GLUT-4 proteins are contained 
 26 
in intracellular vesicles which are predominantly localized to a perinuclear 
compartment in the basal state. The glucose transporter proteins catalyses the rate-
limiting step for glucose uptake and metabolism in skeletal muscle and other insulin 
target tissues. After insulin stimulation, the GLUT-4 containing vesicles are 
translocated to the plasma membrane (Pessin et al., 1999). As circulating insulin 
levels decline, the GLUT-4 transporters return to their interior vesicles. Key to 
terminating the signal cascade is Protein tyrosine phosphatases (PTPs). These proteins 
have a prominent role in the control of insulin receptor (IR) signalling in that they 
dephosphorylate the IR and its substrates and thus serve to inactivate the IR and 
terminate signalling (Chen et al., 1997).  
 
1.4. Beta cell failure and T2D 
 
T2D results from various pathological processes: the first instance being reduced β-
cell mass, progressive decline of β-cell function, chronic insulin resistance and 
impaired insulin secretion (Kudva et al., 1997). However, the mechanisms controlling 
the interplay of these impairments are unclear. Defects in glucose-stimulated insulin 
secretion and an eventual decrease in β-cell mass are important factors in the 
development and progression of T2D (Kahn, 2001). The primary cause of T2D is 
presently unknown.  
 
Insulin resistance is traditionally assessed by insulin’s ability to promote normal 
glucose metabolism, however its physiological role is much broader, and includes the 
metabolism of all three macronutrients (carbohydrates, lipids, and proteins) as well as 
cellular growth. Insulin resistance is a key etiological factor for T2D and plays a role 
in numerous other metabolic disorders including hypertension and atherosclerosis 
(Ferri et al., 1999; Nigro et al., 2006)  
 
At the molecular level, this resistance can occur anywhere in the insulin signalling 
pathway, from receptor binding to downstream signalling events. Insulin sensitivity 
alone has long been recognized to be an important factor determining the magnitude 
of the insulin response to β-cell stimulation (Kahn et al., 1993). An increased 
metabolic demand for insulin due to insulin resistance (resistance to the effects of 
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insulin on glucose uptake, metabolism, or storage) in several tissues usually precedes 
the development of hyperglycaemia. Over a long period of time, chronic insulin 
resistance of peripheral tissues often necessitates elevated concentration of insulin to 
activate the insulin receptor. 
 
In order to maintain normoglycaemia, the beta-cells compensate for this increased 
demand by increasing its secretory capacity, β-cell mass or both (Bruning et al., 1997, 
Polonsky, 2000). Compensation involves expansion of β-cell mass, enhanced insulin 
biosynthesis, and increased responsiveness of nutrient-secretion coupling. In rodent 
models of obesity without diabetes there is an adaptive increase in β-cell mass (Flier 
et al., 2001) while other studies have suggested that the β-cell mass is also adaptively 
increased in non-diabetic obese humans (Kloppel et al., 1985). This hyper-secretion 
of insulin by the pancreatic β-cells to compensate for insulin resistance often leads 
period of normal or near-normal glycaemia.  
 
 
           
 
 
Figure1.2 β-cell secretory response, compensatory insulin release and 
resultant β-cell failure. T2D is characterized by a progressive decline in β-cell 
function and chronic insulin resistance. The trend involves insulin resistance, 
compensatory hyperinsulinemia, β-cell dysfunction and decline in insulin secretion. 
Figure adapted from Bergenstal et al., 2001. 
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However at some point, this period is followed by β-cell failure, partly due to the 
individual’s inability to sustain the β-cell compensatory response. The exact cause of 
β-cell failure is not yet known.  Failure of pancreatic β-cells to continue the increased 
compensatory insulin secretion that is sufficient to meet the metabolic demand often 
leads to T2D (Ferrannini et al., 2005). These abnormalities result in reductions in 
insulin release in response to glucose, changes in pulsatile and oscillatory insulin 
secretion, increased rates of glucose release by the liver and kidney as well as 
decreased clearance from the circulation (O’Rahilly et al., 1988; Polonsky et al., 
1988).  
 
β-cell failure often results in elevated blood glucose level which can exert deleterious 
effects on β-cell function. The ensuing hyperglycaemia worsens the insulin resistance 
and further impairs β-cell function, thus creating a vicious circle (Skyler, 1998). 
Another consequence of prolonged exposure to hyperglycaemia is desensitization of 
the β-cells to glucose stimulation (Eizirik et al., 1992). Decreased responsiveness to 
stimuli such as arginine or sulfonylureas in islets from type 2 diabetic patients have 
previously been reported and raises the question of whether glucotoxicity may also 
impede late steps in insulin secretion (Del Guerra et al., 2005) 
 
A number of factors have been suggested as possibly linking insulin resistance and 
beta-cell dysfunction in the pathogenesis of T2D. The likely mechanisms of early β- 
cell demise include oxidative stress, endoplasmic reticulum (ER) stress and 
glucolipotoxicity (Laybutt et al., 2007; Poitout and Robertson, 2008; Xu et al., 2009). 
T2D is also associated with marked impairment of mitochondrial function in β-cells 
with an increased expression of uncoupling protein-2 (UCP-2), leading to lower ATP 
levels, decreased ATP/ADP ratio in response to glucose, and reduced insulin secretion 
(Brown et al., 2002; Anello et al., 2005). The cause of damage to β-cells is thus likely 
to be multifactorial. 
 
One of the major question in ongoing research is whether current forms of therapy can 
affect the decline in β-cell function in T2D. In humans, increased β-cell mass has 
been observed in the pancreas of obese compared with lean non-diabetic subjects 
(Butler et al., 2003). Data from the United Kingdom Prospective Diabetes Study 
(UKPDS) indicated that there is a progressive deterioration in β-cell function over 
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time in T2D mellitus condition regardless of therapy allocation, insulin, 
chlorpropamide, glibenclamide, or metformin treatment (UKPDS-33, 1998; UKPDS-
34, 1998). In this study, the pancreatic islet function was also found to be about 50% 
of normal at the time of diagnosis, independent of the degree of insulin resistance and 
a reduction in β-cell mass of about 60% was shown at necropsy.  
 
The reduction of β-cell mass can be attributed to accelerated apoptosis and decreased 
neogenesis, however impaired β-cell function and possibly β-cell mass were found to 
be reversible, particularly at early stages of the disease. This can be explained by the 
fact that new islet formation and ß-cell replication are normal in diabetic and obese 
individuals (Meier et al., 2006; Butler et al., 2007). In another UKPDS sub-study, 
Sulfonylureas were used and failed to stop the β-cell decline however metformin 
administration resulted in an improvement of 51% to 66% in β-cell function in the 
first year of therapy but a decrease to 38% at 6 years (UKPDS, 1995). This outcome 
shows that attempts to stimulate insulin secretion and improve insulin action with 
drug therapies were only temporarily helpful but were ultimately unable to prevent 
progressive β-cell dysfunction.  
 
Based on these studies it is now clear that ß-cell exhaustion, desensitization of the β-
cells, lipotoxicity, amyloid deposition and a reduction in β-cell mass are major 
contributory factors to β-cell failure and the development of T2D. The data outlined 
above also shows that the major defect leading to a decrease in β-cell mass in T2D is 
increased apoptosis, while new islet formation and β-cell replication are normal. 
Individuals with T2D, whether lean or obese, have about a 50% decrease in β-cell 
mass. In this regard, therapeutic approaches designed to arrest apoptosis and improve 
insulin sensitivity could be significant in protecting the β-cells and also provide 
alternative physiological solution in the management of T2D. This approach could 
prove to be very effective in that it might actually reverse the disease to a degree 
rather than just palliate glycaemia. 
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1.5. The adipose tissue: role as an endocrine organ  
 
1.5.1. Adipose tissue: Background and function  
 
The adipose tissue is no longer considered to be a passive and inert tissue mainly 
devoted to energy storage, insulation and mechanical support but is emerging as an 
active endocrine organ participating in regulating whole-body physiology. Previously 
the adipose tissue has long been known to synthesize and store triglyceride in periods 
of nutritional abundance and hydrolyse and release non-esterified fatty acids (NEFA) 
when they are needed in response to fasting (Spiegelman et al., 1993).  
 
During adipose tissue development, genes that code for lipogenic and lipolytic 
enzymes that are involved in lipid transport are induced to carry out adipocyte 
function (Linhart et al., 2001; Daval et al., 2006). The activities of these enzymes in 
triacylglycerol biosynthesis and lipolysis are tightly controlled by nutritional and 
hormonal conditions e.g. feeding causes an induction whereas fasting causes 
suppression of lipogenic enzymes (Paulauskis et al., 1989).  
      
1.5.2. Types of Adipose tissue 
 
Adipose tissue can be divided into 2 major types: white adipose tissue (WAT) and 
brown adipose tissue (BAT). WAT represents the vast majority of adipose tissue in 
humans and is the physiological site of triglyceride storage during energy 
consumption and NEFA release when energy expenditure exceeds energy intake 
(Vázquez-Vela et al., 2008). Adipose tissue also surrounds internal organs and 
provides some protection for these organs from jarring. The overall picture of the 
central functions of WAT has changed radically in recent years, with white fat now 
being viewed as a major endocrine organ, secreting both critical hormones and a 
number of protein factors in addition to fatty acids which play either a local or 
systemic role (Mohamed-Ali et al., 1998).  
 
Alternatively, BAT is a specialized adipose tissue depot which has a role in non-
shivering thermogenesis and energy expenditure, particularly in small mammals and 
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human neonates (Gesta et al., 2007). BAT transfers energy from food into heat 
especially through oxidation of fatty acids in mitochondria resulting in production of 
large amounts of heat. Its lipid reserves are depleted when the animal is exposed to a 
cold environment, and the colour darkens. In contrast to white fat, brown fat is richly 
vascularised and has numerous un-myelinated nerves which provide sympathetic 
stimulation to the adipocytes (Kawate et al., 1994). Brown fat is most prominent in 
newborn animals. In human infants it comprises up to 5% of body weight, then 
diminishes with age to virtually disappear by adulthood 
 
1.5.3. Adipose tissue formation and transcription regulators 
 
There are a series of elaborate network of transcriptional events which regulate pre-
adipocyte differentiation (adipogenesis) and adipocyte function and also coordinate 
expression of hundreds of proteins responsible for establishing the mature fat-cell 
phenotype. In the past decade transcriptional activation of adipocyte genes has been 
the focus of much research. Members of the CCAAT enhancer-binding protein 
(C/EBP-α β and δ) and PPAR (PPAR-γ) families of transcription factors have been 
shown to be critical in directing adipocyte-specific gene expression and adipogenesis 
(Rosen et al., 2002). Compelling evidence shows that C/EBP-α is required for 
adipocyte differentiation (Tang et al., 2004). This is clearly illustrated in 
investigations with C/EBPα “knock-out” mice in which the adipose tissue fails to 
develop normally, accompanied by accumulation of triglyceride which is the hallmark 
of white adipose tissue (Wang et al., 1995). The other transcription factor that has 
been implicated in adipose differentiation is sterol regulatory element-binding 
protein-1c (SREBP-1c), one of three SREBPs found in animal cells (Tontonoz et al., 
1993; Yokoyama et al., 1993). 
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Figure 1.3 Transcription factors involved in adipocyte development. The 
major transcriptional factors involved in the adipogenic include proteins belonging to 
the CCAAT/enhancer binding protein family (C/EBP), peroxisome proliferator-
activated receptor-γ (PPAR-γ) and adipocyte determination and differentiation 
dependent factor 1, also known as sterol regulatory element-binding protein 1 (SREB-
1). These play a key role in the complex transcriptional cascade during adipocyte 
differentiation. Exposure of preadipocytes to adipogenic inducers e.g. insulin, 
glucocorticoids, agents that elevate cAMP and foetal bovine serum in cell culture, 
activates expression of several transcription factors that converge on PPAR-γ. PPAR-
γ then induces C/EBP-α expression, and together, these factors oversee terminal 
adipogenesis 
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Adipose differentiation is accompanied by changes in cellular morphology, hormone 
sensitivity, gene expression and a dramatic accumulation of intracellular lipid. The 
ability to regulate specific key genes of lipogenesis or lipolysis could theoretically 
allow control of fat deposition. Troglitazone is one of the thiazolidinediones that 
activate the peroxisome proliferator activated receptor-gamma (PPAR-γ), which is 
expressed primarily in adipose tissues and offers new therapeutic possibilities for a 
variety of metabolic disorders. 
 
1.5.4. Adipose tissue: endocrine and secretory function 
 
In recent years, a line of evidence has demonstrated a much more complex function of 
adipose tissue as an endocrine organ that releases hormones into the blood stream to 
take part in physiological activities of the body with potential implication in insulin 
resistance, obesity and diabetes (Kim et al., 2000). These adipocyte derived hormones 
are collectively called adipokines. One of the most important adipokines is leptin, a 
peptide hormone with numerous actions, including influences on energy homeostasis 
and neuro-endocrine and immune function. This remarkable understanding has helped 
to clearly define the role adipocytes play in regulation of metabolism, energy intake, 
and fat storage and possible secretory and endocrine function. 
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Figure 1.4 Biological functions of adipocytes. Previously, adipocytes were 
considered to be inert and passive reservoir for energy storage releasing fuel as fatty 
acids and glycerol in time of fasting or starvation. More recently it has become clear 
that adipocytes are highly active metabolic and endocrine organ that secrete important 
hormones, cytokines, vasoactive substances, and other peptides.  
 
 
Adipose tissue was first suggested to have endocrine functions by Siiteri PK and co 
workers in 1987 who identified the ability of adipose tissue to interconvert steroid 
hormones. During this time adipose tissue was identified as a major site for the 
production of adipsin, an endocrine factor that is markedly down-regulated in rodent 
obesity (Flier et al., 1987). Adipsin is a member of the serine protease gene family 
whose principal site of synthesis is the adipose tissue. Another group was able to 
show that adipsin is secreted and is present in the peripheral circulation (Cook et al, 
1987). In this regard, adipsin may be viewed as the first specific candidate for such a 
class of fat cell-derived regulatory molecules. The subsequent identification and 
characterization of leptin in 1994 transformed views of the tissue and of obesity and 
firmly established adipose tissue as an endocrine organ (Zhang et al., 1994). Leptin 
has since been shown to have profound effects on appetite and energy balance and its 
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discovery has focused attention on the role of proteins secreted by adipose tissue. The 
recognition of leptin's important roles especially its effects on reducing food intake in 
both rodents and man stimulated the search for other proteins secreted by adipose 
tissue. 
 
Over the past decade, enormous progress has been made in recognising the complex 
nature of the adipose tissue as a secretory organ as well as a site of the regulation of 
energy storage. Adipose tissue metabolism is extremely dynamic, and the supply of 
and removal of substrates in the blood is acutely regulated according to the nutritional 
state. Adipose tissue is highly specialized in its role as an endocrine organ and 
regulation of energy storage, fatty acid metabolism, and glucose homeostasis 
(Cornelius et al., 1994). Genes involved in lipid metabolism and glucose homeostasis 
are prominently expressed in the fat tissue. These include: fatty acid synthase, the 
fatty acid binding protein aP2, lipoprotein lipase, phosphoenolpyruvate 
carboxykinase, malic enzyme, glyceraldehyde-3-phosphate dehydrogenase and Glut-4 
(Moustaid et al., 1991, Spiegelman et al., 1983, Hunt et al., 1986, Cornelius et al., 
1988 and Beale et al., 1992). 
 
The receptors for insulin, insulin-like growth factor 1 and adrenergic compounds are 
expressed in adipocytes (Reed et al., 1980, Campfield et al., 1995 and Feve et al., 
1990). This is quite significant to the adipose tissue due to their lipogenic and 
lipolytic activity. During times of increased food intake and/or decreased energy 
expenditure, surplus energy is deposited efficiently in adipose tissue in the form of 
neutral triglycerides under the mediation of key lipogenic enzymes. Excessive 
accumulation results in obesity. However, in times of nutritional deprivation and/or 
increase in energy expenditure requirements, the lipid reserves are usually released to 
provide fuel for energy generation. This latter process is mediated by lipases 
contained in the adipocyte which break down triglycerides into glycerol and fatty 
acids that are used in fatty acid oxidation liver, muscle, and BAT (Schweiger et al., 
2006) 
 
The studies of animal models which completely lack adipose tissue have provided 
tremendous insights into the physiological role of adipose tissue (Shimomura et al., 
1998). Genetic manipulation to alter adipose depots has enabled functional dissection 
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of obesity and its metabolic sequel. An early model from Bruce Spiegelman’s 
laboratory used transgenic mice in which an attenuated diphtheria toxin A chain gene 
was expressed specifically in adipose with the aim of reducing adiposity (Ross et al., 
1993). Transgenic mice with high-level of toxin expression resulted in newborn 
lethality accompanied by fatty fluid in the peritoneum with the mice dying after birth.  
 
In addition to secretion and fat storage, the adipose tissue is emerging as a key 
regulator of many physiological functions including energy homeostasis, glucose and 
lipid metabolism. Knowledge of specific signalling pathways involved will be key to 
unravelling the primary causes of T2D and various metabolic diseases related to 
obesity.  
 
1.6. Adipose tissue changes in obesity and link to T2D 
 
1.6.1. Obesity, adipogenesis and diabetes 
 
Obesity is an energy balance disorder in which nutrient intake chronically exceeds 
energy expenditure often characterized by an overgrowth of adipose tissue and excess 
storage of calories as triglyceride (Dvorak et al., 1997). Obesity is associated with 
adipose cell hypertrophy, and more severe forms also show adipose cell hyperplasia 
(Kahn, 1992). Adipose tissue plays an important role in glucose homeostasis and 
affects insulin sensitivity in other tissues. The important endocrine function of adipose 
tissue is emphasized by the adverse metabolic consequences of both adipose tissue 
excess (obesity) and deficiency (malnutrition).  
 
Epidemiological studies have shown that the risk for T2D and presumably insulin 
resistance rises as body fat content measured by body mass index (BMI) increases 
from the very lean to the very obese, implying that the amount of body fat has an 
effect on insulin sensitivity (Colditz et al., 1990). The expansion of adipose cell 
number (hyperplastic growth) can occur at virtually any time in response to marked 
overfeeding (Ailhaud et al., 1992). The prevention of obesity is thus very likely to 
reduce the incidence of T2D.  
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Figure 1.5 Role of nutrition and adipose tissue development. (a) Changes 
in the balance of diet e.g. conditions of nutritional deprivation induce anti-adipogenic 
signals emanating from both pre-adipocytes and mature adipocytes which restrain pre-
adipocyte differentiation. (b) Continuous food intake especially high fat diet (over-
nutrition) results in hypertrophic adipocytes which secrete factors that stimulate 
preadipocyte differentiation. These include both positive adipogenic factors and 
factors that block negative adipogenic signals. (c). Disruption of local signalling 
networks during chronic over-nutrition leads to impaired adipogenesis and adipose 
expandability. This, in turn, results in adipocyte hypertrophy and dysfunction, and 
secondary adipose inflammation, in addition to ectopic lipid accumulation at extra-
adipose sites (e.g. liver and muscle), which together, contribute to the pathogenesis of 
insulin resistance. Key:             = inhibition, =            stimulation 
 
 
The World Health Organization currently defines ‘overweight’ as a BMI of 25–29.9 
kg/m2 and obese as a BMI >30 kg/m2 (WHO Expert Committee 1995). Small 
adipocytes in lean individuals have been shown to promote metabolic homeostasis 
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while enlarged adipocytes as those found in obese individuals have been shown to 
recruit macrophages and release of a range of factors that predispose toward insulin 
resistance and also promote inflammation. A large number of studies have found that 
an increased body mass index correlates with increased plasma concentrations of 
inflammatory adipokines and acute phase proteins (Bastard et al., 2000). This has re-
defined the adipose tissue not only as a key component of the endocrine system, but 
also of the immune system. 
 
1.6.2. Obesity and insulin resistance 
 
Two complementary theories have been proposed to explain the pathophysiological 
link between obesity and insulin resistance. The first theory which relates to adipose 
tissue expandability proposes that when adipose tissue expands to its threshold level, 
its storage capacity becomes saturated (Virtue and Vidal-Puig, 2008). The capacity of 
adipose tissue mass to expand is the key determinant as to whether obesity leads to 
metabolic complications. As a result, it becomes less able to amass more fat. Once 
this stage is reached, excess fat is redirected towards other organs, such as the liver, 
pancreas or muscle. In these organs, lipid accumulation can be toxic and induce 
insulin resistance (Schrauwen, 2007) 
 
The second hypothesis proposes that the excessive accumulation of fat in adipose 
tissue can alter the secretion pattern of adipokines (Weyer et al., 2000; Trayhurn and 
Wood, 2004; Skurk et al., 2007). Suggestive evidence shows that some of these 
adipokines e.g. leptin modulate insulin sensitivity not only in adipose tissue but also 
in other metabolically relevant organs, such as liver or muscle (Bastard et al., 2002; 
Farooqi et al., 2002). The patho-physiological link between the increase of fat mass, 
namely obesity, insulin resistance and cardiovascular complications is thus becoming 
clearer as the roles of these adipokines emerge. 
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1.6.3. Adipokines and T2D 
 
Obesity is associated with a low-grade inflammation of WAT which can subsequently 
lead to insulin resistance and impaired glucose tolerance. In obesity, WAT is 
characterized by abnormal adipokine production and secretion of a wide range of 
inflammatory molecules which result in activation of some pro-inflammatory 
signalling pathways and induction of several biological markers of inflammation 
(Hotamisligil et al., 1993, Fried et al., 1998). The altered adipokine production in 
obesity has been shown to have local effects on WAT physiology but also systemic 
effects on other organs including the pancreatic beta-cells (Bastard et al., 2002; 
Sartipy et al., 2003).  
 
 
 
Figure 1.6 Adipose tissue secreted factors and β-cell function / failure. 
Pathways leading to insulin resistance associated with obesity which are induced by 
adipokines, free fatty acids, and chronic inflammation in adipose tissue.  
Figure adapted from Kasuga, 2006. 
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Inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6) 
have also been shown to be increased in obese individuals compared with lean 
subjects (Hotamisligil et al., 1993). Insulin resistance involves a broad range of 
interactions and dysfunction in feedback mechanism that takes into account the 
interplay between nutrition, glucose, insulin and adipokines in various tissues of 
metabolic importance. Although there is a clear association between obesity in 
particular visceral obesity and the development of insulin resistance, the underlying 
mechanisms involved in obesity-related insulin resistance are complex and not fully 
defined. 
 
Obese animals and humans have been shown to have characteristic over-production of 
pro-inflammatory adipokines e.g. tumour necrosis factor-alpha (TNF-α), IL-6 and 
resistin by WAT, and a deficiency in anti-inflammatory adipokines e.g. adiponectin 
(Kern et al., 2003; Lihn et al., 2003). Inflammation and adiposity cause insulin 
resistance by interfering with insulin signalling pathways. In mice, inflammatory 
serine 307 phosphorylation of IRS-1 interferes with insulin signalling (Qiao et al., 
2002).  It has previously been reported that TNF-α can directly lead to insulin 
resistance by inducing serine phosphorylation of the insulin receptor, which inhibits 
insulin signalling (Hotamisligil et al., 1994). It is thus clear that TNF-α plays a causal 
role in the insulin resistance of experimental animals since neutralization of TNF-
alpha in obese fa/fa rats caused a significant increase in the peripheral uptake of 
glucose in response to insulin (Hotamisligil et al., 1993). However, despite 
inflammatory activity in animal studies, neutralization of TNF-α activity has proved 
ineffective in ameliorating insulin sensitivity in diabetic patients (Ofei et al., 1996).  
 
Interleukin 6, a major pro-inflammatory cytokine, is produced in a variety of tissues, 
including activated leukocytes, adipocytes, and endothelial cells. Elevated 
concentrations of interleukin-6 are associated with development of T2D (Fernandez-
Real et al., 2000, Pradhan et al., 2001). In vivo infusion of human recombinant IL-6 
has been shown to induce gluconeogenesis, subsequent hyperglycaemia, and 
compensatory hyperinsulinemia (Stith et al., 1994). Elevated levels of IL-6 can thus 
be used to predict the development of T2D illustrating the possible role for 
inflammation in diabetogenesis. 
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Adiponectin and leptin have each been demonstrated to increase rates of fatty acid 
(FA) oxidation thus decreasing muscle lipid content and also increase insulin 
sensitivity in lean and obese rodents (Steinberg et al., 2002; Fruebis et al., 2001). 
Adiponectin is a 30-kDa adipose-derived hormone that appears to play an important 
role in regulating energy homeostasis and insulin sensitivity (Yamauchi et al., 2002). 
Adiponectin levels have been shown to be decreased in insulin-resistant states such as 
obesity and T2D (Berg et al., 2001; Kubota et al., 2002). Injection of adiponectin 
decreases plasma glucose levels by suppressing glucose production in the liver and 
injection of the globular domain of adiponectin decreases elevated fatty acid levels by 
oxidizing fatty acids in muscle (Berg et al., 2001; Combs et al., 2001; Fruebis et al., 
2001). Adiponectin-deficient mice develop premature diet-induced glucose 
intolerance and insulin resistance, and increased serum fatty acids (Kubota et al., 
2002; Maeda et al., 2002). In contrast, transgenic overexpression of adiponectin in 
mice leads to improved insulin sensitivity, glucose tolerance, and lower serum fatty 
acids (Maeda et al., 2002; Combs et al., 2004). These observations suggest that 
adiponectin ameliorates insulin resistance in lipoatrophic mice and T2D mice and 
may be a major insulin-sensitizing hormone secreted by adipose tissue. However, the 
physiological role of adiponectin in vivo is not yet clear because the conclusions have 
been primarily based upon gain of function experiments 
 
1.6.4. Adipose tissue and enzyme malfunction in glucose 
homeostasis 
 
Adipose tissue also plays an important role in glucose homeostasis and affects insulin 
sensitivity in other tissues. As previously illustrated, the GLUT-4 mediates insulin-
stimulated glucose uptake in adipocytes and muscle by rapidly moving from 
intracellular storage sites to the plasma membrane. In obesity and T2D, GLUT-4 
expression is decreased in the adipose tissue but preserved in the muscle (Shepherd et 
al., 1999). The role of adipose GLUT-4 in glucose homeostasis has previously been 
determined. In one study, selective depletion of GLUT-4 in mice adipose tissue led to 
impaired glucose tolerance and insulin resistance but with preserved adipose mass. 
However unexpectedly, these mice developed insulin resistance in muscle (despite 
preservation of GLUT-4) and liver, manifested by decreased biological responses 
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(Abel et al., 2001). This suggests that glucose transport in adipose tissue plays a vital 
role in glucose homeostasis and the selective down-regulation of GLUT-4 in the 
adipose tissue as seen in human obesity and T2D (Shepherd et al., 1999) may 
contribute to insulin resistance in other insulin target tissues. 
 
There is also clear evidence that the size and distribution of adipose stores influence 
metabolism in human disease. Obesity-induced insulin resistance is affected by the 
total amount of adipose tissue, localization and body fat distribution (Evans et al., 
1984) with weight gain ordinarily preceding insulin resistance, and weight loss 
improving it (Groop et al., 1993). Surgical removal of visceral fat has also been 
shown to delay the onset of diabetes and improve the insulin effect on hepatic glucose 
production in Zucker Diabetic Fatty (ZDF) model of obesity and diabetes (Gabriely et 
al., 2002). Understanding the mechanisms regulating adipose formation and function 
should provide valuable information in the fight to combat the growing incidence of 
obesity and related metabolic diseases.  
 
There are huge gaps in the current knowledge about the mechanism of action of 
various adipokines. Resistin and resistin-like molecules (RELM) receptors have not 
yet been identified and major advances are still being made in the understanding of 
biological function of leptin. Ongoing research continues to shed light on the role of 
adipose tissue with new identification of adipokines being reported. A better 
understanding of neuronal input and potentially output from adipose tissue is vitally 
important especially in light of current realization that many metabolic phenomena in 
peripheral tissues are directly controlled through central neuronal circuits, particularly 
through central pathways of nutrient sensing.  
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1.7. Resistin and beta cell function 
 
1.7.1. Resistin: Origin and structure   
 
Resistin is a 12.5-kDa peptide hormone belonging to a novel class of cysteine-rich 
secreted proteins termed as the resistin-like molecules RELM and the FIZZ (found in 
inflammatory zone) (Steppan et al., 2001). Mouse resistin is exclusively expressed in 
white adipose tissue while human resistin is mainly expressed in circulating 
mononuclear cells (Steppan and Lazar, 2004). The mouse resistin gene encodes a 114 
amino acid polypeptide including a 20 amino acid signal sequence. Human resistin is 
a dimeric protein containing 108 amino acids (Holcomb et al., 2000) and it is 
synthesized and secreted selectively from adipose tissue.   
 
Resistin was discovered by three different independent groups using modern genomic 
approaches (Steppan et al., 2001; Kim et al., 2001; Holcomb et al., 2000). Kim and 
co-workers used microarray analyses and were able to identify resistin as adipose 
secretory factor (ADSF) while Holcomb’s group initially found resistin, which they 
termed 'FIZZ3', as an expressed sequence tag related to a protein they found to be 
induced during lung inflammation. 
 
However it was Steppan and co-workers who were the first to demonstrate that both 
resistin mRNA and protein expression were markedly reduced in rodents treated with 
insulin-sensitizing thiazolidinedione in vitro, with the majority of subsequent in vivo 
data supporting these observations (Moore et al., 2001, Way et al., 2001; Steppan and 
Lazar, 2002). These reports suggest a potential mechanism for obesity-related insulin 
resistance and also shed light on a potential mechanism of action for 
thiazolidinedione. No effects of RELMα on metabolic control have yet been reported, 
though its homology with resistin suggests they may have related function.  
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1.7.2. Resistin: proposed biological function 
 
Several cellular mechanisms and pathways of insulin resistance have been described. 
Serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been shown to 
inhibit insulin action by blocking insulin receptor/IRS-1 interaction (Aguirre et al., 
2002). Fatty acid induced insulin resistance utilises this mechanism and is mediated 
by increased protein kinase C (PKC) and IRS-1 Ser (307) phosphorylation and 
decreased IRS-1 tyrosine phosphorylation (Yu et al., 2002).  
 
Resistin has been shown to produce insulin resistance and glucose intolerance when 
injected into normal mice (Steppan et al., 2001) however the precise mechanisms by 
which resistin causes insulin resistance are still unclear. Defects in the insulin-
signalling cascade to glucose uptake in skeletal muscle have been identified in people 
with T2D. Resistin has been proposed to induce insulin resistance by disrupting the 
insulin signalling pathways in insulin target tissues, however the mechanism by which 
resistin initiates and elicits signals is not well established.  
 
Considerable debate exists regarding the role of resistin in the pathophysiology of 
insulin resistance in human and animals. Resistin has previously been shown to 
promotes endothelial cell activation (Verma et al., 2003) and angiogenesis (Mu et al., 
2006) highlighting the important role this adipokine may play in vascular disorders. 
Resistin has also been shown to inhibit essential functions of polymorphonuclear 
leukocytes resulting altered immune response (Cohen et al., 2008). Understanding 
how resistin molecules modulate the activity of components of this insulin-signalling 
pathway and so result in decreased insulin action on glucose metabolism might be a 
promising tool for identifying the aetiology of T2D. 
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1.7.3. Resistin: obesity and T2D 
 
Serum resistin is elevated in diabetes and obesity (Kim et al., 2001; Azuma et al., 
2003) hence it has been suggested that resistin may have a causative role in the insulin 
resistance and T2D (Steppan et al., 2001). Functionally, administration of resistin 
resulted in impaired glucose tolerance and insulin sensitivity in wild-type mice, while 
immuno-neutralization of circulating resistin in diet-induced obese mice resulted in 
reduced blood glucose levels and significantly improved hyperglycaemia and insulin 
sensitivity (Steppan et al., 2001). However, the physiological role of resistin in 
humans and the mechanism by which it neutralizes insulin action in rodents are still 
unclear. 
 
A series of studies have been carried out since the initial discovery of resistin; some 
of which have provided data that support the original findings while others are 
conflicting. Insulin action is markedly impaired in individuals with visceral obesity 
(Carey et al., 1996) and expression of resistin mRNA has been shown to be 
significantly higher in the visceral fat compared to subcutaneous fat depot (Gabriely 
et al., 2002). Serum resistin levels and expression in WAT have previously been 
reported to be reduced in fasted mice and increased on re-feeding (Kim et al., 2001; 
Steppan et al., 2001) suggesting diet may also play a significant role. 
 
The skeletal muscle has long been considered the major site of insulin-stimulated 
glucose uptake. Treatment of L6 rat skeletal muscle cells with recombinant resistin 
resulted in reduced insulin-stimulated glucose uptake and decreased insulin-
stimulated GLUT-4 translocation (Palanivel et al., 2006). The results also showed that 
resistin regulates the function of IRS-1 and Akt-1 by down-regulating production and 
tyrosine phosphorylation of IRS-1. In another study, prolonged exposure of rat 
skeletal muscles cells to resistin resulted in decreased GLUT-4 translocation and 
reduced glucose uptake in response to insulin (Fan Hong-qi et al., 2007). These 
reports are in agreement with previous studies (Satoh et al., 2004; Steppan et al., 
2001) demonstrating the possible role of resistin as a potential direct regulator of 
glucose homeostasis in rodents.  
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However in direct contrast, Way and co-workers showed that resistin gene expression 
was significantly decreased in adipose tissue of several different murine models of 
obesity including ob/ob, db/db, tub/tub, and KKAy mice compared with their lean 
counterparts (Way et al., 2001). Surprisingly, resistin expression was also decreased 
in obese mice and increased in ob/ob mice and Zucker diabetic fatty (ZDF) rats in 
response to PPAR-γ agonists. This outcome raises serious questions concerning some 
of the previous reports since it has previously been hypothesised that one of the ways 
thiazolidinediones exert their effect is through downregulation of resistin expression. 
The precise mechanism however by which PPAR-γ activation by thiazolidinediones 
improves insulin sensitivity is still unclear.  
 
Levy and colleagues reported that there was no difference in resistin expression in the 
epididymal fat pad of Fischer 344 rats, a model of age induced insulin resistance, 
compared with age-matched, insulin-sensitive Sprague Dawley rats (Levy et al., 
2002). Initial reports by Steppan et al., in experimental animals indicated that resistin 
gene expression increases with adiposity and with insulin resistance (Steppan et al., 
2001). In this regard, resistin gene expression in the insulin-resistant, obesity-prone 
Fischer 344 rats should be higher than in Sprague Dawley rats, however this is not the 
case. This outcome clearly shows that resistin did not play a role in the insulin 
resistance characteristic of young Fischer 344 rats which raises further questions 
about the physiological role of resistin.  
 
Degawa and co-workers demonstrated that resistin protein is present in human 
adipose tissue and blood, and that there is significantly more resistin in the serum of 
obese subjects compared to lean subjects (Degawa-Yamauchi et al., 2003). This 
finding supports previous observations on resistin mRNA expression and suggests 
that resistin expression in adipose tissue is a combination from both adipocytes and 
other cells in the tissue. This outcome is also in agreement with a report which 
indicated that resistin protein was present in both adipocytes and stromal vascular 
cells of the adipose tissue (McTernan et al., 2002b).  
 
In as much as the study by Degawa-Yamauchi and colleagues used two different 
techniques to examine resistin protein in human; the parameters used in the study 
appear to be inconsistent and raises questions on the reliability of the study outcome. 
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For instance, the investigators compared lean and obese individuals of profoundly 
different ages and gender distribution. The lean group had a mean age of 33 ± 2 yr 
compared with 47 ± 1 yr in the obese group. Age-related changes in insulin resistance 
have previously been described with glucose tolerance shown to deteriorate with age 
(Boden et al., 1993). It is possible that similar changes may influence resistin 
expression, an issue that was not properly addressed. From these reports, puzzling 
questions can be raised on the expression and exact regulation of adipose resistin, and 
thus on its physiological function. 
 
The regulation of hepatic gluconeogenesis is an important process in the adjustment 
of the blood glucose level, and pathological changes in the glucose production of the 
liver are a central characteristic in T2D. Under normal circumstances, insulin inhibits 
hepatic glucose production when plasma glucose levels increase. Resistin has been 
shown to attenuate this effect of insulin by promoting increases in plasma glucose 
concentration (Rajala et al., 2003). This is a key step of resistin involvement in the 
pathophysiology of T2D since the rate of hepatic gluconeogenesis is considerably 
increased in patients with T2D compared with control subjects, thereby contributing 
significantly to the fasting hyperglycaemia in diabetes (Accili, 2004). In another 
study, resistin was reported to induce insulin resistance, but did not affect glucose 
output in rat derived hepatocytes (Liu Feng et al., 2008). Resistin was also shown to 
attenuate insulin-stimulated glycogen synthesis, phosphorylation of IRS, protein 
kinase B/Akt, GSK-3 as well as markedly inducing the gene and protein expression of 
SOCS-3, a known inhibitor of insulin signalling (Steppan et al., 2005; Niederwanger 
et al., 2007).   
 
Metformin is a commonly used antidiabetic drug known to decrease hepatic glucose 
production. Therefore, it would be expected that metformin, an insulin-sensitizing 
drug would have a down-regulatory effect on resistin expression in adipose tissue as 
resistin has been shown to increase hepatic glucose output (Muse et al., 2004; 
Rangwala et al., 2004). In one study, metformin treatment was reported to improve 
hyperglycaemia and hyperinsulinemia in obese diabetic db/db mice; however results 
also unexpectedly showed that resistin protein expression in adipose tissue was 
increased by metformin treatment (Fujita et al., 2002). This is in sharp contrast to the 
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proposed inflammatory role of resistin function as proposed by Steppan and co-
workers. 
 
Conversely, mice lacking the adipocyte hormone resistin exhibit low blood glucose 
levels after fasting, due to reduced hepatic glucose production, suggestive of a normal 
physiological role for resistin in glucose homeostasis (Banerjee et al., 2004). 
Identification of resistin receptor and signalling pathways that mediate its action and 
analysis of the phenotypes resulting from deletion or over-expression of resistin in 
transgenic mice will help to further define the biological roles of this adipokine. The 
regulation of resistin thus still remains a subject of controversy, in particular, the 
question of its modulation in obesity emerging from contradictory results. Debate thus 
still exists regarding the role of resistin in the pathophysiology of insulin resistance. 
Further studies are needed to determine the mode of regulation and biological 
functions of resistin and whether it is an effector of insulin resistance in obesity. 
 
 
1.8. Visfatin and beta cell function 
 
1.8.1. Visfatin: Origin and structure  
 
Visfatin also known as pre-B cell colony-enhancing factor (PBEF) or nicotinamide 
phosphoribosyltransferase (Nampt) is a novel adipokine that is highly expressed in 
visceral fat and up-regulated in obesity and T2D (Berndt et al., 2005; Chen et al., 
2006). It was during a search for novel cytokine-like molecules secreted from human 
peripheral blood lymphocytes that visfatin was first identified as PBEF (Samal et al. 
1994). The visfatin gene encodes for a 52 kDa secreted cytokine composed of 491 
amino acids that acts as a growth factor for early stage B cells, even though it lacks a 
signal peptide (Samal et al. 1994).  
 
However it was after visfatin was reported as a visceral fat-derived adipokine 
implicated in the development of obesity-associated insulin resistance and T2D that 
the molecule drew much attention (Fukuhara et al., 2005). In this report, visfatin was 
shown to be up-regulated during adipocyte differentiation and detected in cell culture 
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media and plasma. The Fukuhara et al., Science article has since been retracted on the 
basis that some preparations of visfatin did not bind the insulin receptor in their 
experiments. Subsequent studies have however revealed additional biological 
activities that suggest both intracellular as well as extracellular localization of visfatin 
(Rongvaux et al., 2002; Revollo et al., 2007b). 
 
In addition to adipocytes, visfatin is expressed in many other tissues, where it has 
been linked to a variety of functions such as inflammatory responses and inhibition of 
apoptosis (Jia et al., 2004). Most notable is the expression in skeletal muscle, liver, 
and immune cells hence it is likely that these tissues, whose function is altered in 
obesity, may be responsible for lower levels of circulating visfatin in obesity (Samal 
et al., 1994). Previous reports have raised questions regarding the clinical relevance of 
visfatin, as it is ubiquitously expressed in different cell types (Jia et al., 2004; 
Ognjanovic and Bryant-Greenwood, 2002; Curat et al., 2006; Rongvaux et al., 2002). 
However, recent studies support the view that visfatin is a true adipokine that is 
clearly expressed and secreted by human adipocytes (Haider et al., 2006a; Kralisch et 
al., 2005a and Pagano et al., 2006) 
 
The crystal structure of visfatin relating to its enzymatic function in nicotinamide 
mononucleotide (NMN) biosynthesis from nicotinamide has previously been 
determined (Kim et al., 2006). The crystal structure of visfatin/nampt clearly 
demonstrates that the protein belongs to the dimeric class of type II 
phosphoribosyltransferases (Wang et al., 2006; Khan et al., 2006; Kim et al., 2006) 
1.8.2. Visfatin: proposed biological function 
Visfatin is an adipokine that has been proposed to participate in glucose homeostasis 
due to its reported glucose-lowering effect. Initially visfatin was thought to have 
insulin mimicking functions, stimulating glucose utilization in peripheral tissues; 
however the precise mechanisms have not been fully elucidated. A previous report 
which as previously illustrated has since been retracted suggested that visfatin binds 
to insulin receptor at a distinct site from that of insulin (Fukuhara et al., 2005) while 
other studies reported no effect (Revollo et al., 2007b). This study sought to 
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investigate whether the reported insulin-like effects can be observed in clonal rodent 
pancreatic β-cells. 
Research on visfatin is ongoing and various roles continue to emerge. Until now, 
visfatin has been shown to exert three distinct activities of vital importance to cellular 
function. Within the cell and possibly outside the cell, visfatin functions as an enzyme 
commonly referred to as intracellular nicotinamide phosphoribosyl transferase 
(iNampt) that catalyzes the rate-limiting step in mammalian nicotinamide adenine 
dinucleotide (NAD+) biosynthesis (Rongvaux et al., 2002; Van der Veer et al., 2005). 
Visfatin has been shown to induce the production of the pro-inflammatory cytokines 
IL-1β, IL-6 and TNF-α in human monocytes (Moschen et al., 2007). Therefore, 
visfatin appears to be a multifunctional protein acting as a hormone, cytokine, and/or 
enzyme. 
As previously illustrated visfatin is abundantly expressed and secreted by adipocytes 
however the reported insulin mimetic activity of this adipokine remains controversial. 
The effects of visfatin are not restricted to glucose homeostasis. As illustrated in the 
previous paragraph, visfatin has been reported to lead to increased levels of cytokines, 
whereas insulin does not show cytokine-inducing effects, suggesting that induction of 
cytokines by visfatin may be mediated by engagement of unidentified receptor 
(Moschen et al., 2007; Stephens and Vidal-Puig, 2006). It is also possible that there 
may be no visfatin receptor at all and visfatin solely be an enzyme. Further studies of 
visfatin's physiological role may lead to new insights into glucose homeostasis and 
new therapies for metabolic disorders such as diabetes. 
NAD+ has been known for several decades as a classic coenzyme with a well-
established role in cellular redox reactions. As illustrated previously, Nampt has both 
intra- and extracellular forms in mammals. Intracellular Nampt (iNampt) is an 
essential enzyme in the NAD biosynthetic pathway while the extracellular form of 
this protein has been reported to act as an adipokine.  
Visfatin’s enzymatic activity was originally reported in 1957 however it was until 
2001 that the gene encoding Nampt was first identified in Haemophilus ducreyi 
(Preiss and Handler, 1957; Martin et al., 2001). Recent progress in the field of NAD 
biochemistry has fuelled new interest in the NAD biosynthetic pathways with several 
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lines of evidence implicating this activity in a broad range of biological functions. 
Reports from recent findings have indicated that mammals predominantly use 
nicotinamide rather than nicotinic acid as a precursor for NAD+ biosynthesis. Nampt 
is the rate-limiting enzyme that catalyzes the transfer of a phosphoribosyl group from 
5-phosphoribosyl-1-pyrophosphate to nicotinamide, forming nicotinamide 
mononucleotide (NMN) and pyrophosphate (Revollo et al., 2007a; Revollo et al., 
2007b). NMN is then converted to NAD+ by nicotinamide mononucleotide 
adenylyltransferase ((NMNAT). 
 
 
Figure 1.7 (Garten et al., 2008): Visfatin actions in the NAD+ biosynthetic 
pathway. Nampt)/Visfatin synthesize NMN from nicotinamide in a mammalian 
NAD+ biosynthetic pathway. The rate-limiting step in the biosynthetic pathway is the 
transfer of a phosphoribosyl residue from 5-phosphoribosyl-1-pyrophosphate (PRPP) 
to nicotinamide catalyzed by Nampt to produce NMN. The NMN produced is then 
converted to NAD by Nmnat.  
 
Different cells utilize different strategies to make NAD+. In mammals, tryptophan, 
nicotinic acid and nicotinamide are three major precursors for NAD+ biosynthesis 
(Magni et al., 1999; Rongvaux et al., 2003). Tryptophan is an essential aromatic 
amino acid whose role as an a NAD+ precursor was first suggested by nutritional 
studies which showed that diets supplemented with tryptophan were able to cure 
 52 
human pellagra (Krehl et al., 1945). Pellagra is a disease characterized by a 
nicotinamide deficiency. Quinolinic acid (2, 3-pyridine dicarboxylic acid) reacts with 
5-phosphoribosyl-1-pyrophosphate (PRPP) in the presence of magnesium ions to give 
rise to nicotinic acid mononucleotide (NaMN). The reaction is catalysed by quinolinic 
acid phosphoribosyltransferase (QPRTase) (Nishizuka et al., 1963). NaMN is then 
converted to desamido-NAD (NaAD) by a nicotinic acid mononucleotide 
adenylyltransferase (NaMNAT). The NaAD is finally converted into NAD by a NAD 
synthase (NADS) (Preiss and Handler, 1958; Magni et al., 1999). 
 
1.8.3. Visfatin function and link to obesity and T2D 
 
Visfatin is an endocrine, autocrine as well as paracrine protein with many functions 
including enhancement of cell proliferation, biosynthesis of nicotinamide mono- and 
dinucleotide and hypoglycaemic effect (Sommer et al., 2008). Visfatin has also been 
shown to exert insulin mimetic and pro-inflammatory effects, also functioning as an 
intracellular enzyme to produce NAD (Rongvaux et al., 2002; Moschen et al., 2007). 
The observation that visfatin has insulin-mimetic functions has raised the hypothesis 
that a dysregulation of the activity of this molecule may contribute to the metabolic 
syndrome and diabetes. The multiple effects of visfatin has been proposed to be 
achieved by its role as an intra and extracellular NAD biosynthetic enzyme (Revollo 
et al., 2007a; Revollo et al., 2007b) 
 
Visfatin expression and plasma concentrations are substantially increased with obesity 
in animals and humans (Berndt et al., 2005). It has been shown that visceral fat is 
considerably reduced through weight loss after non-reversible surgical procedures e.g. 
gastric banding (Pontiroli et al., 2002). However dietary approach as a solution to 
combating obesity is unsatisfactory since it is a complex, multi-factorial chronic 
disease involving environmental, genetic and metabolic components. Reduction of 
visceral fat would thus be linked to downregulation of visfatin levels. In one study 
visfatin concentration levels were shown to be increased in extremely obese 
individuals (BMI >40). However the elevated plasma visfatin and leptin 
concentrations were reportedly reduced after weight loss by gastric banding surgery 
(Haider et al., 2006c). This suggests that visfatin may be involved in the beneficial 
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effect of weight loss and subsequent improvement of insulin resistance. Adiponectin 
concentration which is suppressed in obese state was shown to be increased. The 
changes reported in leptin and adiponectin are consistent with previous studies (Van 
Dielen et al., 2002; Yang et al., 2001).  
 
In contrast to this, a separate study reported that massive weight loss after 
gastroplastic surgery in obese patients was accompanied by an increase in circulating 
concentrations of visfatin (Krzyzanowska et al., 2006b). This finding is consistent 
with results of Pagano and co-workers who found reduced visfatin plasma 
concentrations in obese subjects compared with lean subjects (Pagano et al., 2006). 
 
After the retracted report by Fukuhara et al., regarding insulin mimetic activity of 
visfatin, many research papers have been published on the topic, with controversial 
findings. In humans, plasma levels of visfatin were found to be elevated in subjects 
with visceral-fat accumulation and T2D and also in women with gestational diabetes 
(Chen et al., 2006; Hammarstedt et al., 2006; Krzyzanowska et al., 2006a). It was 
consequently hypothesized that visfatin could play a role in the regulation of insulin 
sensitivity in humans and possibly link obesity to its complications.  
 
In vitro studies showed that visfatin treatment increased glucose uptake in adipocytes 
and osteoblasts bearing resemblance to the actions of insulin with enhanced tyrosine 
phosphorylation of insulin receptor, IRS-1 IRS-2, and Akt (Moschen et al., 2007; Xie 
et al., 2007). These reports indicate that the regulation of glucose uptake, by visfatin 
in human adipocytes and osteoblasts involves insulin receptor phosphorylation which 
is the same signal-transduction pathway used by insulin.  
 
The relationship between visfatin and obesity is however controversial. In one study, 
it was reported that plasma visfatin and mRNA expression in subcutaneous fat were 
positively correlated with adiposity (Berndt et al., 2005) while another study reported 
a markedly higher visfatin / PBEF expression was present in visceral fat, compared 
with subcutaneous fat (Fukuhara et al., 2005). In contrast, Pagano and co-workers 
showed that, in human obesity, plasma visfatin and its mRNA in subcutaneous 
adipose tissue were significantly lower in obese subjects, compared with normal-
weight controls however higher visfatin mRNA was found in visceral adipose tissue 
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of obese subjects, compared with lean controls; suggesting a divergent regulation of 
visfatin in different fat depots (Pagano et al., 2006).  
 
The findings obtained by Fukuhara et al. may be different due to the limited 
observations as only two subjects groups were considered. Subsequent studies have 
shown a high variability of visfatin / PBEF expression in adipose tissue which is a 
possible explanation of this discrepancy in the reports from the different groups. In a 
previous study, enzymatic function of visfatin was shown to require dimerization 
hence it may circulate as a dimer in human serum (Kim et al., 2006; Revollo et al., 
2007a). This may have implications on the immunological detection as well as 
biological actions of visfatin. Differences in the qualitative and quantitative detection 
of visfatin by immunoassays need to be considered in clinical association studies of 
visfatin, obesity and diabetes due to possible differences in the specificity of the 
immunoassays applied. This may help explain the conflicting observations that have 
previously been reported. 
 
Subsequent clinical studies have confirmed the association between visfatin and 
diabetes with certain reports showing that circulating visfatin is increased with 
progressive ß-cell deterioration (Chen et al., 2006; Dogru et al., 2007; Lopez-Bermejo 
et al., 2006; Varma et al., 2007). These studies also showed that visfatin is highly 
expressed in subcutaneous fat of lean and more insulin sensitive subjects however this 
observation is attenuated in subjects with high intramyocellular lipids, low insulin 
sensitivity and high levels of inflammatory markers. The link between visfatin and 
beta-cell function is further emphasised by reports indicating regulatory effect of 
glucose and insulin on visfatin concentrations in humans (Haider et al., 2006a). 
Findings from this study showed that circulating visfatin concentrations are increased 
by hyperglycaemia; however this effect was suppressed by exogenous 
hyperinsulinaemia or somatostatin infusion. Glucose signalling for visfatin release 
was also reported to involve the PI3-kinase/AKT pathway.  
 
It has been suggested that visfatin is also regulated by hormones known to alter 
insulin sensitivity and pro-inflammatory adipose-secreted factors.  In one study, 
visfatin mRNA expression in 3T3-L1 adipocytes was significantly down-regulated by 
growth hormone (GH), tumour necrosis factor-alpha (TNF-α) and ß-adrenergic 
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agonist isoproterenol (Kralisch et al., 2005b). GH has long been known to potently 
antagonize insulin action on insulin sensitive tissues such as muscle, fat and liver 
(Frank, 2001) while several studies have shown that TNF-α potently induces insulin 
resistance with the serum levels of TNF-α increased in human and murine obesity 
(Peraldi et al., 1996). These reports suggest a direct regulation of visfatin mRNA 
expression by insulin resistance-inducing hormones that might constitute an important 
element in the pathogenesis of obesity related insulin resistance. This further supports 
the view that visfatin might be an interesting novel candidate linking core components 
of obesity and insulin resistance. 
 
The increase in visfatin expression is not uniform in all models of obesity. Although 
visfatin has been reported as having insulin-like qualities, there is no data to indicate 
that serum concentrations change acutely or in any way after eating especially glucose 
rich diet. The evidence of a direct link between visfatin genotype and human T2D is 
thus still weak and more molecular, physiological and clinical studies are needed to 
determine the role of visfatin in the aetiology and pathogenesis of T2D. Precise 
understanding of physiological and molecular actions of visfatin will lead to the 
discovery of effective therapeutic intervention. Novel manipulations which promote 
visfatin signalling and function may be promising strategies to attenuate the 
inflammatory pathways in the β-cells and ultimately reduce the progression of 
obesity-related insulin resistance. 
 
As the list of adipokines continues to grow, it has become apparent that factors that 
control the production of adipokines vary according to the species under study thus 
future work will require elaborate approaches in animal models and especially 
humans to elucidate the biology of adipokines and their impact on diseases. 
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1.9. Aims of this study 
 
The molecular mechanisms underlying the link between obesity and T2D have been 
elusive. It is therefore important to characterize the mechanisms of insulin resistance 
associated with obesity in order to develop effective therapeutic approaches to T2D. 
An accumulating body of evidence suggests that inflammation may play a crucial 
intermediary role in pathogenesis, thereby linking diabetes with a number of 
commonly coexisting conditions thought to originate through inflammatory 
mechanisms. In this regard, substantial amount of experimental evidence suggest that 
resistin and visfatin, two adipokines that are highly expressed in obese and diabetics 
compared to normal and lean individuals are associated with hyperglycaemia, insulin 
resistance, and overt T2D. 
 
Cross-sectional investigations have provided conflicting reports on the role resistin 
and visfatin may play in inflammation and aetiology of T2D. Additional 
experimentation is thus required to shed more light on resistin and visfatin physiology 
and pathophysiological role.  
 
The aim of this study was therefore to investigate the effect of the adipokines visfatin 
and resistin on beta-cell function and regulation of key genes involved in glucose 
homeostasis. This involved assessing the ability of recombinant resistin and visfatin to 
directly alter insulin secretion in clonal pancreatic beta-cells and to investigate the 
effect of resistin and visfatin on insulin receptor expression and activation, MAPK 
signalling and beta-cell viability. 
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Chapter 2 
 
Materials and Methods 
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2.1. Materials 
 
For equipments, kits, reagents and materials, please refer to Appendix 1  
 
2.1.1. Cell lines 
 
The rat clonal pancreatic BRIN-BD11 cells were a gift from Professor Peter Flatt, 
University of Ulster, Coleraine, Northern Ireland, UK.  
 
The clonal mouse pancreatic βTC-6 cells were purchased from the American Type 
Culture Collection (ATCC) collection (LGC Promochem, UK).  
 
 
2.1.2. Antibodies 
 
Actin             Santa Cruz Biotechnology Inc. 
 
Goat anti rabbit IgG HRP            Autogen Bioclear (UK) LTD 
 
Insulin receptor antibody                                     Abcam (UK) LTD 
 
Insulin receptor (phosphor Y972) antibody     Abcam (UK) LTD 
 
Phospho MAPK (ERK1/2)                     Cell signalling technology Inc 
 
MAPK (ERK1/2)                                     Cell signalling technology Inc 
 
Visfatin antibody                             Abcam (UK) LTD 
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2.1.3. Buffers 
 
2.1.3.1. Preparation of 5X Sample loading buffer 
 
250 mM TrisHCl pH6.8    12.5ml 
10% SDS                            10g 
30% Glycerol      30ml 
5% β-mercapitalethanol    5ml 
0.02% bromophenol blue    52ml 
 
2.1.3.2. Protein extraction buffer 
 
20mM Tris 
150mM NaCL 
1mM EDTA 
1% Triton X 
 
2.1.3.3. Running buffer (1X) 
 
Tris-Glycine-SDS PAGE Buffer (10X)  100ml 
Distilled water     900ml 
 
2.1.3.4. Transfer buffer (1X) 
 
Tris-Glycine Electro-Blotting Buffer (10X)  100ml 
Methanol      200ml 
Distilled water     700ml 
 
2.1.3.5. Blocking solution 
 
BSA (Bovine Serum Albumin)   5g 
Tris buffered saline-Tween 20   100ml                                        
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2.1.3.6. Tris buffered saline (TBS) 10X 
 
Tris Base      24.22g 
NaCl       80g 
Water       986ml 
HCL (Absolute – add in the hood)   14ml 
pH       7.6 
 
2.1.3.7. Tris buffered saline with tween 20 (TBS-tween) 
 
10X Tris buffered saline     100ml 
Distilled water     900ml 
Tween 20      500µl 
 
2.1.3.8. Cell lysis buffer 
 
(20 mmol/l Tris,  
150 mmol/l NaCl,  
1 mmol/l EDTA,  
1% Triton X,  
Protease inhibitor cocktail 
Phosphatase inhibitor 
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2.2. Cell culture 
 
2.2.1. General tissue culture for Brin-BD11 and βTC-6 cells 
 
The insulin-secreting rat β-cell line BRIN-BD11 cells and mouse βTC-6 cells were 
cultured in RPMI 1640 medium supplemented with 11 mM glucose, 10% foetal 
bovine serum, 2 mM  L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
The cells were seeded at 3 x 106 cells per flask and maintained in 175cm3 vented 
tissue culture flask in humidified incubator at 37oC in 5% CO2 and 95% air 
atmosphere and routinely passaged upon attaining 80% confluence (determined by 
microscopic inspection). All cells used in experiments were between passages 25 to 
45. 
 
2.3. Cell Treatment  
 
2.3.1. Cell Viability Assay and Cell Death Assay 
 
Cell viability was determined using CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (MTS) kit. The cells were plated out at a density of 2 × 104 cells 
per well in a 96-well plate and grown overnight to attach. The cells were serum 
starved and then treated with various doses of resistin, visfatin and NMN for 24, 48 
and 72 hours. For 48 and 72 hour experiments, treatment media was supplemented 
with 1% serum since the ß-cells are particularly sensitive to oxidative stress resulting 
from withdrawal of survival factors in serum. Upon completion of treatment, 
treatment media was aspirated and replaced with 100µl of fresh serum free media. 20 
µl of MTS reagent was added into each well of the 96-well assay plate and incubated 
for further 2 hours. The absorbance at 510 nm was recorded using an ELISA plate 
reader. The percentage of the absorbance of treated cells was calculated against 
untreated cells. 
 
To determine cell death, βTC-6 cells were seeded at a concentration of 2 x 104 cells 
per well, in a 96-well cell culture plates containing RPMI 1640 medium supplemented 
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with 10% foetal calf serum, 2 mM L-glutamine, penicillin (400 IU/ml) and 
streptomycin sulphate (200 µg/ml) overnight to attach.  The cells were then treated 
with different concentrations of resistin for 48 hours in serum depleted media to 
ensure serum depletion induced cell death. Upon completion of treatment, treatment 
media was aspirated and replaced with 100µl of fresh serum free media. 20 µl of MTS 
reagent was added into each well of the 96-well assay plate and incubated for further 
2 hours. Absorbance was read at 510. 
 
2.3.2. Cell Count 
 
Cells were seeded at an initial density of 1 × 106 cells per flask in a 25cm3 vented 
tissue culture flask and grown overnight to attach. The cells were then treated with 
recombinant resistin (20ng/ml and 40ng/ml) in RPMI 1640 serum free media and 
cultured in a humidified incubator at 37oC in 5% CO2 and 95% air atmosphere for 24 
hours. After completion of treatment, the cells were trypsinized and centrifuged at 
500g for 5 minutes. Cell pellet was re-suspended in fresh culture media and cell count 
conducted using a Coulter counter.  
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2.4. Real Time RT-PCR studies 
 
2.4.1. Primer Design 
 
All primers were designed using the reference sequence in the NCBI Nucleotide 
sequence database. Specificity of all primer sets were confirmed using melt-curve 
analysis and sequencing where appropriate. 
 
Primer Strand Primer Sequence 
Mouse Actin Sense GCTGTATTCCCCTCCATCGTG 
 Anti-sense CGTCCCAGTTGGTAACAATGCC 
rat GAPDH Sense GGAGTCTACTGGCGTCTTCA 
 Anti-sense ATGAGCCCTTCCACGAT 
Mouse Insulin receptor Sense AATGGCAACATCACACACTACC 
 Anti-sense CAGCCCTTTGAGACAATAATCC 
Mouse GcgR Sense TTGGCGATGACCTCAGTGTG 
 Anti-sense AACCAGCAATAGTTGGGTATGATG 
Rat resistin Sense AGAAGGCACAACCGTCACT 
 Anti-sense CCGCTGTCCAGTCTATGCT 
Mouse visfatin Sense GCCTCCTGGATTTTCTCTTTG 
 Antisense AACAATACCCACCCAACACAA 
 
 
Table 2.1 All the primers were supplied by VH Bio Limited, UK except for rat 
GAPDH and rat visfatin which was supplied by PrimerDesign Ltd, Southampton, UK. 
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2.4.2. Total RNA extraction and quantification 
 
Beta-cells were treated with resistin or visfatin for 24 hours in serum free media 
supplemented with 11mM glucose. After treatment, the cells were collected, washed 
in ice cold PBS and centrifuged at 300g for 5 minutes. Pelletted cells were re-
suspended in 175µl of SV RNA cell lysis buffer and passed through a 21-guage 
needle to shred high molecular weight DNA. 350µl of SV RNA Dilution Buffer was 
added to the 175µl cell lysate and mixed by inversion. The solution was then placed in 
a heat block at 70˚C for 3 minutes and thereafter centrifuged at 14,000g for 10 
minutes at room temperature before being transferred to a fresh eppendorf.  
 
200µl of 95% ethanol was added to the lysate, and thoroughly mixed using a pipette. 
The solution was then transferred to a silica membrane spin column assembly and 
centrifuged at 14,000g for 1 min. The spin basket was removed from the assembly 
and the run through solution discarded. The spin basket was then replaced and 600µl 
of SV RNA Wash Solution added to the spin column and centrifuged at 14,000g for 1 
min. The collection tube was emptied and DNase I treatment performed.  
 
600µl of SV RNA Wash Solution was added to the spin column and centrifuged at 
14,000g for 1 min. The collection tube was emptied and 250µl SV RNA Wash 
Solution added and centrifuge at 14,000g for further 2 minutes. The cap from the spin 
tube was removed by twisting and the spin basket transferred to 1.5 ml elution tube. 
95µl of nuclease free water was directly added to the membrane, ensuring complete 
cover of the surface. This was centrifuge at 14,000g for 1 minute. The spin basket was 
removed and discarded. 5µl of RNase inhibitor was added to the collected RNA. The 
collected RNA quantified and stored at -80˚C.  
 
Quantification of total RNA was performed using Genequant technology by 
measuring absorbance of at 260/280nm. Sample absorbance, concentrations and 
260/280 ratios were recorded. Only samples with a ratio > 1.7 were used, any ratio 
below this mark was discarded. 
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2.4.3 mRNA Reverse Transcription 
 
1µg of total RNA in each sample was reverse transcribed using the cDNA Synthesis 
Kit in a 50µl reaction volume containing nuclease free water, AMV RT buffer, 
Oligo(dt)15 primer, dNTP mix and avean monoblastoma virus (AMV) reverse 
transcriptase for 1 hour at 40oC. The resulting cDNA was stored at -20oC. 
  
2.4.4. SYBR® Green Real time RT-PCR studies for gene 
expression analysis 
 
The real-time RT-PCR reactions were performed using the iCycler Real-Time PCR 
Detection System. Reaction volumes used were 25µl containing 5µl of diluted cDNA 
(1 in 2 dilution), 1µl of each pair of primers, 5.5µl nuclease free water and 12.5µl of 
SYBR Green Mastermix. Two housekeeping genes (Actin and GAPDH) were 
amplified in separate reaction to normalize results. Denorm software was used to 
analyse the data hence the reason for selecting Actin and GAPDH as housekeeping 
genes. Thermal cycling conditions included: 
 
95o C for 1 minute (initial denaturing) 
95oC for 30 seconds 
58oC for 30 seconds 
95oC for 30 seconds 
72oC for 10 minutes (final extension) 
 
Each sample reaction was run in triplicate and expression quantified as the number of 
cycles (CT) after which fluorescence exceeds the background threshold minus the CT 
for the housekeeping control (∆CT). The RT-PCR statistical analysis was performed 
using student T test for two group comparisons and analysis of variance (ANOVA) 
for multiple comparisons. The relative expression levels were calculated by the 
formula 2- ∆∆CT, comparing treatment samples and untreated control samples.  
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2.4.5. Analysis of gene expression profiles using RT² 
Profiler™ PCR Array 
 
The expression profiles of selected target genes specific to diabetes was investigated 
using Mouse Diabetes RT² Profiler™ PCR Array. The kit contains primers for 84 
genes involved in beta cell function and T2D; plus wells for negative controls and 
four housekeeping genes which were used to normalise the data. Total RNA of the 
treated samples (resistin and visfatin treated) and untreated control was extracted and 
quantified spectrophotometrically as described in section 2.4.2. cDNA synthesis and 
preparation to the array were done in triplicate as described in section 2.4.3. Reactions 
were all performed using the iCycler Real-Time PCR Detection System in 96-well 
reaction plates. Thermal cycling conditions included: 
 
95o C for 1 minute (initial denaturing) 
95oC for 30 seconds 
58oC for 30 seconds 
95oC for 30 seconds 
72oC for 10 minutes (final extension) 
 
Results were analysed using a spreadsheet analysis template provided by the supplier 
(SABioscience Corp). For each set of triplicates, the mean value for each gene was 
determined and used to calculate the fold-changes (treatment versus untreated 
control). Relative gene expressions were calculated by using the 2−∆∆Ct method, in 
which Ct indicates the fractional cycle number where the fluorescent signal reaches 
detection threshold. 
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2.5. Western Blot and protein work 
 
2.5.1. Protein extraction (whole cell extracts) for expression 
studies 
 
β-cells were treated in serum-free media with the desired concentration of resistin or 
visfatin for 24 hours. Following experimental treatments, media was aspirated and 
collected. Cells in the flasks were washed once with ice-cold PBS and collected. Total 
cellular protein was extracted from untreated and treated cells for 1 h at 4 °C in a 
detergent based cell lysis buffer (for preparation, refer to section 2.1.3.8). Samples 
were then spun at 13000g for 10 minutes at 4o C and supernatant collected for protein 
quantification assay and Western blot analysis. The collected protein was quantified 
using a proprietary protein quantification kit (DC protein assay; section 2.5.3) and 5X 
sample loading buffer was added (for preparation; refer to section 2.1.3.1) after 
quantification. The mixture was immediately boiled at 95oC for 5 minutes to reduce 
and denature the protein. Samples were stored at -20oC until use.  
 
2.5.2. Cell Lysis/Protein Extraction for signalling studies 
 
Cells were cultured in six-well plates overnight to attach prior to treatment. After 
attaining confluence the cells were pre-incubated in serum free media for four hours 
after which the various treatment compounds were administered directly into the 
media. Upon completion of treatment, the cells were washed in ice-cold PBS and 
lysed in ice-cold cell lysis buffer (for preparation; refer to section 2.1.3.8). The cells 
were scraped off the plates and transferred to an appropriate eppendorf tube. The cell 
suspension (cells and lysis buffer) was collected and centrifuged at 13000g for 10 
minutes. The supernatant was then collected for protein quantification assay and 
western blot or ELISA analysis.  
 
 
 
 
 68 
2.5.3. DC Assay Protein Quantification 
 
Protein content in cell lysates was determined using the DC Protein Assay Kit (Bio-
Rad). The concentration of the unknown protein samples was determined by 
comparing the absorbance at 690 nm to the standard curve prepared using BSA 
(Bovine Serum Albumin) protein standards. All samples were quantified in triplicate 
and averages used in quantification. 
 
2.5.4. SDS-PAGE and Western Blot Analysis  
 
For Western blot analysis equal amounts of solubilised proteins (40µg) were resolved 
by SDS-PAGE using running buffer (for preparation, refer to section 2.1.3.3) at 200V 
for 1 hour. The percentage resolving gel used was determined based on the size of 
protein analysed (8 to 12%). The proteins were then transferred to nitrocellulose 
membranes in transfer buffer at 100V for 1 hour (for preparations, refer to section 
2.1.3.4). All membranes were stained with Ponceau-S protein staining solution to 
assess transfer efficiency. The membranes were then washed in distilled water to 
remove the Ponceau-S stain and air-dried overnight. 
 
To reduce non-specific antibody binding, the nitrocellulose membranes were blocked 
with 5% bovine serum albumin (BSA) dissolved in TBS-tween (TBS-T) for 1 hour at 
room temperature. The membranes were then incubated with primary antibody (of 
protein under investigation) dissolved at the required concentrations in 1% BSA 
overnight at 4°C. After incubation, the membranes were subjected to two 5 minute 
washes in TBS-T. Bound antibodies were detected by incubation with HRP labelled 
secondary antibody for 1 h at room temperature. The membranes were then washed 
five times for 5 min each, in TBS-tween and exposed to Enhanced 
Chemiluminescence (ECL+) detection solution for 5 minutes. The membranes were 
viewed using Storm® Phosphorimager using blue laser to measure fluorescence at 
600mV. 
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2.5.5. MAPK Activation Assay  
 
Activation of the MAPKs ERK1/2 and p38 was analysed using a proprietary phospho-
specific ELISA kit (RayBio® Cell-Based ELISA Sampler Kit). 30,000 cells were 
seeded into each well in a 96 well plate and incubated for overnight at 37oC, 5% CO2. 
The cells were then serum starved for 4 hours and treated with 200ng/ml visfatin, 
100µM NMN and 100nM Phorbol 12-myristate 13-acetate (PMA). The detection 
reagents were added to cells grown and attached to a 96-well plate. The plate was 
incubated overnight at 4°C, which gives the best detection of target protein. After 
incubation, plate contents were discarded and washed 4 times. 100µl of detection 
antibody was added to each well and sealed with tape and the plate incubated for 1 
hour at 37°C. The plate was again washed 4 times. 100µl of 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate was added to each well and sealed with tape 
and the plate incubated for further 10 minutes at 37°C or 30 minutes at 25°C. 100µl of 
stop Solution was then added to each well with gentle shaking and absorbance read at 
450 nm  
 
2.5.6. Insulin Receptor Activation Assay 
 
Activation of the insulin receptor was analysed using a proprietary phospho-specific 
ELISA kit (RayBio® Cell-Based ELISA Sampler Kit). 30,000 cells were seeded into 
each well in a 96 well plate and incubate for overnight at 37oC, 5% CO2. The cells 
were then serum starved for 4 hours and treated with various concentrations of 
visfatin (50ng/ml, 200ng/ml and 500ng/ml) and 10nM insulin as positive control. The 
detection reagents were added to cells grown and attached to a 96-well plate. The 
plate was incubated overnight at 4°C, which gives the best detection of target protein. 
After incubation, plate contents were discarded and washed 4 times. 100µl of 
detection antibody was added to each well and sealed with tape and the plate 
incubated for 1 hour at 37°C. The plate was again washed 4 times. 100µl of TMB 
substrate was added to each well and sealed with tape and the plate incubated for 
further 10 minutes at 37°C or 30 minutes at 25°C. 100µl of stop Solution was then 
added to each well with gentle shaking and absorbance read at 450 nm 
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2.6. Determination of insulin secretion 
 
To determine the effect of resistin on insulin secretion, glucose responsive clonal 
rodent pancreatic beta-cell line BRIN-BD11 was used. The cells were plated out at a 
density of 2 × 104 cells per well in a 96-well plate and incubated overnight in RPMI-
1640 tissue culture medium supplemented with 10% foetal calf serum, 100 iu/ml 
penicillin and 100 µg streptomycin to attach. The cells were subsequently treated with 
0, 20 and 40ng/ml resistin for 24-hours in serum free RPMI. After treatment, the cells 
were immersed in serum free RPMI media containing 2.25mM glucose for 1 hour and 
then stimulated with 22mM glucose for another 1 hour. The media from this last 
treatment was collected and assayed for insulin content using a proprietary Rat insulin 
ELISA (Mercodia, Sweden). 
 
For visfatin and NMN, glucose responsive clonal rodent pancreatic beta-cell line 
βTC-6 cells were pre-incubated at 37oC for 1 hour in 2.25mM glucose. After pre-
incubation, the medium was removed, and cells were treated with visfatin in 2.25mM 
glucose for 1 hour. For high glucose study, the cells were pre-incubated in 2.25mM 
glucose and then treated with visfatin in 22mM glucose for 1 hour. After incubation, 
the treatment medium was collected and centrifuged at 13,000g for 5 minutes. The 
supernatant was collected and assayed for insulin content using a proprietary Mouse 
insulin ELISA (Mercodia, Sweden). The effect of NMN on insulin secretion was 
determined using the same procedure as visfatin. 
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2.7. Statistical analysis 
 
Statistical analysis was performed using the GraphPad® Prism software Version 4.0 
(GraphPad Software, San Diego) and Microsoft Excel 2003 (Microsoft Corporation, 
WA), based on the mean values of independently reproduced experiments. Data were 
presented as mean±SEM of treated samples compared to the untreated control. 
Significant differences between treatment and control values were determined by the 
2-tailed student t-test and 1-way ANOVA with Tukey's post-test. 
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Chapter 3 
 
Regulation of beta-cell line viability 
by visfatin and resistin 
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3.1. Introduction 
 
Pancreatic β-cells have a dense capillary network, which is essential for the necessary 
provision of nutrients to allow for accurate glucose sensing, and to disperse hormones 
to the systemic circulation (Virtanen et al., 2008). In response to glucose sensing, 
sufficient β-cells are required to maintain normal glucose concentrations, as 
demonstrated by the development of diabetes when β-cell mass is decreased 
surgically or by β-cell toxins (Goodner et al., 1989, Kjems et al., 2001).  
 
The ability to preserve or enhance β-cell mass and function would thus have 
important therapeutic implications. The relationship between insulin resistance, 
deficient β-cell mass, and impaired insulin secretion is still poorly understood 
however. This is partly because it is still not possible to assess β-cell mass in vivo in 
humans due to difficulty in obtaining pancreatic tissue, since the tissues are only 
available from a deceased organ donor (Bonner-Weir S, 2000).  
 
Regulation of β-cell mass is largely a balance between β-cell replication and apoptosis 
(Butler et al., 2003). Developing new ways to replenish the deficit in β-cell mass in 
diabetes is vital to new and successful therapies. Ongoing research is aimed at 
regeneration of insulin producing cells by triggering the body to grow its own new β-
cells either by neogenesis or replication of existing ones or by islet transplantation 
(Lipsett and Finegood, 2003; Shapiro et al., 2006).  
 
Hypertrophic adipocytes have been shown to produce excess secretory factors which 
alter β-cell function (Guerre-Millo, 2004). Recently, visfatin has been reported to 
exert beneficial functions on glucose and lipid metabolism, as well as insulin 
sensitivity (Sun et al., 2009) while resistin has been shown to exhibit inflammatory 
properties (Steppan et al., 2001). Viability of pancreatic β-cells and isolated islets is 
one of the main obstacles limiting β-cell adaptation in times of stress. The purpose of 
this study was to investigate the effects of resistin and visfatin on cell viability of 
clonal pancreatic β-cells.  
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3.2. Materials and methods:  
 
Details of materials and methods used in the experiments for this chapter can be found 
in chapter 2  
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3.3. Results 
 
3.3.1. 1. The effect of resistin on β-cell cell viability over 24 
hours 
 
Figure 3.1.1 shows the result of 24-hour treatment of βTC-6 cells with resistin. 
Incubation with resistin significantly increased β-cell viability at 5, 10 and 20 ng/ml 
but not at concentrations higher than this. The increase was maximal at 10 ng/ml 
(45% increase compared to control; p<0.05).  
 
 
 
Figure 3.1.1 Resistin increases βTC-6 cell viability at physiological 
concentrations.  Cell viability was determined using modified MTS assay. The 
results show a marked difference with the low concentration reported in lean non-
diabetics (20ng/ml) causing an increase in cell viability while high concentration 
associated with obesity and diabetes (40ng/ml) not eliciting any increase compared to 
control. The values represent means and standard error of the mean (SEM). * p≤0.05 
using ANOVA and Tukey's multiple comparison test for the comparison between 
untreated and resistin treated cells. (n = 5). 
 76 
3.3.1.2. The effect of resistin on β-cell cell number over 24 
hours 
 
To assess whether the increases in cell viability seen in Figure 3.1.1 were due to 
proliferative changes in the βTC-6 cells, a total cell count was carried out. This 
technique showed that the number of cells significantly increased after 24-hour 
incubation with 20ng/ml resistin compared to untreated cells (p<0.05). This increase 
might initially appear modest at only about 20% compared to untreated cells, but as 
the treatment period was only 24-hours this is still an interesting finding. This 
suggests that resistin promotion of cell viability is at least in part through increased 
cell proliferation. However since this increase in cell number is not as drastic as the 
marked increase in viability illustrated in Figure 3.1.1, it is possible that there could 
be other mechanisms by which resistin promote cell viability.  
 
 
Figure 3.1.2 Resistin increases βTC-6 cell total cell number. Total cell 
count determined using a Coulter counter. The experiment was repeated three times. * 
p≤0.05 using ANOVA for the comparison between untreated and resistin treated cells 
(n = 3). 
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3.3.1.3. The effect of resistin on serum-depletion induced β-
cell death  
 
To determine whether resistin can protect β-cells against serum depletion induced cell 
death, mouse βTC-6 cells were cultured with or without resistin for 48 hours. Sub-
confluent βTC-6 cells were treated with a range of resistin concentrations (0-40ng/ml) 
in serum deprived media. As expected, serum withdrawal over 48 hours triggered cell 
death of the βTC-6 cells however resistin did not exert any protective effects from cell 
death induced by serum depletion at any of the concentrations tested.  
 
 
 
Figure 3.1.3 Resistin does not protect βTC-6 cells from serum-depletion 
induced cell death. βTC-6 cells were cultured in varying concentration of resistin 
(5 to 40ng/ml) for 48 hours. After incubation, viability of the cells was measured 
using modified MTS assay. The results show that resistin did not have any protective 
effects from serum depletion induced cell death (n = 5). SD=serum depletion without 
resistin; control= complete media; SD+5, 10, 20, 30 and 40=doses of resistin 
 78 
3.3.1.4. The effect of resistin on β-cell cell viability over 48 
hours 
 
The previous results showed that resistin promotes β-cell viability by limited increase 
in proliferation but without attenuating cell death. To further explore the long term 
effects of resistin, viability of the β-cells over 48 and 72 hours was determined. As 
illustrated in Figure 3.1.4., the effect of resistin on cell viability declined after 48 
hours with a slight non-significant increase at 1 and 5ng/ml in cell viability and a non-
significant downward trend in cell viability with increasing resistin concentrations 
compared to basal. 
 
 
 
Figure 3.1.4 Resistin treatment has no significant effect on cell viability 
over 48 hours. The cells were treated with resistin for 48 hours in media 
supplemented with 1% serum and cell viability determined using modified MTS 
assay. The β-cells are particularly sensitive to oxidative stress resulting from 
withdrawal of survival factors in serum, for this reason treatment medium for the β-
cells was supplemented with 1% serum for long term study (48 and 72 hours) (n = 5). 
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3.3.1.5. The effect of resistin on β-cell cell viability over 72 
hours 
 
Further treatment with resistin over 72 hour period resulted in non-significant increase 
in cell viability of βTC-6 cells at 1, 5 and 10ng/ml and a non-significant downward 
trend in at 30 and 40ng/ml. This result shows that prolonged exposure to resistin has 
no significant effect in promoting survival of the mouse βTC-6 cells. 
 
 
 
Figure 3.1.5 Resistin treatment results in a non-significant increase in 
cell viability after 72 hours. βTC-6 cells (1 x 104 cells per well) were plated in a 
96 well plate. The cells were treated with resistin (0-40ng/ml) for 72 hours in medium 
supplemented with 1% serum and cell viability determined using modified MTS 
assay. Results are expressed as percent relative to control cells in serum-free medium 
(n = 5). 
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3.3.1.6. The effect of 24-hour exposure to low visfatin 
concentration on β cell viability 
 
The effect of visfatin at low circulating concentrations on βTC-6 cells was tested. 
Exposure of the cells to visfatin at low circulating concentrations for 24 hours did not 
induce any significant effect in cell viability. The results show that visfatin treatment 
at levels similar to those found in circulation neither promotes nor attenuates cell 
viability of the β-cells over 24 hours.  
 
 
 
 
Figure 3.1.6 Visfatin has no effect on βTC-6 cell viability over 24 hours. 
βTC-6 cells (2 x 104 cells per well) were seeded out in 96 well and treated with 
visfatin for 24 hours. Cell viability was determined using modified MTS assay. 
Results are expressed as percent relative to control cells in serum-free medium (n= 5). 
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3.3.1.7. The effect of 48-hour exposure to low visfatin 
concentrations on β-cell viability 
 
Treatment of βTC-6 cells with visfatin for 48 hours at concentrations from 0 to 
50ng/ml resulted in no significant effect on cell viability of βTC-6 cells. 
 
  
 
Figure 3.1.7 Low visfatin concentration does not promote cell viability 
over 48 hours. βTC-6 cells (1 x 104 cells per well) were plated in a 96 well plate 
and treated with visfatin for 48 hours in media supplemented with 1% serum. Results 
are expressed as percent relative to control cells in serum-free medium (n=5)  
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3.3.1.8. The effect of 72-hour exposure to low visfatin 
concentrations on β-cell viability 
 
Subsequent treatment with visfatin over 72 hour period resulted did not have a 
significant effect on cell viability of βTC-6 cells. This result shows that prolonged 
exposure of the cells to visfatin does not promote survival of the mouse βTC-6 cells 
 
 
 
Figure 3.1.8 Effects of visfatin on cell viability of βTC-6 cells over 72 
hours. βTC-6 cells (1 x 104 cells per well) were plated in a 96 well plate. The cells 
were treated with visfatin for 72 hours in media supplemented with 1% serum and cell 
viability determined using modified MTS assay. Results are expressed as percent 
relative to control cells in serum-free medium (n=5). 
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3.3.1.9. The effect of 24-hour exposure to high visfatin 
concentrations on β-cell viability  
 
Circulating visfatin concentration has been shown range from 0.4ng/ml in healthy 
children (Haider et al., 2006b) to 90ng/ml in gestational diabetes (Krzyzanowska et 
al., 2006a) with other studies proposing a possible higher concentration as there is 
only one ELISA test kit for visfatin that is presently commercially available (Phoenix 
Peptides, Karlsruhe, Germany). A higher concentration of visfatin compared to low 
circulating concentration has also been proposed due to the dramatic elevation of 
visfatin levels in the visceral adipose tissue of obese mice (Sethi and Vidal-Puig, 
2005). Exposure of β cells to high concentrations of visfatin for 24 h resulted in a 
gradual decrease in cell viability with a significant decrease observed at 500ng/ml.   
 
 
 
Figure 3.1.9 Visfatin decreases βTC-6 cell viability at high 
concentrations. βTC-6 cells were plated in a 96 well plate and cell viability 
determined using modified MTS assay. Results are expressed as percent relative to 
control cells in serum-free medium (n=5). The values represent means and standard 
error of the mean (SEM). ** denotes significant (P < 0.01)  
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3.3.2.0. The effect of 48-hour exposure to high visfatin 
concentrations on β-cell viability  
 
To further investigate the long term effect of high visfatin concentrations, the mouse β 
cells were exposed for 48 or 72 hours to varying high concentrations of visfatin in 
treatment media supplemented by 1% serum. A relatively marked effect was observed 
when the β-cells were exposed to these elevated levels over longer time episodes. 
Unlike 24h, both 400 and 500ng/ml treatments significantly reduced viability of the β 
cells.    
 
 
 
Figure 3.2.0 Visfatin decreases βTC-6 cell viability at high 
concentrations over 48 hours. βTC-6 cells were treated with visfatin for 48 
hours in medium supplemented with 1% serum, and cell viability determined. There 
was a significant decrease in cell viability at concentrations of 400 and 500ng/ml. The 
values represent means and standard error of the mean (SEM). * p≤0.05 and ** 
p≤0.01 using ANOVA and Tukey's multiple comparison test for the comparison 
between untreated and visfatin treated cells. (n=5). 
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3.3.2.1. The effect of 72-hour exposure to high visfatin 
concentrations on β-cell viability  
 
The exposure of the βTC-6 cells in long-term culture to elevated levels of visfatin for 
72 hours resulted in significant reduction in cell viability. There was no effect on cell 
viability between 100 to 300ng/ml however a significant decline was evident at 400 
and 500ng/ml treatment compared to untreated control.   
 
 
 
Figure 3.2.1 Visfatin decreases βTC-6 cell viability at high 
concentrations over 72 hours. βTC-6 cells (2 x 104 cells per well) were plated in 
96 well plate. The cells were treated with visfatin for 72 hours in medium 
supplemented with 1% serum, and cell viability determined using modified MTS 
assay. There was a significant decrease in cell viability at concentrations of 400 and 
500ng/ml. ** p≤0.01 using ANOVA and Tukey's multiple comparison test for the 
comparison between untreated and visfatin treated cells. (n=5). 
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3.3.2.2. The effect of 24-hour exposure to NMN on β-cell 
viability  
 
To further address the mechanism by which elevated levels of visfatin regulate β-cell 
viability, the role of NMN (a product from the visfatin enzymatic reaction) on 
viability of the β cells was assessed. The cells were cultured for 24 hours in serum 
free media with various treatment concentrations of NMN. As for 48 and 72 hours, 
treatment media supplemented with 1% serum in the absence or presence of NMN 
was used. The results show that NMN did not influence the viability of the βTC-6 
cells and parallel experiments performed over 48 and 72 hours demonstrated that 
longer term exposure to NMN by itself has no influence β cell viability. 
 
 
 
 
Figure 3.2.2 NMN did not have any effect on beta cell viability over 24 
hours. βTC-6 cells (2 x 104 cells per well) were plated in a 96 well plate. The cells 
were treated with NMN for 24 hours, and cell viability determined using modified 
MTS assay as previously illustrated (n=5). 
 87 
3.3.2.3. The effect of 48-hour exposure to NMN on β-cell 
viability  
 
To further evaluate the long term effects of NMN on β cell viability, the cells were 
subjected to treatment over 48 hour period. Exposure of βTC-6 cells to NMN for 48 
hours resulted in a small but non-significant decrease viability of the beta cells at 
highest concentration. 
 
 
 
Figure 3.2.3 Exposure to NMN results in a non-significant decrease β 
cell viability over 48 hours. βTC-6 cells (2 x 104 cells per well) were plated in a 
96 well plate. The cells were treated with NMN for 48 hours in media supplemented 
with 1% serum, and cell viability determined using modified MTS assay as previously 
described (n=5). 
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3.3.2.4. The effect of 72-hour exposure to NMN on β-cell 
viability 
 
72 hour treatment of NMN treatment resulted in a small but non-significant decrease 
viability of the beta cells at 100nM. 
 
 
Figure 3.2.4 Exposure to NMN results in a non-significant decrease β 
cell viability over 72 hours. βTC-6 cells (2 x 104 cells per well) were plated in 96 
well plate. The cells were treated with NMN for 72 hours in media supplemented with 
1% serum, and cell viability determined using modified MTS assay as previously 
described. (n=5). 
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3.4. Discussion 
 
The capacity of β-cell mass to increase in the face of insulin resistance is very 
important to β-cell function because it prevents or delays the onset of T2D (Del Prato 
et al., 2004). Proliferation of pancreatic β-cells is a major event in the development of 
β-cell mass, thus there is considerable interest in understanding the mechanisms that 
stimulate pancreatic islet cell growth and differentiation. Little is known about the 
capacity, mechanisms, or timing of growth in β-cell mass in humans and animals. In 
as much as numerous advances have been made, major gaps in understanding the 
developmental biology of the β-cell remain to be elucidated.  
 
Varieties of hormones, growth factors, metabolites and cytokines have been 
implicated in the regulation of pancreatic β-cell viability (Saldeen, 2000). To evaluate 
the direct effects of resistin on β-cell viability, serum-starved cells were treated for 24 
hours with increasing concentrations (0 to 40ng/ml) of resistin. For the duration of 24 
hour treatment, as has been reported in a publication based on this study (Brown et 
al., 2007), resistin promotes cell viability in clonal mouse pancreatic βTC-6 cells. 
This observation is supported by two studies in a different cell type which showed 
that resistin promotes cell activation, proliferation and migration in endothelial cells 
(Verma et al., 2003; Mu et al., 2006). 
 
The maximal stimulatory effects of resistin of up to 45% on βTC-6 cell viability was 
achieved at concentration of 20 ng/ml (P <0.01) as compared to the untreated control, 
which is comparable with the clinical plasma levels of resistin in lean non-diabetic 
subjects (Fujinami et al., 2004; Yannakoulia et al., 2003). A higher dose of 40 ng/ml 
which is the reported concentration in obesity and diabetic patients (Fehmann et al., 
2002; Zhang et al., 2003) did not promote viability as compared to the untreated 
control (P >0.05). These data in Figure 3.1.1 strongly suggest that resistin is involved 
in β-cell survival and confirm the effect of resistin on continued existence of 
pancreatic β-cells. Based on these observations, it is possible that at the lower and 
more ‘physiological’ levels, resistin may act as a beta-cell growth factor maintaining 
beta-cell mass from stress induced by excessive accumulation of fat in adipose tissue. 
However at the much higher ‘pathological’ concentrations, the observed proliferative 
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effect diminishes, potentially suggesting that the protective effective could be 
defective in times of elevated serum resistin concentrations. 
 
Studies in rodents have shown that there is a compensatory increase in β-cell mass in 
response to insulin resistance or obesity (Bonner-Weir et al., 2000). Thus the 
stimulatory effect of resistin illustrated above highlights the potential role of this 
adipokine in β-cell survival. Clinically, this is a vital novel finding since protection of 
pancreatic β-cells from stress and inflammatory induced cell death is key to 
developing successful therapeutic interventions.  
 
The mode of action by which resistin exerts its effect on β-cell viability is still 
unknown. The possibility that increase in viability required induction of proliferation 
and / or decrease in cell death was considered. Thus in the next series of experiments, 
the effect of resistin on cell death and total cell number was determined. The results 
show an increase in cell number after 24 hour treatment with 20ng/ml resistin 
compared to untreated control and no effect resulting from 40ng/ml treatment. The 
increase resulting from 20ng/ml resistin treatment was by a small margin of only 20% 
compared to control. This is not sufficient to sustain the cell survival in comparison 
with the trend observed in Figure 3.1.1 between concentrations of 5 to 20ng/ml. This 
implies that resistin may be promoting viability of the β-cells by increase in cell 
number and a different mechanism.  
 
β-cell death was induced by the removal of survival factors that accompanies serum 
withdrawal. Serum starvation is a widespread working model for inducing cell death 
and apoptosis in different cell types (Granata et al., 2004).  As expected, culture of 
βTC-6 cells in medium devoid of serum led to a marked cell death over 48 h (Figure 
3.1.3). However, the extent of this response was not reduced when the cells were also 
exposed to resistin at various concentration ranges of 1 to 40ng/ml during the period 
of serum withdrawal. Resistin did not exhibit any protective effects confirming that 
reduction in β-cell death was not required for the observed response in viability 
(Figure 3.1.1) and therefore doesn’t protect from apoptosis at least in this model of 
cell death.  
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It is vital to note that resistin expression is up-regulated in the obese insulin resistant 
state in the adipose tissue of rodents and humans (Steppan and Lazar, 2004; 
McTernan et al., 2002b), suggesting that this adipokine may provide a physiological 
adaptation by improving survival of the β-cells as they cope with increased insulin 
demand. Irrespective of the mechanisms involved, this study together with concurrent 
studies involving other cell types (Verma et al., 2003; Mu et al., 2006) has revealed 
that resistin has the unique capacity to promote viability via different pathways in 
pancreatic β-cells even though it is regarded as an inflammatory molecule. 
 
The effect of resistin on cell viability of the β-cells over the long term was also 
examined. Resistin did not have any effect on β-cell viability over 48 and 72 hours. 
The time course study reveals that resistin prolonged survival of the β-cells in serum 
deprived media during the 24 hour episode however the effect diminished over the 48 
and 72 hour periods. The observed effect over 24 hours is physiologically important 
because if cellular stress is not delayed or eliminated or cells fails to recover from the 
stressful insult, apoptosis ensues (Donath et al., 1999).  
 
Visfatin has only recently been discovered as an adipokine, and as such, its 
physiological and/or patho-physiological role in the β-cells is only beginning to 
emerge. In this study, the effects of a range of concentrations of visfatin on the 
viability of mouse βTC-6 cells were evaluated. Two concentration ranges were used: 
a set of concentrations mirroring that seen in circulation (0 to 50ng/ml) and a higher 
range of concentrations (100 to 500ng/ml) representing what might be seen in 
localised tissue where visfatin is secreted. The low visfatin concentrations did not 
elicit any effect on the viability of the β-cells (Figure 3.1.6, 3.1.7. and 3.1.8.). This 
suggests that low circulating concentrations of visfatin are not physiologically vital in 
β-cell survival. 
  
Treatment with the high visfatin concentrations resulted in a significant decrease in 
viability of the β-cells. The modified MTS assays revealed that cell viability was 
significantly impaired in βTC-6 cells after 24h, 48h and 72h treatments (Figure 3.1.9, 
3.2.0. and 3.2.1.). The elevated visfatin concentrations may in part mimic the situation 
in type 2 diabetes where ß-cells are already insulted by various stressful conditions 
such as exposure to high cytokine concentration and oxidative stress (Robertson et al., 
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2004; Akerfeldt et al., 2008). In one previous study, circulating visfatin was shown to 
be increased with progressive beta-cell deterioration (López-Bermejo et al., 2006). 
The observations outlined in this study (Figure 3.1.9, 3.2.0. and 3.2.1) might be 
directly correlated to these previous reports and help to illustrate the negative 
regulatory influence of high visfatin concentrations on the β-cells in obese and T2D 
states. The precise mechanisms involved in this cytotoxic action of visfatin remain to 
be defined, but are probably multifactorial.  
 
One major highlight is the decline in cell survival as a result of the high visfatin 
concentration range used and time episode employed. From the results illustrated in 
Figure 3.1.9, 3.2.0 and 3.2.1, treatment with elevated levels of visfatin is more potent 
in decreasing cell viability over longer period of time. There was no effect with 
400ng/ml visfatin over 24 hours; however a significant decrease (p < 0.05) in viability 
of the β-cells was observed with this concentration (400ng/ml) after 48 and 72 hours.  
Based on these observations, it is conceivable that prolonged exposure of ß-cells to 
elevated concentrations of visfatin as observed in the obese state may lead to reduced 
survival and subsequent β-cell dysfunction. 
 
Visfatin has recently been shown to exhibit robust NAD+ biosynthetic activity with 
NMN acting as a key intermediate (Revollo et al., 2004). To investigate whether the 
observed effects of visfatin was via the production of NMN, the effect of NMN on 
cell viability was investigated. As illustrated in Figure 3.2.2, 3.2.3 and 3.2.4 NMN did 
not have any effect on cell viability of the β cells both in the short term (24 hours) and 
long term (48 and 72 hours) suggesting that visfatin may elicit this effect through a 
different and yet to be identified pathway. This might be a cell specific effect as NMN 
has been shown to upregulate cell viability in prostate cancer cells (personal 
communication Dr J Brown, University of Warwick). Since visfatin receptor is yet to 
be identified its mode of action remains elusive. Reversing the deleterious effects of 
elevated visfatin concentrations and understanding possible mechanism of action 
could thus prove a vital tool in improving β-cell function.  
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Chapter 4 
 
Gene expression profiling of 
cultured clonal pancreatic β-cells 
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4.1. Introduction 
 
The expression of functional and regulatory genes by pancreatic β-cells is vital to 
maintaining glucose homeostasis and ensuring secretion of sufficient insulin in 
response to glucose to meet the metabolic demand. Dysregulation of any of the β-cell 
specific genes could result in alterations in β-cell differentiation, survival and insulin 
secretion, all of which are potentially implicated in the onset of T2D (Kutlu et al., 
2009).  
 
The adipose tissue is now known to be a central player in the pathogenesis of insulin 
resistance associated with obesity (Kershaw and Flier, 2004). Circulating adipokines 
regulate the function of pancreatic β-cells at multiple levels: Adiponectin has 
previously been shown to rescue the β-cells from cytokine and fatty acid-induced 
apoptosis (Rakatzi et al., 2004) and play a key role in mediating insulin resistance in 
the β-cells (Retnakaran et al., 2005) while leptin has been shown to suppress insulin 
secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells 
(Kieffer et al., 1997). Chronic exposure to elevated levels of adipokines is thus likely 
to modulate β-cell function over the longer term and eventually bring about adaptive 
changes in gene expression. Regulation of β-cell and adipocyte specific gene 
expression is one of the most important targets for the prevention of obesity and 
amelioration of insulin sensitivity (Shepherd et al., 2009).  
 
The aim of this study was to assess the effect of the adipokines resistin and visfatin on 
the expression profile of genes involved in obesity, β-cell function and onset of T2D. 
To do this, mouse βTC-6 cells were exposed for 24 h to resistin or visfatin. The 
expression profile of the related genes was analyzed using Mouse Diabetes RT² 
Profiler™ PCR Array kit.  
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4.2. Materials and methods:  
 
Details of materials and methods used in the experiments for this chapter can be found 
in chapter 2 
 
4.3. Results 
 
4.3.1. Effects of resistin on gene expression profile in mouse 
βTC-6 cells 
 
RT-real time PCR array analysis of transcripts expressed in βTC-6 cells exposed to 
resistin resulted in altered patterns of gene expression. A total of 84 gene transcripts 
were analysed.  Upon analysis of the regulated genes, 14 genes were identified which 
were significantly up-regulated while 5 genes were significantly downregulated. 
Table 4.1 shows details of the genes that were significantly altered after resistin 
treatment. A list of all the gene transcripts analysed but which were not significantly 
altered by resistin treatment can be found in Appendix 2.1. 
 
 
Description Fold Change p value 
Ace 1 Angiotensin-converting enzyme -1.382 0.00153 
CD28 CD28 antigen 1.447 0.00295 
Ctla4 
Cytotoxic T-lymphocyte-associated 
protein 4 3.102 0.0287 
Foxc2 Forkhead box C2 2.297 0.0345 
G6pc Glucose-6-phosphatase, catalytic 1.350 0.00101 
G6pd2 Glucose-6-phosphate dehydrogenase 2 3.102 0.00706 
Gcg Glucagon -1.047 0.0392 
Gpd1 
Glycerol-3-phosphate dehydrogenase 1 
(soluble) 3.102 0.0310 
HNF4a Hepatic nuclear factor 4 1.047 0.0457 
Il6 Interleukin 6 1.447 0.0261 
Inppl1 Inositol polyphosphate phosphatase-like 1 2.194 0.0381 
Ins1 Insulin I 1.023 0.0443 
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Mapk14 Mitogen-activated protein kinase 14 2.297 0.0118 
Mapk8 Mitogen activated protein kinase 8 2.297 0.0329 
Pax4 Paired box gene 4 -1.414 0.0528 
Pfkfb3 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 17.549 0.00962 
Pik3cd 
Phosphatidylinositol 3-kinase catalytic 
delta  31.269 0.0260 
Retn Resistin -1.259 0.000656 
Slc2a4 
Solute carrier family 2 (facilitated glucose 
transporter),member 4 2.701 0.0352 
Stx4a syntaxin 4A (placental) 17.549 0.00582 
Tcf2 Transcription factor 2 32 0.000214 
Vamp3 Vesicle-associated membrane protein 3 -6.349 0.0269 
Vegfa Vascular endothelial growth factor A -4.702 0.0103 
 
 
Table 4.1 RT-PCR array data for β-cells treated with resistin. Gene 
Expression Analysis of resistin treated βTC-6 cells using Mouse Diabetes RT² 
Profiler™ PCR Array. Analysis of differential expression was performed using the 
spreadsheet provided by the array company. Significant differences between the 
treatment and the control samples were analyzed with a 2-tailed student t-test (p< 
0.05, n = 3). Values represented are average fold change for significantly regulated 
gene compared with non-treatment control (p<0.05). CD28, Ctla4, Foxc2, G6pc, 
G6pd2, Gpd1, HNF4a, Il6, Inppl1, Ins1, Mapk14, Mapk8, Pfkfb3, Pik3cd, Slc2a4, 
Stx4a, Tcf2 genes were significantly upregulated by resistin treatment whilst Ace 1, 
Gcg , Pax4, Retn, Vamp3, Vegfa genes were significantly downregulated compared to 
control cells. 
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4.3.2. Schematic representation of resistin regulation of 
insulin sensitivity based on the results from PCR array study 
 
 
Figure 4.1 Effect of resistin on mRNA expression of Mapk8, Inppl1 and 
IL-6 and potential downstream effects in insulin signalling pathways. The 
phosphorylated insulin receptor binds to and phosphorylates IRS proteins, which 
inturn phosphorylates various downstream signaling proteins. Of critical importance 
is PI3K which makes PI(3,4,5)P3 from PI(4,5)P2 upon stimulation. Increase in Inppl1 
mRNA by resistin could potentially result in decreased PI(3,4,5)P3 synthesis and 
inhibit the actions of downstream molecules e.g. Akt/PKB and subsequent decrease in 
glucose uptake. Mapk8 has been shown to increase IR serine phosphorylation. Up-
regulation of Mapk8 by resistin could thus promote this effect and subsequently 
reduce IR tyrosine phosphorylation which inturn deacreses Glut-4 translocation. The 
same effect is observed with IL-6 has also been shown to inhibit Glut-4 translocation. 
Key: IR=insulin receptor, IRS=isulin receptor substrate, PI3K=Phosphatidylinositol-3 
kinase, PIP3= phosphatidylinositol triphosphate 
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4.3.3. Effects of visfatin on gene expression profile in mouse 
βTC-6 cells 
 
RT-real time PCR array analysis of 84 genes was performed to reveal genes regulated 
by visfatin. It is evident that visfatin treatment significantly alters the expression 
patterns of genes involved in inflammation, including proinflammatory cytokines and 
genes associated with obesity, insulin secretion, insulin resistance and the early onset 
of T2D. Comparison of differentially expressed genes between the visfatin treated cell 
samples and untreated controls indicated that a total of 12 genes were significantly 
altered (p<0.05). The details are illustrated in Table 4.2. A list of all the gene 
transcripts analysed but which were not significantly altered by visfatin treatment can 
be found in Appendix 2.2. 
 
             
 Description Fold Change p value 
Ace 1 Angiotensin-converting enzyme -3.732 0.0157 
Akt2 Protein kinase B, beta 24.251 0.000668 
CD28 CD28 antigen 97.006 0.00251 
CeaCam 
Carcinoembryonic antigen-related cell 
adhesion molecule pseudogene 1 -2.828 0.0178 
DPPIV Dipeptidyl-peptidase 4 1.0968 0.0751 
HNF4a Hepatic nuclear factor 4 16 0.0118 
Ins1 Insulin I 8.979 0.0369 
Mapk8 Mitogen activated protein kinase 8 -1.122 0.0386 
Nfkb1 
Nuclear factor of kappa light chain gene 
enhancer in B-cells 1, p105 40.317 0.0189 
PPARa 
Peroxisome proliferator activated receptor 
alpha -1.259 0.0434 
Stx4a Syntaxin 4A (placental) 17.549 0.0352 
Tcf2 Transcription factor 2 32 0.00313 
UCP2 Uncoupling protein 2, mitochondrial -1.289 0.00479 
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Table 4.2 RT-PCR array data for β cells treated with visfatin. Gene 
Expression Analysis of visfatin treated mouse βTC-6 cells using Mouse Diabetes RT² 
Profiler™ PCR Array. The Superarray system compared the relative levels of mRNA 
expressed in βTC-6 cells with or without visfatin treatment. Analysis of differential 
expression was performed using the spreadsheet provided by the array company. 
Significant differences between the treatment and the control samples were analyzed 
with a 2-tailed student t-test (p< 0.05, n = 3). Values represented are average fold 
change for each gene compared with non-treatment control. Akt2, CD28, DPPIV, 
HNF4a, Ins1, Nfkb1, Stx4a, Tcf2 mRNA was significantly upregulated upon visfatin 
treatment whilst Ace 1, CeaCam, Mapk8, PPARa, UCP2 genes were significantly 
downregulated. 
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4.3.4 Schematic representation of visfatin regulation of insulin 
secretion based on the results from PCR array experiments 
 
 
 
Figure 4.2 The role of visfatin in the regulation of insulin secretion. The 
potential pathways involved in visfatin induced insulin secretion are schematically 
depicted. Loss of HNF4-α function has previously been shown to result in reduced 
insulin secretion via KATP channel activity. Upregulation of HNF4-α mRNA by 
visfatin highlights a possible pathway of visfatin induced insulin secretion. UCP2 
proteins have been shown to impair mitochondrial ATP generation and alter KATP 
channel activity with subsequent reduced insulin secretion. Down-regulation of UCP-
2 mRNA by visaftin illustrates a potential pathway by which visfatin promotes insulin 
secretion. A similar effect is observed with decreased PPAR-α mRNA. Insulin gene 
transcription is a vital regulatory process in insulin biosynthesis, a process which 
precedes insulin secretion. TCF2 / HNF1-β is known to be involved in transcriptional 
regulation of the insulin gene and the observed increase in TCF2 and insulin mRNA 
by visfatin illustrates possible involvement of visfatin in this process.   
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4.3.5 Schematic representation of visfatin regulation of insulin 
sensitivity based on the results from PCR array experiments 
 
 
 
Figure 4.3 Schematic illustrations of genes regulated by visfatin and 
potential effects on signaling pathways of insulin and glucose uptake. 
Akt2/PKB, a downstream molecule of PI3-kinase has been implicated in insulin-
signaling pathway and known to regulate GLUT-4 trafficking. Akt2 mRNA 
upregulation by visfatin illustrates a possible pathway by which visfatin regulates 
glucose uptake. Mapk8 activation has been shown to be involved in serine 
phosphorylation of IR and subsequently reduced tyrosine phosphorylation of IR and 
glucose uptake. The observed reduced transcription activity of this molecule by 
visfatin highlights a possible pathway by which visfatin improves insulin sensitivity. 
Syntaxin 4 (Stx4a) knockout mice have previously been shown to have reduced 
insulin-stimulated glucose uptake with parallel reduction in GLUT-4 translocation. 
This highlights the role of this protein in glucose homeostasis and the observed 
upregulation by visfatin demonstrate a potential pathway in visfatin regulation of 
GLUT-4 vesicle trafficking and glucose uptake.  
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4.4. Discussion 
 
In this study, the gene expression profile of clonal mouse pancreatic β-cells treated 
with resistin and visfatin was examined using real time PCR array. It is evident that 
treatment of βTC-6 cells with both visfatin and resistin leads to up-regulation or 
down-regulation of a number of genes involved in signal transduction and 
inflammation, including pro-inflammatory cytokines and genes associated with 
secreted factors and transcription activity. The current results provide novel 
observations that may help to define the underlying molecular pathways by which the 
adipokines resistin and visfatin may contribute to obesity-related changes in β-cell 
function and alterations that may result in insulin resistance and onset of T2D. 
 
Elevated serum resistin in human diabetes and rodent diabetic models is often 
associated with inflammation (McTernan et al., 2002a). The pro-inflammatory nature 
of resistin is more evident from the ability of the protein to stimulate the production of 
inflammatory cytokines including TNF-α and IL-12 (Silswal et al., 2005). The present 
study shows that treatment of β-cells with 40ng/ml resistin resulted in up-regulation 
of iL-6 mRNA expression by 1.447 fold (p=0.0261), an observation which implicates 
this adipokine in potential inflammatory response in the β-cells. Interestingly, the 
concentration eliciting this response is associated with obesity, T2D and inflammatory 
response (Fehmann et al., 2002; Zhang et al., 2003). This observation is clinically 
significant as elevated levels of C-reactive protein (CRP) and IL-6 have previously 
been shown to predict the development of type 2 diabetes (Pradhan et al., 2001). 
Interleukin-6 also induces insulin resistance in 3T3-L1 adipocytes (Rotter et al., 
2003). Conversely, IL-6 has also been shown to protect pancreatic β-cells from 
inflammatory cytokines-induced cell death (Choi et al., 2004). It is thus possible that 
the promotion of cell viability of beta cells by resistin as observed in Figure 3.1.1 
could be mediated by upregulation of IL-6 mRNA. This highlights a possible dual 
function of IL-6 in resistin activity. 
 
The signalling pathways involved in resistin-induced insulin resistance are still poorly 
understood. The present study demonstrates that resistin treatment significantly 
upregulated Mitogen-activated protein kinase 8 (Mapk8) gene also known as c-Jun N-
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terminal kinase 1 (JNK-1) by 2.297 fold (p=0.0329) compared to control. Mapk8 is 
known to affect insulin signalling and has been implicated in the progression of 
obesity and T2D in humans (Hirosumi et al., 2002). In one published study, 
knockdown of Mapk8 / JNK1 gene expression by siRNA significantly increased 
GLUT-4 translocation in human embryonic kidney cells (Liu et al., 2009) hence 
mRNA upregulation would be expected to elicit opposite effect. Mapk8 has also been 
previously reported to mediate fatty acid-induced cellular insulin resistance (Solinas 
et al., 2006) which further illustrates the molecule’s wider role in responding to 
activation by environmental stress and pro-inflammatory cytokines. The involvement 
of Mapk8 as a negative regulator of the insulin signalling and its up-regulation by 
resistin in the β-cells highlights a possible pathway by which resistin induces insulin 
resistance.  
 
Among the metabolic enzyme-related genes, it is noteworthy that resistin increased 
the expression of mRNAs for glucose-6-phosphate dehydrogenase (G6pd2) by 3.102 
fold (p=0.00706) and Glucose-6-phosphatase (G6pc) by 1.350 fold (p=0.00101). 
G6pc is a key gluconeogenic enzyme which catalyzes the hydrolysis of glucose-6-
phosphate to glucose and inorganic phosphate (Nordlie et al., 1993). Overexpression 
of the glucose-6-phosphatase has previously been shown to attenuate glucose 
sensitivity of insulin secretion in clonal mouse pancreatic beta cells (Iizuka et al., 
2000) suggesting that resistin could have long term effects on β-cell function through 
this observed effect on G6pc. Up-regulation of G6pc mRNA by resistin as 
demonstrated in this study could potentially induce enzymatic activity of glucose-6-
phosphatase and disrupt glucose stimulated insulin secretion. This association 
highlights a possible pathway by which resistin may disrupt beta cell secretory 
function (Nakata et al., 2007). 
 
Glucose-6-phosphate dehydrogenase is one of the major NADPH-producing enzymes 
which catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconate 
(Pandolfi et al., 1995). Overexpression of G6pd has previously been shown to result 
in obesity induced lipid metabolism disorders and insulin resistance (Park et al., 
2005). Metabolic diseases including T2D are closely associated with a failure of lipid 
homeostasis, however molecular mechanisms underlying lipid metabolism disorders 
have not been clearly understood (Kahn BB and Flier JS., 2000). G6pd expression 
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levels in the β-cells may thus be a promising indicator of obesity related insulin 
resistance and defects in insulin secretion arising from fatty acid toxicity. Resistin has 
previously been shown to induce insulin resistance in pancreatic islets and also impair 
glucose-induced insulin release (Nakata et al., 2007). The presently observed up-
regulation of G6pd mRNA by resistin in the ß-cells may represent a pathological 
pathway by which resistin mediates insulin resistance the beta cells and defects in 
insulin release. 
 
The inositol polyphosphate phosphatase-like 1 (Inppl1) gene encodes for the Lipid 
Phosphatase SHIP2 which negatively regulates insulin signalling by disrupting PI3-
kinase pathway (Ishihara et al., 1999; Clement et al., 2001; Marion et al., 2002). PI3-
kinase functions as a lipid kinase producing PI(3,4,5)P3 from PI(4,5)P2 upon 
stimulation by a variety of ligands (Hiles et al., 1992; Stephens et al., 1993). PI 
(3,4,5)P3 acts as a lipid second messenger often after receptor stimulation to activate 
downstream molecules, including Akt which results in translocation of GLUT-4 to the 
plasma membrane (Stephens et al., 1993; Rameh and Cantley, 1999; Saltiel and Kahn, 
2001). Lipid Phosphatase SHIP2 has previously been shown to hydrolyze PI(3,4,5)P3 
to produce PI(3,4)P2, in effect disrupting the PI3 kinase pathway and negatively 
regulating insulin signalling (Ishihara et al., 1999; Sleeman et al., 2005). 
 
Resistin up-regulation of Inppl1 mRNA was by 2.194 (p=0.0381) and is thus 
significant in unravelling the mode of action and negative regulation of insulin 
signalling in the beta and skeletal muscle cells. Previous studies have shown that 
prolonged exposure of resistin to skeletal muscle cells results in decreased GLUT4 
translocation and glucose uptake in response to insulin (Palanivel et al., 2005; Fan et 
al., 2007).  In the beta-cells, Lipid Phosphatase SHIP2 has been demonstrated to be a 
negative regulator of the PI3K signal transduction pathway; with enhanced Akt, 
glycogen synthase kinase 3 (GSK3) and extracellular signal-regulated kinases 1 and 2 
(ERK1/2) phosphorylation in INS1E cells observed following SHIP2 inhibition 
(Grempler et al., 2007). The inhibitory role by resistin to the effects of insulin in the 
beta cells and other target tissues involves disruption of PI3 kinase activity and it is 
interesting to speculate that Inppl1 may be an important gene in regulating resistin 
activity on insulin’s metabolic actions, as many of them require the downstream 
products of PI3 kinase. 
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6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (Pfkfb3) is a potent activator 
of phosphofructokinase-1 (PFK-1), which is a rate-limiting enzyme of glycolysis 
(Pilkis et al., 1995; Okar et al., 2001). In the present study resistin significantly up-
regulated Pfkb3 mRNA by 17 fold. This observation highlights the involvement of 
resistin in regulation of glucose metabolism. Changes in the level and the activity of 
this enzyme would markedly affect both the glycolytic and the glyconeogenic fluxes. 
PFKFB3 gene silencing has previously been shown to decrease glycolysis in HeLa 
cells (Calvo et al., 2006) hence it is possible that up-regulation of Pfkb3 mRNA by 
resistin as illustrated in this study could induce glycolysis in the beta-cells. Studies 
involving other cell types e.g. treatment of L6 rat skeletal muscle cells with 
recombinant resistin resulted in reduced insulin-stimulated oxidation of glucose via 
the Krebs cycle although lactate production was unaltered (Palanivel et al., 2006). 
Oxidative glucose disposal in the target tissues is the main pathway utilised by cells to 
generate ATP and increased non-oxidative glucose disposal by glycolysis and reduced 
Krebs cycle activity by resistin could potentially result in glucose intolerance. The 
effect of resistin on Pfkfb3 mRNA expression illustrated in the PCR array data is a 
starting point and further functional experiments are needed to elucidate potential 
interactions in the beta-cells.  
 
The most highly up-regulated mRNA by resistin treatment in this study was the 
transcription factor 2 (Tcf2) gene, more commonly known as hepatocyte nuclear 
factor 1β (HNF1β) which was increased by 32-fold compared to control. Tcf2 belongs 
to a network of transcription factors expressed in liver, kidney, gut, and pancreatic β 
cells (Coffinier et al., 1999; Reber et al., 2001). It also plays a role in the specific 
regulation of gene expression in these tissues. Mutations of HNF-1β (TCF2) produce 
maturity-onset diabetes of the young, type 5 (MODY5) (Horikawa et al., 1997). 
Affected patients are characterized by an insulin secretion defect. Selective Deletion 
of the Hnf1ß in the beta cells has previously been shown to result in impaired glucose 
tolerance, dysregulated islet gene expression, and reduced glucose-stimulated insulin 
secretion (Wang et al., 2004). The finding that Tcf2 mRNA expression was increased 
suggests a role for resistin in mediating transcription responses during pancreas 
development. This outcome is also consistent with the observed upregulation of 
HNF4-α and Ins1 mRNA by resistin since the insulin gene has previously been shown 
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to be a target gene of hepatocyte nuclear factor-1alpha (HNF-1alpha) and HNF-1beta 
(Okita et al., 1999). 
 
As mentioned in the previous paragraph, the PCR array data presented Table 4.1 also 
demonstrates that resistin induced an increase in Ins1 mRNA by 1.023 fold 
(p=0.0443). Insulin gene is the key regulatory hormone involved in glucose 
homeostasis. The regulation of insulin gene expression in response to increases in 
blood glucose levels is crucial for maintaining normal glucose homeostasis. The 
observed increase in Ins1 mRNA expression highlights a possible mechanism by 
which adipose tissue secreted proteins may regulate insulin secretion. Due to 
increased energy demands in obesity, the increased insulin gene transcription by 
resistin highlights a possible pathway by which the adipose tissue adapts by causing 
increased insulin secretion and subsequent glucose uptake to meet energy needs.  
 
Resistin also increased the expression level of mRNA for, Mapk14, Pik3cd, Slc2a4, 
Stx4a and significantly decreased Gcg, Vamp3 and Vegfa mRNA. Slc2a4 encodes a 
protein that functions as a facilitative glucose transporter in a similar fashion to 
insulin responsive GLUT-4. Stx4a mediates fusion and the translocation of SLC2A4 
and GLUT-4 from intracellular vesicles to the plasma membrane. Pik3cd is a 
downstream effector of tyrosine-phosphorylated insulin receptor substrate proteins.  It 
is unclear; the roles of these molecules with regard to resistin function in the beta-
cells. One possibility is an indirect effect by resistin on other transcription factors or 
regulatory signalling molecules which results in their modulation. These observations 
highlight a more complex function of resistin and further studies are needed to 
elucidate and define its potential role.  
 
Genetic susceptibility to T2D involves many genes, most of which are still unknown. 
Significant alterations in genes controlling transcription were observed with Pax4 
mRNA downregulated while Foxc2 mRNA was strongly upregulated. Pax4 plays an 
important role in the differentiation and development of pancreatic islet β-cells (Sosa-
Pineda et al., 1997). Resistin also upregulated the mRNA for cytotoxic T-lymphocyte-
associated protein 4 (Ctla4) and CD28.  These genes are more commonly associated 
with type 1 diabetes and immune responses and their role in obesity induced insulin 
resistance and T2D is still unclear. Most of the significantly altered genes however are 
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novel targets of resistin and belong to functional classes that can account for most of 
the biological and metabolic effects of this adipokine in the β-cells.  
 
In addition to resistin, the effect of visfatin on mRNA of the β-cell genes was 
investigated. The results from cells treated with visfatin demonstrate altered 
expression of genes involved in insulin signalling pathway, including the down-
regulation of Mapk8 and the up-regulation of Akt2 gene. Akt2 also known as Protein 
kinase B plays a pivotal role in insulin signalling. Evidence in animal models suggests 
that Akt2-deficient mice exhibit insulin resistance and mild diabetes (Cho et al., 
2001). Akt2 activation in response insulin and IGF-1 has been shown to influence 
growth, protein synthesis and glucose metabolism (Brazil and Hemmings, 2001). The 
results in Table 4.2 show that visfatin increased the transcription of Akt2 gene in the 
β-cells by 24-fold. The high fold increase suggests that visfatin has a high potency in 
regulating the gene expression level of Akt2 and may have a therapeutic advantage in 
improving insulin sensitivity. 
 
Mapk8 has previously been shown to increase the phosphorylation of insulin receptor 
substrate-1 (IRS-1) at serine residues which in effect inhibits insulin-stimulated 
tyrosine phosphorylation of IRS-1 (Aguirre et al., 200). In addition, TNF alpha and 
saturated fatty acids which induce insulin resistance are mediated by Mapk8 activity 
(Solinas et al., 2006). Improvement in insulin sensitivity and tyrosine phosphorylation 
by visfatin in rodents (Sun et al., 2009) could be due to its downregulation of Mapk8 
mRNA expression. The increased tyrosine signalling capacity of insulin receptors by 
visfatin observed in Figure 6.1.4 in chapter 6 could also be mediated by the observed 
visfatin downregulation of Mapk8 mRNA expression. 
 
Insulin is a key hormone in glucose homeostasis and regulation of insulin gene 
expression is essential for maintaining this process. Insulin gene transcription in the ß-
cells is induced by increases in blood glucose levels (Efrat et al., 1991). The induction 
of insulin gene is a key step in restoring normal blood glucose levels during 
hyperglycaemia and culminates in insulin secretory response which lowers blood 
glucose. The 8-fold increase in insulin gene transcription by visfatin highlights the 
involvement of this adipokine in the process. It is possible that increased insulin gene 
expression in response to visfatin treatment may result in improved responsiveness of 
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the insulin promoter to acute glucose stimulation or chronic hyperglycaemia 
illustrating a possible pathway by which visfatin improves insulin sensitivity as 
illustrated in a recent report (Sun et al., 2009).  
 
Glucose uptake in the beta cells, skeletal muscle and adipose tissue is mediated by 
insulin-stimulated translocation of GLUT-4 glucose transporters from an intracellular 
vesicular pool to the plasma membrane (Ishihara et al., 1993; Kanai et al., 1993). 
Insulin-stimulated translocation of GLUT4 has previously been shown to involve 
SNARE-complex proteins syntaxin 4 (Stx4a) and SNAP23 (Cheatham et al., 1996). 
Inhibition of syntaxin 4 has been shown to repress insulin-stimulated GLUT4 
translocation (Volchuk et al., 1996) suggesting that this protein plays an essential role 
in insulin-stimulated glucose transport. The high fold increase (17.5 fold) of Stx4a 
gene by visfatin strongly implicates visfatin in this process. Visfatin has previously 
been shown to regulate of glucose uptake in human osteoblasts (Xie et al., 2007). 
Eventhough this effect (glucose uptake) is observed in the osteoblasts and not β-cells; 
it is possible that this insulin-like effect by visfatin is mediated by induction of Stx4a 
gene. 
 
Uncoupling Protein-2 (UCP-2) is an inner mitochondrial membrane transporter which 
disrupts the electrochemical gradient across the inner mitochondrial membrane, 
producing heat instead of ATP from respiration (Li et al., 2000; Brown et al., 2002). 
Overexpression of UCP-2 has previously been shown to suppress glucose-stimulated 
insulin secretion in normal islets (Chan et al., 1999). In a similar fashion, UCP2-
deficient mice had higher islet ATP levels and increased glucose-stimulated insulin 
secretion (Zhang et al., 2001). Visfatin treatment resulted in decreased UCP-2 mRNA 
expression in the β-cells. In one study, Silent Information Regulator T-1 (Sirt1) was 
shown to positively regulate insulin secretion by repressing UCP2 in pancreatic beta 
cells, conversely Sirt1 knockout mice displayed high UCP2 expression (Bordone et 
al., 2006). Sirt1 is a NAD-dependent deacetylase (Imai et al., 2000) and thus closely 
linked to visfatin which catalyses the rate-limiting step in the NAD+ biosynthetic 
pathway (Revollo et al., 2004). In this regard, the observed visfatin induced insulin 
secretion illustrated in Figure 6.2.2 of chapter 6 could partly be mediated by visfatin’s 
ability to suppress UCP-2 mRNA expression in the β-cells. 
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In the same way, the significant downregulation of PPAR-α gene by visfatin could 
also be linked to visfatin action on insulin secretion. In one study, PPAR-α was shown 
to suppress insulin secretion and induce UCP-2 expression in insulinoma cells 
(Tordjman et al., 2002). The suppression of glucose-stimulated insulin secretion in 
this study could be due to the ability of PPAR-α to induce fatty acid oxidation and 
stimulate lipid uptake (Schoonjans et al., 1996; Frohnert et al., 1999) which may 
result in lipotoxicity. Taken together, the reduced transcription activity of both the 
UCP-2 gene and PPAR-a by visfatin suggest the involvement of both genes in 
mediating visfatin induced insulin secretion as observed in Figure 6.2.2 in chapter 6 
of this study. 
 
Hepatocyte nuclear factor 4 alpha (HNF-4α) is a member of the nuclear receptor 
superfamily known to regulate a large number of genes in hepatocytes and pancreatic 
beta-cells (Wang et al., 2000). The dysfunction of this transcription factor has been 
associated with diabetes mellitus. Mutations in the human HNF4-α gene leads to 
maturity onset diabetes of the young subtype 1 (MODY1) (Yamagata et al., 1996). 
HNF4-α is critical to β-cell function and adequate insulin secretion as illustrated by 
HNF4-α knockout mice, which exhibit impaired glucose tolerance and defective 
insulin secretion (Miura et al., 2006). The data outlined in Table 4.2 indicate that 
visfatin up-regulated HNF4 alpha mRNA expression by 16-fold. The increase 
observed in these important transcription factors, HNF4-α and Tcf2 illustrate a 
possible pathway by which visfatin causes an increase in insulin secretion (Figure 
6.2.2) as they are both thought to be involved in insulin gene transcription (Bernardo 
et al., 2008) 
 
Another transcription factor upregulated by visfatin is NF kappa B (NF-κB) which 
plays a major role in inflammatory responses. Visfatin has recently been shown to 
enhance the expression of adhesion molecules in endothelial cells through NF-κB 
activation (Kim et al., 2008). In another study involving endothelial cells, NF-κB 
signalling was shown to mediate visfatin-induced activation of gelatinases factors that 
are essential in the pathogenesis of vascular inflammation (Adya et al., 2008a). In the 
beta-cells, the involvement of NF-κB in the IL-1β induced nitric oxide synthase 
expression and signaling mechanism has previously been demonstrated (Kwon et al., 
1995). Additional studies have shown that cytokines IL-1β, interferon-gamma (IFN-γ) 
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and TNF-α activate NF-κB and induce the production nitric oxide (NO) in human 
pancreatic islets (Flodström et al., 1996).  NO is a key mediator in inflammation. The 
increase in NFkB mRNA by visfatin as illustrated in Table 4.2 highlights a potential 
role for this transcription factor in mediating visfatin function. This is critical to future 
studies since serum visfatin has previously been reported to increase with progressive 
β-cell deterioration (López-Bermejo et al., 2006) suggesting a possible involvement 
of visfatin in inflammatory processes 
 
In conclusion, cDNA RT-PCR array technology represents a powerful technique for 
defining adipokine-regulated genes. The data outlined in this study suggests several 
candidate genes which may be involved in resistin induced β-cell dysfunction and 
visfatin mediated insulin secretion and induction of β-cell sensitivity. They will help 
to better identify the mechanisms involved in obesity induced insulin resistance and 
T2D, a disease characterized by defective regulation of gene expression in response to 
insulin. 
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Chapter 5 
 
Resistin regulation of insulin 
secretion and insulin receptor 
expression 
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5.1. Introduction 
 
β-cells are responsible for maintaining a narrow range of blood glucose levels. This is 
achieved by efficient insulin secretion in response to increases in circulating glucose 
levels and insulin action in the target tissues (Ashcroft et al., 1994). Reduced β-cell 
function has been shown to precede impaired glucose tolerance (IGT) (Festa et al., 
2008). A better understanding of the pathophysiology of glucose intolerance is thus 
vital in preventing the development of T2D or at least delaying the onset. Key to this 
are the signalling cascades by which insulin mediates its effects in the tissues 
involved in glucose utilisation. 
 
Insulin signalling pathways have previously been reported to be present in the 
pancreatic β-cells and their activation following binding of insulin to its receptor has 
been demonstrated (Kulkarni et al., 2002). Disruptions of these pathways have 
profound effects on β-cell function; with knockout of insulin receptor in a β-cell 
specific manner resulting in hyperglycaemia and defects β-cell growth (Otani et al., 
2004). The presence of insulin resistance and defects in pancreatic β-cell function are 
thus key characteristics of type 2 diabetes (Lillioja et al., 1993). Adipocyte secreted 
factors including resistin have been reported as key players in the pathogenesis of 
insulin resistance associated with obesity (Steppan et al., 2001).  
 
Elevated levels of resistin have been proposed to cause insulin resistance and 
therefore may serve as a link between obesity and type 2 diabetes (Steppan et al., 
2001). However, in humans, the physiological role of resistin is far from clear and its 
role in obesity and insulin resistance and / or diabetes is controversial. Studies on 
resistin gene expression have been inconsistent with previous studies rodent and 
animal models reporting conflicting results (Savage et al., 2001; Nagaev et al., 2001). 
The aim of this study was to first characterise the expression of resistin in rodent 
clonal pancreatic β-cells and then establish its role in insulin receptor expression and 
glucose stimulated insulin secretion. 
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5.2. Materials and methods:  
 
Details of materials and methods used in the experiments for this chapter can be found 
in chapter 2 
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5.3. Results 
 
5.3.1. Resistin mRNA is expressed in clonal rat pancreatic β 
cells 
 
Real-time RT-PCR was performed using cDNA derived from clonal rat BRIN-BD11 
cell line to investigate resistin expression in the beta cells. Analysis revealed that 
resistin is expressed in this cell line (Ct values of between 24 and 26 being observed). 
This result suggest that resistin previously described as a adipose tissue specific 
protein is also found in pancreatic β-cells.  
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Resistin is expressed in clonal rat pancreatic BRIN-BD11 
cells. Resistin mRNA expression suggests that resistin is another ‘adipose tissue-
specific’ protein found in pancreatic β-cells. In this expreriment, 1µg of mRNA from 
clonal rat BRIN-BD11 cells was reverse transcribed to cDNA and used in a 25 µl RT-
PCR reaction. To exclude the possibility of genomic DNA contamination, the mRNA 
was DNased before the reverse transcription (RT) reaction. (n=3). 
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5.3.2. Low concentrations of resistin have no effect on insulin 
receptor gene expression  
 
To determine whether resistin at concentrations reported in lean non-diabetics 
modulates insulin receptor gene expression, mouse βTC-6 cells were treated with 
20ng/ml resistin for 24h. Real-time RT-PCR analysis revealed that resistin treatment 
did not have any effect on the levels of insulin receptor (IR) mRNA as compared to 
untreated controls (P>0.05). 
 
 
Figure 5.2 Resistin did not have any effect on Insulin receptor gene 
expression after treatment with 20ng/ml. Total RNA was extracted from 
treated and non-treated cells, reverse transcribed and subjected to quantitative real-
time RT-PCR. Insulin receptor gene expression was normalized to β-actin and 
GAPDH gene expression. Resistin did not have any effect on IR mRNA expression at 
the concentration (20ng/ml) used. Results are the means ± S.E.M. comparing resistin-
treated with untreated control cells. (n=4). 
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5.3.3. Low concentrations of resistin have no effect on insulin 
receptor protein expression  
 
Western blot analysis of insulin receptor protein expression in mouse βTC-6 cells 
showed that resistin does not alter insulin receptor protein expression at 
concentrations reported in lean non-diabetics suggesting absence of pathological 
action at this concentration.  
 
            
 
Figure 5.3 Resistin did not have any effect on insulin receptor protein 
expression. Proteins from lysed cells were separated on 8% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with 
anti insulin receptor antibody. Resistin did not have any effect on insulin receptor (IR) 
protein expression at the concentration (20ng/ml) used. Mouse skeletal muscle cell 
lysate (SM) was used as a positive control. (n=3). 
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5.3.4. Insulin receptor mRNA levels in βTC-6 cells are 
decreased by high resistin concentrations  
 
To further investigate the effect of resistin at concentrations reported in obese type 2 
diabetics, βTC-6 cells were treated with 40ng/ml resistin for 24h. Resistin treatment 
dramatically reduced the levels of insulin receptor mRNA expression by 70% as 
compared to untreated controls.  
 
 
Figure 5.4 Resistin downregulates Insulin receptor gene expression. 
βTC-6 cells treatment with 40ng/ml resistin for 24 hours resulted in reduced IR 
mRNA expression compared to untreated control. Total RNA was extracted, reverse 
transcribed and subjected to quantitative real-time RT-PCR to determine insulin 
receptor mRNA levels and normalized to β-actin and GAPDH expression means. 
(p<0.05). n = 4.  
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5.3.5. Insulin receptor protein levels are decreased by high 
resistin concentrations 
 
The changes noted at the mRNA level were also reflected at the protein level in the 
clonal pancreatic mouse βTC-6 cells. Resistin significantly decreased insulin receptor 
protein expression in resistin treated samples compared to non-treated controls with a 
decrease in detected band intensity of 60% being recorded. 
 
 
                
 
 
 
Figure 5.5 Resistin downregulates Insulin receptor protein expression. 
Western blot analysis of protein extracts shows reduced IR expression in resistin 
treated samples compared to non-treated controls. Total protein was extracted from 
the cell lysate followed by separation using 8% SDS-PAGE and immunoblot analysis. 
Mouse skeletal muscle cell lysate (SM) was used as a positive control. Key: IR = 
insulin receptor (n=3). 
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5.3.6. Resistin has no effect on insulin secretion in BRIN-BD11 
cells  
 
The glucose-responsive clonal rodent pancreatic BRIN-BD11 cell line was used for 
the insulin secretion study. Resistin at concentrations of 20 and 40ng/ml did not exert 
any significant effect on high glucose (22 mmol/l) stimulated insulin secretion over 1 
h from the clonal rat BRIN-BD11 cell line.    
       
 
 
 
Figure 5.6 Resistin did not have any effect on glucose stimulated insulin 
secretion. BRIN-BD11 cells were treated with 0, 20 and 40ng/ml resistin for 24 
hours in serum free RPMI medium. After treatment, the old medium was aspirated 
and replaced by serum free media containing 2.2 mM glucose for 1 hour and then 
stimulated with 22 mM glucose for another 1 hour. The medium from this last 
treatment was then collected and assayed for insulin content using a proprietary Rat 
insulin ELISA. Resistin treatment did not have any effect on GSIS both at 
physiological and pathological concentrations (n = 4). 
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5.4. Discussion 
 
Resistin, a circulating protein derived from adipocytes in rodents has been implicated 
in obesity-associated diabetes (Steppan CM and Lazar MA, 2004). Despite numerous 
studies since its discovery, the role of resistin in insulin sensitivity and obesity 
remains controversial. Previous reports have demonstrated that resistin mRNA is 
expressed in mouse brain and pituitary (Morash et al., 20020) however studies of 
resistin gene expression in humans have given conflicting results (Nagaev et al., 
2001; Engeli et al., 2002) 
 
In order to gain insight into the physiological role of resistin, analysis of resistin gene 
expression in rat BRIN-BD11 cells was performed using real-time RT-PCR. The 
results outlined above demonstrate that resistin is expressed in rat β-cells with Ct 
values of 24 and 26 being observed. This data confirms that resistin, previously 
thought to be an adipose specific protein both in rodents and humans (Steppan et al., 
2001; McTernan et al., 2002b) is also found in the β-cells and raises the question of 
its potential role in β-cell function.  
 
In one previous study resistin deficiency was shown to improve glucose tolerance and 
insulin sensitivity in severely obese mice (Qi et al., 2006). Original studies by 
Steppan and co-workers showed that administration of resistin to mice resulted in 
glucose intolerance, whereas immuno-neutralization of resistin improved insulin 
action (Steppan et al., 2001). These reports illustrate the role of resistin in the 
pathophysiology of T2D and the expression of resistin in the β-cells as illustrated in 
this study may have potential pathological role on β-cell function e.g. mediator of 
inflammation. Further studies are thus needed to identify factors that regulate resistin 
expression in the β-cells. 
 
Insulin mediates its action in glucose homeostasis by first binding to the insulin 
receptor (IR) localized on the cell surface (Gammeltoft, 1984). The regulation of 
insulin receptor expression and activity is thus important in directing insulin to 
specific target tissues involved in glucose utilisation (Desbuquois et al., 1993). β-cell 
specific disruption of the insulin receptor has previously been shown to result in 
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impaired glucose tolerance further illustrating the important role of IR expression in β 
cell function (Kulkarni et al., 1999).  In another study, reduction of IR expression by 
small interfering RNA in MIN6 insulinoma cell lines resulted in alterations in 
expression of numerous genes with diverse functions and disruption of the insulin 
signalling pathway (Ohsugi et al., 2005).  
 
In order to clarify the role of resistin in regulation of insulin receptor at concentrations 
reported in lean non-diabetics and obese diabetic individuals, clonal mouse βTC-6 
cells were treated with 20ng/ml resitin, which is representative of serum levels 
measurable in non-diabetic subjects (Fujinami et al., 2004; Yannakoulia et al., 2003) 
and 40ng/ml which is the reported concentration range in obese T2D (Fehmann et al., 
2002; Azuma et al., 2003; Zhang et al., 2003). Resistin did not have any effect on 
either gene or protein expression of insulin receptor at the lower concentration of 
20ng/ml. 
 
However at 40ng/ml, as has been reported in a publication based on this study (Brown 
et al., 2007), 24-hour treatment of βTC-6 cells with elevated resistin concentration 
(40ng/ml) resulted in a significant decrease in insulin receptor mRNA and protein 
expression compared to control. This effect observed on insulin receptor has profound 
importance. Resistin has previously been shown to induce insulin resistance in 
pancreatic β-cells (Nakata et al., 2007) and rat derived hepatocytes (Liu et al., 2008). 
It is thus possible that this induction of β-cell insulin resistance by resistin could 
involve reduction of insulin receptor expression as reported in this study. 
 
The expression of resistin in the β-cell which is the site of insulin production raises 
the question of the potential role resistin may play in insulin secretion. The secretory 
response to glucose by the β-cells is modulated by a variety of hormones and enzymes 
(Zawalich et al., 1995; Harris et al., 1996). More recently adipose tissue secreted 
factors have been implicated in modulating insulin secretion. Tumour necrosis factor - 
alpha (TNF-α) and leptin, both adipose tissue-derived hormones have previously been 
reported to suppress glucose-stimulated insulin secretion (GSIS) in pancreatic β-cells 
(Zhang et al., 1995; Tsiotra et al., 2001). However the contribution of resistin to the 
regulation of insulin release from pancreatic β-cells has not been fully explored.  
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In this regard the direct actions of resistin on GSIS were investigated. Clonal mouse 
βTC-6 cells were treated with resistin both at 20 and 40ng/ml. As illustrated in Figure 
5.1.7, resistin did not have any effect on GSIS. This is in contrast to a previous study 
which found that resistin decreased GSIS in isolated islet tissue (Nakata et al., 2007). 
The difference could partly be due to the islet tissue used by Nakata et al., which is 
well established as being more glucose-responsive than the clonal pancreatic β-cell 
line used in this study. Further studies using primary β-cells or islets are thus required 
to elucidate the underlying mechanisms of resistin and its pathophysiological role in 
insulin secretion. 
 
Identification of resistin mRNA in the β-cells and the regulatory effect on IR 
expression at pathological concentrations raises the possibility that this adipose tissue 
derived hormone may play a pivotal role in obesity induced insulin resistance. Taken 
together these results demonstrate that resistin elicits it pathological effects only at 
elevated concentrations reported in obese individuals providing a potential link 
between increased adiposity and T2D. 
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Chapter 6 
 
Visfatin regulation of insulin 
secretion and insulin receptor 
signalling in pancreatic beta cells 
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6.1. Introduction 
 
Visfatin has recently been identified as an adipokine that is abundantly expressed and 
preferentially produced in visceral adipose tissue (Berndt et al., 2005; Kovacikova et 
al., 2008). Initial (and subsequently retracted on the basis that some preparations of 
visfatin did not bind the insulin receptor in their experiments) reports indicated that 
visfatin mimics the effects of insulin by binding to the insulin receptor at a site 
distinct from that of insulin, however other studies were unable to reproduce some of 
these results (Revollo et al., 2007b). The physiological role of visfatin in glucose 
homeostasis is thus controversial and remains to be elucidated. More importantly, the 
expression of visfatin has been shown to be regulated by cytokines interleukin-1β (IL-
1β), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6); all of which are 
known to promote insulin resistance (Ognjanovic et al., 2001; Kralisch et al., 2005a; 
Tan et al., 2009).  
 
Insight into the biological functions of visfatin continues to grow with ongoing 
research. Recently Revollo et al., have shown that visfatin is a biosynthetic enzyme 
which mediates its functions in the β-cells via NAD+ biosynthetic pathway (Revollo 
et al., 2007b). Visfatin has also been previously reported to regulate NAD+-
dependent protein deacetylation in human vascular smooth muscle cells, maturation 
and survival (Van der Veer et al., 2005).  
 
In the present study, therefore, the effect of visfatin on insulin receptor activation and 
secretory function of the β-cell was examined. These two components together play a 
critical role in the regulation of glucose homeostasis in the pancreatic β-cells and 
insulin target organs. In addition the effects of visfatin and nicotinamide 
mononucleotide, the product of visfatin’s enzymatic actions, on intracellular 
signalling pathways such as extracellular signal-regulated kinase (ERK 1/2), MAPK 
p38 were investigated.  
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6.2. Materials and methods:  
 
Details of materials and methods used in the experiments for this chapter can be found 
in chapter 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
6.3. Results 
 
6.3.1.1. Visfatin mRNA expression in the pancreatic β-cells 
 
Analysis of mRNA from clonal pancreatic mouse βTC-6 cells showed that visfatin is 
expressed at a relatively high level with Ct values of between 21 and 23 generally 
being observed. Visfatin has previously been shown to be predominantly expressed in 
the visceral adipose tissue in both humans and mice and the high expression level 
observed highlights a potential role, the peptide may play in the pancreatic β-cells. 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.1 Visfatin mRNA expression analysis by real-time quantitative 
RT-PCR. The high visfatin mRNA expression suggests that visfatin is yet another 
adipose tissue-specific protein found in pancreatic β-cells. For this experiment, total 
RNA was extracted from the mouse βTC-6 cells samples and quantified. 1 µg of total 
mRNA was DNAsed to exclude the possibility of genomic DNA contamination and 
reverse transcribed (RT) and amplified in a 25 µl real time RT-PCR reaction. (n=3). 
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6.3.1.2. Visfatin protein expression in the beta cells 
 
To determine whether visfatin is also expressed at the protein level, cell lysates from 
the beta cells were analyzed using western blot. As illustrated in figure 6.1.2, the 
observations noted at the mRNA level were also reflected at the protein level in the 
beta-cells. Finding visfatin at the source of insulin production raises the possibility 
that this adipokine may play a role in insulin secretion, consistent with the notion of 
visfatin being involved in glucose homeostasis (Revollo et al., 2007b).                        
      
 
 
 
Figure 6.1.2 Visfatin Protein is expressed in the beta cells. Western blot 
analysis of protein extracts from clonal mouse βTC-6 cells, separated on 12% SDS-
PAGE and immunoblotted with anti visfatin antibody. As illustrated in the figure, 
visfatin protein is highly expressed in the β-cells. The antibody against visfatin 
recognized bands with apparent molecular masses of 55 kDa which corresponds to 
molecular mass of visfatin. The two lanes for β-cells are from the same lysate sample. 
Mouse skeletal muscle cell lysate (SM) was used as a positive control. (n=3).  
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6.3.1.3. Dose-dependent visfatin regulation of insulin receptor 
phosphorylation 
 
To study the effect of visfatin on insulin receptor phosphorylation, mouse βTC-6 cells 
were stimulated with visfatin and insulin (positive control) or left untreated and 
analysed by ELISA.  
 
 
 
 
Figure 6.1.3 Visfatin stimulates insulin receptor phosphorylation in 
clonal pancreatic mouse βTC-6 cells. Visfatin (50 and 500ng/ml) caused 
significant 104 % (p<0.001) and 178 % (p<0.001) increases in insulin receptor 
phosphorylation respectively. The results show that insulin receptor was significantly 
activated by visfatin after 15 minutes stimulation (p<0.001). Phosphorylated IR was 
determined by ELISA using specific antibody against tyrosine phosphorylated IR. 
Total IR was also determined using anti-total IR based ELISA to normalise data. V50 
= 50ng/ml visfatin, V500 = 500ng/ml visfatin and I = 10nM insulin (positive control) 
(n=4). 
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6.3.1.4. Time-dependent visfatin regulation of insulin receptor 
phosphorylation 
 
To investigate the time course effect of visfatin on insulin receptor activation, 
200ng/ml of visfatin was used to stimulate the cells at 2, 5, 15, 30 and 60 minutes and 
the cells lysed in lysis buffer supplemented with phosphatase inhibitors and protease 
inhibitors. Visfatin induced insulin receptor phosphorylation after 15 minutes. 
 
 
Figure 6.1.4 Visfatin activation of insulin receptor in mouse βTC-6 cells 
(time course). There was no effect of visfatin on tyrosine phosphorylation of IR 
after 2 and 5 minutes. However, visfatin significantly increased insulin receptor 
phosphorylation at 15, 30 and 60 minutes. The maximal IR tyrosine phosphorylation 
was observed after 15 minutes (P < 0.001) and remained significantly higher than 
basal for 60 minutes (p<0.05). Cells were stimulated with insulin (positive control) 
for 15 minutes. Insulin receptor phosphorylation was determined by specific enzyme-
linked immunosorbent assay (ELISA) kit. Values are mean ± SEM, n=4. 
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6.3.1.5. The effect of FK866 on visfatin induced insulin 
receptor phosphorylation 
 
To test whether NMN, a visfatin reaction product is involved in visfatin–IR activation 
in the β-cells, the cells were treated with visfatin and FK866 (a potent visfatin 
inhibitor) for 15 minutes. Co-incubation of visfatin and FK866 significantly 
suppressed the activation of IR induced by visfatin compared to the cells stimulated 
with visfatin alone (p<0.05). These data indicate that IR activation by visfatin in the β 
cells is mediated by NMN. 
 
 
            
 
Figure 6.1.5 FK866 induced reduction in visfatin activation of the insulin 
receptor. βTC-6 cells were incubated with visfatin alone or co-incubated with 
200ng/ml visfatin and 10nM FK866 for 15 minutes and lysed in cell lysis buffer 
supplemented with phosphatase inhibitors and protease inhibitors. The effect of 
FK866 on visfatin induced IR phosphorylation was determined by specific enzyme-
linked immunosorbent assay (ELISA) kit. FK866 significantly reversed the effects of 
visfatin induced insulin receptor activation. n=4 
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6.3.1.6. Time-dependent activation of insulin receptor by NMN  
 
Because the stimulatory effect of visfatin on insulin receptor activation was reversed 
by FK866 (Figure 6.1.5.), it was vital to examine the effect of NMN (visfatin reaction 
product) whose production is inhibited by FK866 in the NAD+ biosynthetic pathway.  
 
 
Figure 6.1.6 NMN time-response curves for insulin receptor activation in 
mouse βTC-6 cells. NMN induced an increase in IR phosphorylation in a similar 
trend to visfatin with the maximal effect attained after 15 minutes (P<0.001). Insulin 
receptor phosphorylation was determined by specific enzyme-linked immunosorbent 
assay (ELISA) kit. Cells were stimulated with insulin (positive control) for 15 
minutes (n=4). 
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6.3.1.7. Visfatin and extracellular signal-regulated kinase (ERK 
1/2) activation 
 
Visfatin has previously been shown to cause activation of the ERK1/2 in endothelial 
cells (Adya et al., 2008b). The effect of visfatin on ERK1/2 activation in the β-cells 
was thus investigated. The cells were exposed to 200ng/ml visfatin at varying times 
(0, 2, 5, 15, 30 and 60 minutes) and phosphorylated, active ERK 1/2 was detected 
using specific enzyme-linked immunosorbent assay (ELISA) kit. PMA was used as a 
positive control. 
 
 
 
Figure 6.1.7 Time-dependent activation of ERK1/2 by visfatin. As shown in 
figure 6.1.7, treatment of cells with 200ng/ml visfatin caused a significant 122% 
increase ERK1/2 phosphorylation after 15 minutes (P<0.001). The level of 
phosphorylated active ERK1/2 was subsequently decreased, and had reached nearly 
the basal level by 60 minutes. Cells were stimulated with PMA (positive control) for 
15 minutes.n=4  
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6.3.1.8. Time-course response of NMN and ERK 1/2 activation  
 
To further elucidate the role of nicotinamide mononucleotide (NMN) which is a 
visfatin reaction product in the NAD biosynthetic pathway, the cells were stimulated 
with NMN for 15 minutes and activity of ERK 1/2 analyzed.  
 
 
 
Figure 6.1.8 Time response curves of ERK 1/2 activation by NMN. The 
cells were stimulated with 100µM NMN at varying times (0, 2, 5, 15, 30 and 60 
minutes). NMN stimulation resulted in ERK 1/2 phosphorylation with the maximal 
effect (105% increase compared to basal) attained after 15 minutes (p<0.01). This 
transient increase in ERK ½ activation is consistent with the time-course increase in 
visfatin and ERK 1/2 activation as illustrated in Figure 6.1.7. Cells were stimulated 
with PMA (positive control) for 15 minutes. Phosphorylated ERK 1/2 was detected 
using specific enzyme-linked immunosorbent assay (ELISA) kit. PMA was used as a 
positive control. n=4 
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6.3.1.9. Effect of FK866 on visfatin induced ERK 1/2 activation  
 
Visfatin has previously been shown to act as a nicotinamide 
phosphoribosyltransferase (Nampt) and mediates its function via biosynthesis of 
nicotinamide mononucleotide. To test this enzymatic activity of visfatin in ERK 1/2 
activation, the cells were co-incubated for 15 minutes with visfatin and FK866 (a 
specific Nampt inhibitor) and ERK 1/2 activation determined using specific enzyme-
linked immunosorbent assay (ELISA) kit. PMA was used as a positive control. 
.  
 
 
 
Figure 6.1.9 FK866 significantly reduces visfatin induced ERK 1/2 
activation. The cells were co-incubated with 200ng/ml visfatin and FK866 (10nM) 
for 15 minutes. The visfatin-induced increase in phosphorylated active ERK 1/2 as 
observed in Figure 6.1.7 was markedly inhibited by FK866 which has been shown to 
act as a highly selective inhibitor of visfatin and thereby inhibiting synthesis of 
visfatin reaction product (NMN) in the NAD biosynthetic pathway. Cells were 
stimulated with PMA (positive control) for 15 minutes. n=4 
 
 135 
6.3.2.0. Comparison of visfatin and (visfatin + FK866) on ERK 
1/2 activation  
 
Co-incubation of visfatin with 10 nM FK866 significantly inhibited visfatin induced 
ERK 1/2 activation (p<0.01). The level of phosphorylated ERK 1/2 was subsequently 
decreased to nearly the basal level in the (visfatin + FK866) samples compared to the 
samples treated with visfatin alone. 
 
 
 
Figure 6.2.0 Comparative analysis of visfatin treated samples and the 
effect of visfatin inhibitor (FK866) on ERK 1/2 activation. Visfatin treatment 
caused a significant increase in ERK1/2 phosphorylation compared to untreated 
control (p<0.001) however FK866 significantly reduced the effect of visfatin on 
ERK1/2 activation compared to visfatin treatment alone (p<0.01) 
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6.3.2.1. Visfatin and MAPK p38 activation 
 
Visfatin has previously been implicated in inflammatory response ((López-Bermejo et 
al., 2006). p38 mitogen-activated protein kinases (MAPK) are a class of MAPK’s 
which are responsive to stress stimuli and activated by a variety of cellular and 
external stress signals including inflammatory cytokines (Kumar et al., 2003). To 
examine whether visfatin’s role in inflammatory response is mediated by MAPK 
signalling pathway, βTC-6 cells were stimulated with 200ng/ml visfatin at varying 
time points.  
 
 
 
Figure 6.2.1 Time response curves of MAPK p38 activation by visfatin. 
No significant effect of 200ng/ml visfatin was seen on p38 activation compared to 
basal. Phosphorylated p38 was detected using specific enzyme-linked immunosorbent 
assay (ELISA) kit. Cells were stimulated with PMA (positive control) for 15 minutes 
n=4. 
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6.3.2.2. Visfatin regulation of on insulin secretion (low 
glucose). 
 
The effect of visfatin on the insulin secretory response of β-cells at a sub-stimulatory 
glucose concentration (2.25mM) was examined. The β-cells were pre-incubated in 
2.25mM glucose and varying concentrations of visfatin (0 – 200ng/ml), visfatin 
200ng/ml + FK866 inhibitor (200 + F) and visfatin 200ng/ml + UO126 inhibitor (200 
+ U) for 1 hour and insulin content assayed using proprietary Mouse insulin ELISA 
kit. 
 
 
 
Figure 6.2.2 Effect of visfatin on insulin release from clonal pancreatic 
mouse βTC-6 cells at low glucose. The exposure of the mouse βTC-6 cells to 
25, 50 and 100ng/ml visfatin did not elicit any secretory response however 200ng/ml 
visfatin evoked significant increase in insulin secretion compared to untreated cells 
(p<0.01). The stimulatory effect of 200ng/ml visfatin on insulin secretion was 
significantly blocked by co-incubation with FK866 (visfatin inhibitor). Co-incubation 
with U0126 (ERK 1/2 inhibitor) did not significantly alter the effects of 200ng/ml 
visfatin on β-cell insulin secretion compared to visfatin alone. Incubation period was 
1 hour. n=6. 
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6.3.2.3. Visfatin regulation of insulin secretion (high glucose) 
 
The effect of visfatin on insulin secretion in elevated glucose conditions (22mM) was 
investigated. In contrast to low glucose conditions, visfatin did not stimulate insulin 
secretion from βTC-6 cells at elevated glucose concentrations.  
              
 
 
Figure 6.2.3 Effect of visfatin on insulin release from clonal pancreatic 
mouse βTC-6 cells at high glucose. The β-cells were incubated for 1 h at 37°C 
in serum free media containing 22 mM glucose and varying concentrations of visfatin 
(0 – 200ng/ml). The media from this last treatment was then collected and assayed for 
insulin content using a proprietary Mouse insulin ELISA. n=6. 
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6.3.2.4. NMN regulation of insulin secretion (low glucose) 
 
Finally, the effect of NMN on insulin secretion was evaluated. Incubation with 10 and 
100 µM NMN caused small but non-significant increase in insulin secretion at low 
glucose. 200ng/ml visfatin was used as a positive control and elicited a significant 
increase in insulin secretion compared to untreated control (p<0.05), n = 5. 
 
 
 
Figure 6.2.4 Effect of NMN on insulin release from clonal pancreatic 
mouse βTC-6 cells at low glucose. The β cells were incubated in for 1 h at 37°C 
in serum free media containing 2.25 mM glucose and varying concentrations of NMN 
(1 – 100µM) and 200ng/ml visfatin. The media from this last treatment was then 
collected and assayed for insulin content using a proprietary Mouse insulin ELISA. 
Key: C=control, N1=1µM NMN, N10=10µM NMN, N100=100µM NMN and 
V200=200ng/ml Visfatin. n=5. 
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6.4. Discussion 
 
Visfatin has been recognized as a potential regulator of glucose homeostasis and 
mediator of obesity-associated insulin resistance (Chen et al., 2006; Haider et al., 
2006b). Visfatin mRNA has previously been detected in human adipocytes (Berndt et 
al., 2005). The results outlined in this study demonstrate the existence of the visfatin 
mRNA transcript and translated protein in the pancreatic β-cells. The high expression 
of visfatin mRNA and protein in the β-cells suggests that the functions of this 
adipokine are not restricted to the adipose tissue or muscle but also involves other 
endocrine organs and thus may act locally in the β-cells as a paracrine / autocrine 
compound. 
 
The existence of visfatin mRNA and protein in the β-cells is of particular interest 
since elevated levels of visfatin has been reported in patients with type 2 diabetes 
(Chen et al., 2006). Sun et al., have recently reported that over-expression of visfatin 
in rats (in vivo) improves insulin sensitivity with notable increase in tyrosine 
phosphorylation of insulin receptor substrate-1 (Sun et al., 2009). On the other hand, 
tumour necrosis alpha-α (TNF-α); an adipokine known to potently induces insulin 
resistance (Stephens & Pekala 1991; Spiegelman & Flier 2001) has been shown to 
suppresses visfatin gene expression in 3T3-L1 adipocytes (Kralisch et al., 2005b). 
Thus, the high expression of visfatin in the β cells may have a possible regulatory 
effect on β-cell function. Further studies focusing on the identification of a potential 
cellular receptor are needed and the signalling pathways involved in its activity. 
 
Initial reports regarding visfatin’s insulin-mimetic effects such as lowering the plasma 
glucose levels and activation of insulin signalling pathway have since remained 
controversial due to conflicting reports (Fukuhara et al., 2005; Xie et al., 2007; 
Revollo et al., 2007b; Sun et al., 2009). In this study, the action of visfatin on insulin 
receptor activation was investigated. The results outlined in figure 6.1.3 show that 
visfatin treatment of clonal mouse βTC-6 cells resulted in increased insulin receptor 
tyrosine phosphorylation compared to untreated controls. This finding is consistent 
with a recent report by Xie H. and co-workers who demonstrated that visfatin induced 
tyrosine phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1) 
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and insulin receptor substrate 2 (IRS-2) in human primary osteoblasts (Xie et al,. 
2007). The magnitude of the effects of visfatin at 50ng/ml on IR activation was 
similar to those seen with insulin and suggests that visfatin may have comparable 
effect to insulin receptor as insulin at this concentration. 
  
Time dependant effect on IR phosphorylation by visfatin in βTC-6 cells was also 
determined using specific enzyme-linked immunosorbent assay (ELISA). Visfatin 
stimulation of the β-cells caused a significant phosphorylation of IR as illustrated in 
Figure 6.1.4 with the maximal effect observed after 15 minutes incubation and 
increased receptor phosphorylation was maintained for 45 minutes. The observed 
effect of visfatin on insulin receptor makes it a potential therapeutic target for insulin 
sensitizing drugs. In one study; rosiglitazone and fenofibrate, commonly used insulin 
sensitizing drugs have been shown to increase the expression of visfatin mRNA in 
visceral fat deposits of Otsuka Long–Evans Tokushima fatty (OLETF) rats (Choi et 
al., 2005). These drugs increased intra-cellular visfatin expression however the 
increase in beta-cell insulin receptor phosphorylation illustrated in this study was due 
to administered (extracellular) visfatin.  
 
However based on the effects of visfatin on insulin receptor (IR) phosphorylation 
illustrated in this study, it is interesting to speculate that the ability of these drugs to 
alleviate dyslipidemia, hyperglycaemia, and insulin resistance in animal models of 
obesity and T2D (Oliver Jr et al., 2001; Wang et al., 2003) could potentially be 
through regulation of visfatin expression. Characterizing the interaction process of 
visfatin-IR activation will be an important next step in an attempt to understand the 
pathways involved in the interaction and also identify possible novel targets for the 
development of anti-diabetic therapy. Further studies are also needed to elucidate the 
effects of intracellular visfatin on insulin receptor phosphosrylation. 
 
As reviewed in the introduction chapter, the involvement of NAD+ biosynthesis in the 
regulation of β-cell function has been established by many groups. Visfatin has 
previously been shown to catalyse the rate-limiting step in the NAD+ biosynthetic 
pathway (Revollo et al., 2004). Visfatin inhibitor FK866 non-competitively binds the 
enzymatic region of visfatin which normally binds nicotinamide thus preventing 
synthesis of NMN which is an intermediate in NAD+ biosynthesis (Kim et al., 2006). 
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The involvement of this enzymatic action in visfatin induced phosphorylation of 
insulin receptor was examined. Briefly cells were treated with FK866 and IR activity 
analysed. 
 
As illustrated in Figure 6.1.5, the ability of visfatin to stimulate IR phosphorylation 
was significantly inhibited effectively by co-incubation with FK866. Reduced 
phosphorylation of IR in the presence of FK866 compared with visfatin treatment 
alone demonstrates a possible inhibition of NMN biosynthesis suggesting visfatin 
enzymatic function and intracellular NAD+ content is involved in mediating this 
process. This observation suggests that visfatin elicits its actions on the insulin 
receptor (atleast in part) via the NAD biosynthetic pathway. To gain more insight into 
the mechanism of action of visfatin on IR activation, the cells were incubated with 
NMN and time-dependent effects on IR phosphorylation were analysed. As illustrated 
in Figure 6.1.6, β-cell stimulation with NMN resulted in a significant increase in 
phosphorylation of IR compared to basal. Moreover, the effect of NMN on IR 
phosphorylation correlated with the observed time course effect of visfatin on IR 
phosphorylation adding further weight to the suggestion that the NAD biosynthetic 
pathway is a key mechanism underpinning this observation. Based on the effects of 
FK866 on IR phosphorylation, it is clear that visfatin function in the β-cell is via its 
enzymatic activity.  
 
Visfatin has previously been shown mediate some of its actions (e.g. angiogenesis) 
via activation of mitogen-activated protein kinase ERK1/2 dependent pathway (Kim 
et al., 2007). The MAPK family of protein kinases are major signalling systems used 
by cells to transduce diverse intracellular signals and regulation of cellular processes. 
However, activation of MAPK by visfatin in the β-cells has not been previously 
described. As illustrated in Figure 6.1.7, visfatin induced activation of ERK1/2 in the 
β-cells with the maximal stimulatory effect observed after 15 minutes of incubation, 
however this effect subsided to near basal after 60 minutes. 
 
Because of the potent effect of FK866 observed in reversing visfatin induced IR 
activation, the possible effect of this inhibitor in enzymatic activity of visfatin in ERK 
activation was examined. As illustrated in Figure 6.1.9, co-incubation with FK866 
significantly blocked visfatin induced activation of ERK1/2 compared to visfatin 
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alone. The diminished phosphorylation of ERK1/2 by visfatin resulting from 
treatment with FK866 suggests that NMN or the NAD+ pathway are necessary for 
ERK1/2 activation in these cells. Treatment with NMN itself resulted in a significant 
activation of ERK1/2, further confirming the involvement of NMN in the ERK1/2 
activation process.  
 
Recently, studies have implied that visfatin may emerge as an element in the 
regulation of inflammation. Oki et al., demonstrated that serum visfatin levels are 
positively correlated with the serum levels of interleukin-6 (IL-6) and C-reactive 
protein (CRP) both of which are inflammatory markers (Oki et al., 2007). Other 
investigations have shown that visfatin induces the production of IL-6 and TNF-α in 
human monocytes (Moschen et al., 2007). These the associations between markers of 
inflammation and visfatin indicate that circulating visfatin may reflect inflammation 
status. A report indicating an increase in serum visfatin with progressive β-cell 
deterioration suggests it may be involved with inflammatory processes in the β-cells 
(López-Bermejo et al., 2006).  
 
To gain insight into the mechanisms by which visfatin promotes inflammatory 
process, the effect on MAPK signalling was examined. p38 MAPKs are members of 
the MAPK family that are activated by a variety of environmental stresses and 
proinflammatory stimuli and involved in mediating various inflammatory processes 
(Furukawa et al., 2003). Selective inhibition of p38 MAPK has previously been 
shown to reduce TNF-alpha and free fatty acids (FFAs) induced inflammation (Ju et 
al., 2003; Chai et al., 2007). As illustrated in Figure 6.2.1, visfatin did not induce p38 
activation in the β-cells suggesting that p38 signalling does not mediate visfatin-
induced inflammation. 
 
Visfatin has previously been suggested to play a role in regulating insulin secretion 
(Revollo et al., 2007b). The observations illustrated from this report were however 
based on intracellular actions of visfatin as opposed to administered visfatin. In the 
present study the role of visfatin in regulating insulin secretion in-vitro was examined. 
Between 5 and 100ng/ml, visfatin did not elicit any effect on insulin secretion at low 
glucose, however at the higher concentration of 200ng/ml there was a significant 50% 
increase in insulin secretion compared to untreated cells (p<0.01). Although this is a 
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relatively small increase in insulin secretion, it is still within a range which makes it 
physiologically relevant. This observation demonstrates that at low glucose condition, 
visfatin is a potential secretagogue of insulin secretion in mouse β-cells.  
 
The findings illustrated in the previous paragraph provide new insight into the 
molecular functions of visfatin in glucose metabolism. The present study provides 
evidence demonstrating that visfatin regulates insulin secretion in the pancreatic β-
cells. The low concentrations of visfatin did not induce insulin release from the β-
cells; however increasing the dosage of visfatin to 200ng/ml conveys beneficial 
effects on glucose homeostasis due to the enhanced insulin secretion. The high 
visfatin expression in the beta-cells and the regulatory effect on insulin secretion 
makes it a potential target for therapeutic interventions for the prevention and 
treatment of obesity induced insulin resistance. 
 
The intracellular signalling pathways involved in the visfatin-induced modulation of 
insulin release were investigated using pharmacological inhibitors of NAD+ 
biosynthesis and MAPK activity, all of which are known to be important in the β-cell. 
Previous studies have shown that activation of MAPKs is closely involved in insulin 
transduction pathways and glucose stimulated insulin secretion (Frödin et al., 1995). 
Co-incubation with visfatin inhibitor FK866 significantly blocked visfatin induced 
increase in insulin secretion (p<0.01). Co-incubation with the ERK1/2 signalling 
pathway inhibitor UO126 however did not alter the effects of visfatin on insulin 
secretion. This result suggests that although MAPK may be activated by visfatin as 
illustrated in Figure 6.1.7, this pathway is not mechanistically involved in visfatin 
induced insulin release. 
 
The observed effect of co-incubation with visfatin and FK866 suggests that visfatin 
regulation of insulin secretion is mediated by its ability to synthesize NMN since 
FK866 non-competitively binds the enzymatic region of visfatin which normally 
binds nicotinamide (the substrate in mammalian NAD biosynthesis). In order to 
confirm this observation, the β-cells were stimulated with NMN in similar conditions 
to visfatin and effect on insulin secretion determined. As illustrated in Figure 6.2.4, 
NMN did not significantly increase insulin secretion in the βTC-6 cells. This suggests 
the involvement of a more complex mechanism in mediating the actions of visfatin in 
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insulin secretion. It is thus possible that, in addition to blocking the ability of visfatin 
to bind nicotinamide as previously described (Kim et al., 2006) FK866 also blocks 
other pathways which are yet to be identified e.g. additional metabolites to NMN.  
  
The effect of visfatin incubation in the presence of high glucose concentrations was 
also examined. As illustrated in Figure 6.2.4, visfatin did not elicit any effect on 
insulin secretion at any of the treatment concentrations used. It is unclear why visfatin 
evoked a strong stimulatory effect on insulin secretion at low glucose and not at high 
glucose although it is possible that increases were masked by glucose-induced 
changes in basal secretion. 
 
In conclusion, the observations outlined in this study suggest that visfatin has a 
regulatory role in beta-cell function and insulin receptor signalling, possibly through 
NAD biosynthetic activity. The high mRNA expression of visfatin in the β-cells and 
its ability to activate IR makes it a potential useful target for future drug therapies of 
T2D especially insulin-sensitizing drugs. The effect of visfatin on insulin secretion is 
evident from the results outlined in this study however the mechanism by which 
visfatin elicits this effect is unclear. Further investigation will be necessary to test 
potential pathways involved in this process. 
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and Future Work 
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7.1. Final Discussion 
 
Previously, the role of adipose tissue was considered to be little more than inert and 
passive storage for fat during times of caloric excess. However, in recent years it has 
become increasingly apparent that adipose tissue, besides storing the excess dietary 
energy in the form of triglycerides, is a very active secretory organ (Kim et al., 2000). 
The number of adipose tissue secreted factors/adipokines has expanded rapidly ever 
since the initial discovery of adipsin (Siiteri et al., 1987) and leptin (Zhang et al., 
1994). Some adipokines have been shown to exert inflammatory response leading to 
the development of insulin resistance associated with obesity (Hotamisligil et al., 
1994; Pradhan et al., 2001) while others have been shown to be protective against 
insulin resistance and T2DM (Berg et al., 2001; Combs et al., 2001; Steinberg et al., 
2002).  
 
At the onset of this study, there was very little published data regarding the effects of 
resistin and visfatin in the beta cell, with only conflicting reports existing over the role 
of resistin in beta cell function. The initial experimental aim of this study was thus to 
clarify the role of resistin and visfatin in the regulation of beta cell function, viability 
and key genes involved in beta cell function. This would hopefully provide an insight 
into the roles of these adipokines in beta cell function (or dysfunction) and a basis for 
subsequent investigation. 
 
As discussed in chapter three, resistin treatment at 20ng/ml which is the reported 
concentration in lean non-diabetics significantly increased β-cell viability over 24 
hours however a higher dose of 40ng/ml which is the reported concentration in 
obesity and diabetic patients did not promote viability of the β-cells. This observed 
effect on viability was not associated with suppressed cell death under serum-
deprived conditions, but rather with increased proliferation. This outcome was 
consistent with previous reports which indicated similar proliferative effects in 
endothelial cells (Verma et al., 2003; Mu et al., 2006). The action elicited by resistin 
is crucial for the beta cell function since dysregulation of β-cell proliferation has 
previously been shown to be a crucial feature in the pathogenesis of type 2 diabetes 
(Ackermann et al., 2007). These effects are also critical to sustaining the secretory 
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function of the β-cells and maintain normoglycaemia. Adipose tissue is also one of 
the target organs for insulin. As such, these observations highlight a possible 
mechanism by which adipose tissue secreted factors contribute to β-cell survival thus 
fulfilling its primary role of insulin secretion to meet increased demand from enlarged 
adipose cell. 
 
Visfatin did not have any effects on β-cell viability at the low concentration however 
supraphysiological visfatin concentrations significantly reduced β-cell viability. This 
shows that the low circulating concentration of visfatin do not regulate β-cell mass 
however the supraphysiological concentrations have a negative regulatory effect in-
vitro. Previous reports have indicated that circulating visfatin concentrations is lower 
in healthy young subjects compared to those in patients with diabetes (Chan et al., 
2006; Haider et al., 2006a; Haider et al., 2006b; Krzyzanowska et al., 2006a). It is 
thus possible that the low circulating visfatin concentrations do not elicit any effect on 
beta cell survival however subsequent increase in concentration as those observed in 
diabetes and obesity have pathological consequences.  
 
In a recent study, serum visfatin concentrations were shown to increase with 
progressive β-cell deterioration (López-Bermejo et al., 2006), suggesting this 
adipokine may be involved with inflammatory processes in the β-cells. Even though 
most reports of the circulating levels of visfatin are well below these concentrations 
(400 and 500ng/ml), some studies have suggested far higher circulating 
concentrations of visfatin (Chan et al., 2007). The observed effect on cell viability is 
thus significant as progressive deterioration of β-cell function is often associated with 
a loss of β-cell mass (Prentki and Nolan, 2006) which subsequently affects secretory 
capability of the pancreatic islet. 
 
Resistin has been demonstrated to exert a wide range of effects including regulation 
of metabolic pathways such as glucose and lipid metabolism (Steppan et al., 2001; 
Palanivel et al., 2006). Regulation of these processes involves controlling the proteins 
implicated in these pathways both at mRNA translation level and the respective gene 
expression level. Recent advances in genomic analysis technology have led to 
identification of genetic profile alterations of important genes involved in glucose 
metabolism and subsequent consequences in pathogenesis of T2D. As demonstrated 
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in previous studies, defects in the expression of genes involved in glucose 
homeostasis may be important in the aetiology of T2D (Garvey et al., 1992; 
Pendergrass et al. 1998; Ducluzeau et al., 2001). 
 
In this study, resistin treatment resulted in significant alterations in the expression 
profiles of key genes involved in β-cell function. From the results illustrated in 
chapter 4, it is clear that the IL-6 and MAPK-8 mRNA expressions are profoundly 
increased in the β-cells after resistin treatment. Interleukin-6 is known to induce 
insulin resistance while MAPK-8 negatively affects insulin signalling. The observed 
alteration in the mRNA expression of these molecules by resistin highlights a possible 
pathway by which resistin induces insulin resistance in mouse beta cells. It is 
important to note that fatty acid induced insulin resistance is mediated by MAPK-8 
(Solinas et al., 2006) further illustrating the significance of this signalling molecule as 
a mediator of β-cell dysfunction. 
 
Resistin treatment produced changes in the mRNA levels of a few selected enzymatic 
genes. Among the genes under investigation, the mRNA expression for glucose-6-
phosphate dehydrogenase (G6pd2) and Glucose-6-phosphatase (G6pc) were 
significantly up-regulated. Upregulation of G6pc and overexpression of G6pd2 has 
previously been shown to result in increased hepatic glucose output and obesity 
induced lipid metabolism disorders respectively (Park et al., 2005). In the beta cells, 
overexpression of the glucose-6-phosphatase has previously been shown to attenuate 
glucose sensitivity of insulin secretion (Iizuka et al., 2000). Glucocorticoid treatment 
has also been shown to inhibit glucose-induced insulin release via stimulation of G6pc 
activity in the beta cells (Ling et al., 1998). Glucose-6-phosphatase thus appears to be 
an important mediator of GSIS.  Enlarged adipose tissue which leads to altered 
adipokine secretion in this case resistin may result in induction of these genes 
regardless of the metabolic state. The increased mRNA levels of these genes 
illustrates novel ways by which elevated concentrations of resistin regulates beta cell 
function and the pathological effect of increased adiposity on beta cell function.   
 
Based on these observations, it is apparent that resistin modulates a variety of 
transcriptional changes in the beta cells, which represents the molecular basis of its 
action in the beta cells e.g. the effect on insulin receptor expression as illustrated in 
 150 
chapter 3. The resistin concentration exerting these genetic alterations is similar to 
that reported in obese and T2D (Fehmann et al., 2002; Zhang et al., 2003) and thus 
highlights a possible mechanism by which the regulation of a cluster of genes 
involved in insulin action and glucose metabolism may be affected by altered 
adipokine production and secretion. 
 
In addition to resistin, visfatin treatment resulted in significant changes in the 
expression profiles of key beta cell genes. Visfatin treatment resulted in down-
regulation of Mapk8 mRNA and the up-regulation of Akt2. These are important 
signalling molecules in glucose homeostasis and alteration in expression or activity 
could have serious ramifications. Akt2-deficient mice have previously been shown to 
exhibit insulin resistance and mild diabetes (Cho et al., 2001) while activation of this 
molecule in response insulin positively influences glucose metabolism (Brazil and 
Hemmings, 2001). The 24 fold increase of Akt2 mRNA shows that visfatin has a high 
potency in regulating the gene expression level of Akt2 and may have a therapeutic 
advantage in improving insulin sensitivity in the beta-cells. 
 
Conversely MAPK8 has been shown to increase the serine phosphorylation of insulin 
receptor substrate-1 (IRS-1) which in effect inhibits insulin-stimulated tyrosine 
phosphorylation of IRS-1 (Aguirre et al., 2000). From the results in Table 4.2, it is 
clear that visfatin significantly reduced Mapk8 mRNA expression by -1.122 fold. In a 
recent study, visfatin was shown to improve insulin sensitivity and insulin receptor 
substrate tyrosine phosphorylation in rodents (Sun et al., 2009). This report is 
consistent with the results illustrated in chapter 6 (Figure 6.1.4) which shows that 
visfatin activates insulin receptor in the β-cells. The observed effects of visfatin have 
the potential to improve insulin sensitivity and reverse obesity induced insulin 
resistance. It is thus possible that the actions of visfatin as illustrated by Sun et al., 
and in Figure 6.1.4 of this study could be mediated by induction of Akt2 gene and 
suppression of MAPK8 mRNA expression. 
 
Visfatin treatment also resulted in an 8-fold increase in insulin mRNA. The 
transcription and subsequent translation of insulin gene is important in maintaining 
sufficient insulin supply after repeated glucose challenges. The upregulation of insulin 
mRNA by visfatin is of great significance as induction of insulin gene is a key step in 
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restoring normal blood glucose levels during hyperglycaemia. Consistent with the 
visfatin effect on insulin gene was a decrease in UCP-2 and PPAR-α mRNA 
expression in the β-cells all of which are known to be involved in suppression of 
insulin secretion in response to glucose (Chan et al., 1999; Tordjman et al., 2002). 
These observations shed light on the possible processes involved in visfatin induced 
insulin secretion as illustrated in Figure 6.2.2 of chapter 6. In addition to this, there 
was a significant increase in key transcription factors HNF4-α and Tcf2 as a result of 
visfatin treatment. This is significant and consistent with the observed effects on 
insulin and UCP-2 genes as both HNF4-α and Tcf2 are both involved in insulin gene 
transcription (Bernardo et al., 2008). It also further highlights a possible pathway by 
which visfatin causes an increase in insulin secretion as observed in Figure 6.2.2. 
 
The observations illustrated in chapter 5 paint a picture of a potential role of resistin 
in the pathophysiology of insulin resistance and T2D. The results outlined in the 
present study show that insulin receptor expression both at mRNA and protein level is 
downregulated by resistin. Several mechanisms by which obesity influences insulin 
resistance have been suggested in recent years. The reported physiological 
concentration of resistin (20ng/ml) did not have any effect on insulin receptor 
expression; however the elevated concentrations (40ng/ml) elicited this negative 
response (Figure 5.4 and 5.5). It is now clear from previous studies that increased 
adipose tissue mass results in altered adipokine production (Weyer et al., 2000; Skurk 
et al., 2007). The negative effects on insulin receptor expression by elevated resistin 
concentrations illustrate how increased adiposity negatively regulates insulin receptor 
expression and highlights a possible link between obesity and insulin resistance. 
 
The result illustrated in Figure 5.1 show that resistin mRNA is highly expressed in the 
beta cells.  The high expression of resistin in the beta cells and the effects on insulin 
receptor expression illustrate a potential role of this adipokine in the pathophysiology 
of T2D. Multiple defects in insulin signalling transduction pathways e.g. reduced 
insulin receptor expression levels and tyrosine kinase activity have been identified as 
major contributory factors to insulin resistance (Leng et al., 2004; Musi et al., 2006). 
It is thus possible that resistin induced insulin resistance in the pancreatic islets 
(Nakata et al., 2007) is mediated by its ability to reduce insulin receptor expression in 
the beta cells as illustrated in this study. This is consistent with a previous report 
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which demonstrated that serum resistin is increased in T2D subjects (McTernan et al., 
2002a) highlighting a link between elevated levels and T2D. Initial studies by Steppan 
et al., showed that circulating resistin levels are decreased by the anti-diabetic drug 
rosiglitazone (Steppan et al., 2001). This makes resistin a potential target for diabetes 
therapy.  
 
Previous studies involving visfatin and the insulin receptor have been controversial. 
Right in the middle of the study, the “Science” journal article (Fukuhara et al., 2005) 
which outlined visfatin as an insulin mimetic adipokine and on which initial 
experiments of this study was based on was retracted. It should be stated however that 
only some of the experiments from this retracted paper were criticised. At this point, 
the experimental results from this study showed that visfatin stimulation resulted in 
activation of insulin receptor and the subsequent question was how. As time 
progressed various reports continued to emerge with some showing visfatin action to 
be similar to insulin (Moschen et al., 2007; Xie et al., 2007) while others suggesting 
the contrary (Pagano et al., 2006). However it was not until Revollo et al., illustrated 
the involvement of NAD+ biosynthetic pathway that visfatin function in the β-cells 
began to become clear (Revollo et al., 2007b). Their study did not find evidence of 
visfatin insulin mimetic activity as previously reported by Fukuhara et al., e.g. 
activation of insulin receptor (Fukuhara et al., 2005) however they demonstrated that 
visfatin induced insulin secretion was via NAD+ biosynthesis.  
 
This study therefore sought to evaluate whether the observed activation of insulin 
receptor was via NAD biosynthesis. As illustrated in Figure 6.1.3 and 6.1.4, visfatin 
activates insulin receptor in the beta-cell in a concentration and time dependant 
fashion. To evaluate the involvement of NAD+ biosynthesis in mediating the actions 
of visfatin in insulin receptor activation, the cells were co-incubated with visfatin and 
specific Nampt inhibitor FK866 and analyzed by phospho-specific insulin receptor 
sandwich ELISA. FK866 significantly reversed the effects of visfatin in activating 
insulin receptor while NMN treatment resulted in activation of insulin receptor, 
demonstrating that the reduced visfatin activity on insulin receptor is due to the lack 
of the NAD+ biosynthetic activity of Nampt. The results presented here demonstrate 
that enzymatic activity of visfatin and not the insulin mimetic activity as previously 
claimed by Fukuhara et al., plays an essential role in activation of insulin receptor. 
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This adipokine is thus a potential pharmacological target in reversing insulin 
resistance.  
 
Visfatin has previously been shown to activate MAPK in other cell types (Adya et al., 
2008b). To test whether this observation extends to the beta cells, βTC-6 cells were 
stimulated with visfatin and the effect on MAPK activity analysed using phospho 
ERK1/2 ELISA. The results in chapter 6 show that visfatin activates ERK1/2 with the 
maximal effect observed after 15 minutes. To test the involvement of NAD 
biosynthesis in this process, the cells were treated with NMN and in a separate 
experiment, co-incubated with the specific NAMPT inhibitor FK866. As illustrated in 
chapter 6, NMN stimulation resulted in activation of ERK1/2 in a similar fashion to 
visfatin however the visfatin induced phosphorylation of ERK1/2 was significantly 
reduced by FK866. This suggests that visfatin effects on ERK1/2 activity are 
mediated by NAD biosynthesis as FK866 non-competitively binds the enzymatic 
region of visfatin which normally binds nicotinamide. This finding is important to the 
beta cell function since increased ERK1/2 activity has previously been shown to 
correlate with glucose stimulated insulin secretion (Frödin et al., 1995). 
 
Most recently, it has been proposed that visfatin plays a key role in the regulation of 
insulin secretion (Revollo et al., 2007b). In this study Revollo et al., showed that 
NMN was able to restore insulin secretion in islets extracted from visfatin knockout 
mice. This conclusion was however drawn on findings based on intracellular actions 
of visfatin, as opposed to administered visfatin. The findings illustrated in chapter 6 of 
this study show that administered visfatin induces insulin secretion in the β-cells and 
thus suggest that visfatin has an vital role both as intra- and extracellular regulator of 
pancreatic beta-cell function. This observation indicate an important physiological 
role for visfatin as a potential regulator of insulin secretion and highlights a role by 
which adipose secreted factors induce insulin secretion to increase metablic activity 
(glucose metabolism) and meet increased energy resulting from obesity. 
 
As previously illustrated in chapter 6, the MAPK ERK1/2 are significantly activated 
by visfatin (p=0.001). The potential requirement for ERK activity and visfatin 
enzymatic activity in insulin secretion was examined. The cells were co-incubated 
with ERK1/2 inhibitor U0126 and Nampt inhibitor FK866. As illustrated in chapter 6, 
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U0126 co-incubation did not significantly alter the effects of 200ng/ml visfatin on 
insulin secretion compared to visfatin alone. Insulin secretion occurred normally in 
these experiments even when ERK activity was blocked demonstrating that visfatin 
induced insulin secretion is not mediated by MAPK signalling. 
 
Co-incubation with FK866 however significantly blocked this increase in insulin 
secretion induced by visfatin (p<0.01). This result implies that visfatin effect on 
insulin secretion is mediated by its ability to synthesize NMN however NMN on its 
own did not significantly increase insulin secretion in the beta cells, suggesting the 
possible existence of additional signalling pathway or the possibility that FK866 
blocks visfatin in other ways. The nature of this postulated additional signal is still not 
known, although the results illustrated in chapter 6 have ruled out involvement of the 
MAPK ERK1/2 pathways in visfatin induced insulin secretion. This outcome suggests 
a more complex mechanism for the actions of visfatin on insulin secretion which 
remains to be established. 
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7.2. Conclusion 
 
The identification of resistin mRNA in the beta cells show that the role of this 
adipokine is not restricted in the adipose tissue but also other endocrine organs. The 
effect of resistin in promoting cell viability illustrates the role of this adipokine in 
regulating beta cell mass. It is clear from this study that resistin promotes beta cell 
survival and may prove protective to the beta cells when subjected to stress. In this 
study, resistin downregulated insulin receptor expression both at transcription and 
translation level suggesting a potential link between increased adiposity and insulin 
resistance. Te high resistin mRNA expression in the β-cells suggests that resistin 
might be having paracrine or autocrine effects. 
 
Visfatin is also highly expressed in the beta cells and like resistin is not restricted to 
the adipose tissue but other endocrine organs. The high visfatin concentrations 
significantly reduced β-cell viability suggesting that the elevated concentrations as 
those observed in obesity and T2D have a negative regulatory effect on beta cell 
survival. Visfatin stimulation of the beta cells resulted in activation of the insulin 
receptor via NAD+ biosynthesis. This result demonstrates that the ability of visfatin to 
activate insulin receptor is not due to the insulin mimetic properties as previously 
suggested by Fukuhara et al., but rather enzymatic. Visfatin treatment of the beta cells 
in low glucose induced insulin secretion however the process seems to be mediated by 
a more complex mechanism which may involve a known or unknown signalling 
molecule. It is clear from this study that resistin has a potential role linking obesity 
and insulin resistance while visfatin could potentially improve insulin sensitivity due 
to its effects on insulin receptor and also play a critical role in regulating insulin 
secretion in the beta cells. 
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7.3. Future work 
 
It is slightly clear based on the results of this study how resistin and visfatin might be 
working in the beta cells or in any of the cell types discussed in the introductory 
chapter. These adipokines are presumably acting by binding to their respective 
putative receptors or by making NMN in the case of visfatin. Further work is thus 
needed to clearly identify these receptors. To further unravel the physiological roles 
of these adipokines, in the case of resistin; future studies should involve the use of 
beta cell-specific resistin knockout mice to determine the contribution of this 
adipokine in beta cell function and the phenotype of type 2 diabetes e.g. insulin 
resistance. Additional experiments examining the subcellular localisation of visfatin 
and resistin in the beta-cell will also be vital in understanding the roles of these 
adipokines in beta cell function. 
 
Although SOCS-3 and MAPK signals are known to mediate major actions of resistin 
in various cell types, it is possible that many other pathways exist in the resistin 
signalling. Due to the effect of resistin on insulin receptor expression as illustrated in 
chapter 5, it would be important to clarify the mechanism by which putative resistin 
receptor and insulin receptor signal transduction systems could cross-talk with each 
other. Further analysis will be necessary to clarify this potential interaction. 
 
Resistin treatment resulted in increased viability of the beta cells. Various signalling 
molecules are involved in cell proliferation and the different forms of cell death 
including apoptosis and necrosis. These factors play a crucial role in beta cell 
survival. Additional studies will be necessary to further delineate molecular 
mechanisms responsible for resistin-induced increase in viability of the beta cells. 
 
The data in chapter 6 show that visfatin induces insulin secretion. This effect was 
reversed by visfatin inhibitor FK866. As previously illustrated, FK866 non-
competitively binds the enzymatic region of visfatin which normally binds 
nicotinamide thus preventing synthesis of NMN which is an intermediate in NAD 
biosynthesis. Although the data outlined show that NMN on its own did not induce 
insulin secretion, the results reported here provide evidence that at least one additional 
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signalling pathway is necessary for visfatin function in inducing insulin secretion. 
Further studies should be performed to identify the exact pathways involved in 
visfatin signal. It is also possible that unknown or other known intermediates which 
are inhibited by FK866 are involved in visfatin induced insulin secretion. Additional 
studies should be employed to clarify this. 
 
Glucose-stimulated biphasic insulin secretion involves at least two glucose sensing 
pathways: the KATP channel-dependent and KATP channel-independent pathways. 
Future work should examine whether visfatin and its reaction product NMN have any 
significant effects on KATP channels or other downstream components involved in 
insulin secretion as illustrated in Figure 1.0. 
 
The results in chapter 5 and 6 show that resistin and visfatin are highly expressed in 
the beta cells. Additional studies are needed to identify the factors regulating 
intracellular resistin and visfatin. Since resistin exerts pathological effects at elevated 
concentrations corresponding with those observed in obesity and T2D, selective 
depletion of this adipokine might have a powerful therapeutic impact. Since the effect 
of resistin is not localised to the adipose tissue but rather endocrine, identifying 
factors that reduce the expression and release from adipocytes could potentially alter 
circulating levels and have positive impact in reversing insulin resistance associated 
with increased adiposity.  
 
Visfatin effect in activating insulin receptor makes it a potential target for insulin 
sensitizing pharmacological agents. The described relationships of rodent visfatin 
expression and the observed effect on insulin receptor and MAPK phosphorylation 
illustrated in this study may not readily be translated to humans. Therefore, further 
studies are needed to clarify the role of this adipokine in human metabolism e.g. 
experiments on human islets.  
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Appendices 
 
Appendix 1 
 
Appendix 1.1 Equipment 
 
Block heater                                    Wolf Laboratories, York, UK 
 
Centrifuges                                                                                      M.S.E Mistral 2000,   
       Fisons Instrumentation, U.K. 
 
CO2 incubator                                                                               Jensons Scientific Inc.   
                                                                                            Bridgeville, PA 15017, USA 
 
Coulter counter Z1                  Beckman Coulter limited 
                  High Wycombe, UK 
 
Genequant Pharmacia                                                                    Biotech Inc. NJ, USA 
 
Hybaid PCR Express thermocycler                                              Hybaid, Action Court,   
                                                                                                                 Middlesex, UK 
       
ImageQuant™ TL image analysis software                       GE Healthcare Life Sciences   
                                                                                                     Amersham, Bucks, UK 
 
Inverted microscope Celti,                                                Optical Instruments, Belgium 
 
Labsystems Multiskan MS                                                              Labsystems, Finland 
 
Magnetic Stirrer Hotplate                                               Stuart Scientific, Beacon Road,  
                       Staffordshire, UK 
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Mini-PROTEAN 3 cell           Bio-Rad Laboratories Ltd,                                                         
Electrophoresis system                                              Hemel Hempstead, UK 
                       
Mini Trans-Blot cell                   Bio-Rad Laboratories Ltd,   
    Hemel Hempstead, UK 
 
PhosphorImager™ technology                                          GE Healthcare Life Sciences  
             Amersham, Bucks, UK 
 
Platform Shaker STR6        Stuart Scientific, Beacon Road, 
                                Staffordshire, UK 
 
PowerPac 1000 Power Supply                                               Bio-Rad Laboratories Ltd,  
             Hemel Hempstead, UK 
 
iCycler Real-Time PCR Detection System                          Bio-Rad Laboratories Inc. 
                       Hercules, CA 94547, USA 
 
Rocker                                                                               Wolf Laboratories, York, UK 
 
Vortex                                   Sigma-Aldrich Company Ltd,  
                                                                                                                       Dorset, UK 
 
Water baths                                                             Grant Instruments (Cambridge) Ltd,  
                                                                                                                 Cambridge UK 
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Appendix 1.2 Specialised kits 
 
CellTiter 96 AQueous One Solution                                                          Promega UK, 
Cell Proliferation Assay (MTS) kit.                                                    Southampton, UK 
 
Mouse insulin secretion ELISA kit                                                    Mercodia, Sweden 
 
Mouse Diabetes RT² Profiler™ PCR Array                        SABiosciences Corporation 
            MD 21703, USA 
 
Rat insulin secretion ELISA kit                                                          Mercodia, Sweden 
 
RayBio Cell-Based Phospho-Insulin Receptor B                         RayBiotech, Inc. USA 
ELISA kit 
 
RayBio Cell-Based ERK1/2 (activated)                                       RayBiotech, Inc. USA 
ELISA kit 
 
RayBio Cell-Based p38 MAPK (Thr 180/Tyr 182)                     RayBiotech, Inc. USA 
ELISA kit 
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Appendix 1.3 Reagents and chemicals 
 
Acetone                                                                               BDH Laboratories Supplies,   
                                                                                                                 Poole, England 
 
Albumin from bovine serum           Sigma-Aldrich Company Ltd,   
                                                                                                                       Dorset, UK 
 
Ammonium persulphate          Sigma-Aldrich Company Ltd,   
                                                                                                                       Dorset, UK 
 
AMV reverse transcriptase                                           Promega UK, Southampton, UK 
AMV RT buffer                                                            Promega UK, Southampton, UK 
 
Beta mercaptoethanol                  Bio-Rad Laboratories Ltd 
                                                                                                    Hemel Hempstead, UK                                                                                   
 
Bionic™ Buffer, 10x                Sigma-Aldrich Company Ltd,   
                                                                                                                       Dorset, UK 
 
Complete, Mini Protease Inhibitor Cocktail Tablets             Roche Diagnostics GmbH,  
                                    Mannheim, Germany 
 
D (+) Glucose solution 45%                                             Sigma-Aldrich Company Ltd,  
                                                                                                                       Dorset, UK 
 
DC Protein Assay Kit                                                             Bio-Rad Laboratories Ltd,   
                                                                                          Hemel Hempstead, UK 
 
DMSO                                                                              Sigma-Aldrich Company Ltd,  
                                                                                                                       Dorset, UK 
 
dNTP mix                                                                     Promega UK, Southampton, UK        
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ECL Plus™ Western Blotting Detection Reagent                      GE Healthcare UK Ltd 
                                                                                                     Amersham, Bucks, UK 
 
Ethanol                                                                                BDH Laboratories Supplies,  
               Poole, England 
 
Ethidium bromide                                                             Sigma-Aldrich Company Ltd,   
                                          Dorset, UK 
 
Fetal calf serum                                                                           PAA Laboratories Ltd,  
           Yeovil, UK 
        
Hanks Balanced salt solution                     Sigma-Aldrich Company Ltd,  
                                                                                                                       Dorset, UK 
 
‘Hi-Pure’ Low EEO agarose gels                                    BioGene Ltd., Kimbolton, UK 
 
Human resistin               Cambridge Biosciences Ltd 
                        Cambridge, UK 
 
Hydrochloric Acid                                                              BDH Laboratories Supplies,   
     Poole, England 
 
Hyper Ladder IV – 100bp ladder                                             Bioline Ltd, London, UK 
 
L-glutamine                                                                      Sigma-Aldrich Company Ltd,  
           Dorset, UK 
 
Magnesium sulphate                                                           BDH Laboratories Supplies,   
                                   Poole, England 
 
Methanol                                                                             BDH Laboratories Supplies,  
                   Poole, England 
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β Nicotinamide mononucleotide          Sigma-Aldrich Company Ltd,  
                                                                                                                       Dorset, UK 
 
Non-essential amino acid solution          Sigma-Aldrich Company Ltd,  
                                                                                                                       Dorset, UK 
 
Nuclease-Free Water                                                    Promega UK, Southampton, UK 
 
Oligo (dT) 15 Primer                                                    Promega UK, Southampton, UK 
 
Phosphate buffered saline                                                 Sigma-Aldrich Company Ltd,   
                                                                                                                       Dorset, UK 
Phosphatase inhibitor cocktail                                          Sigma-Aldrich Company Ltd,   
                                                                                                                       Dorset, UK 
 
Penicillin–Streptomycin solution Hybri-Max®              Sigma-Aldrich Company Ltd,   
                                                                                                                       Dorset, UK 
 
Pre-Aliquoted Reddy MixTM PCR Master-Mix                                  Abgene Limited,  
           Epsom, UK 
 
Protein standard                                                               Sigma-Aldrich Company Ltd,  
           Dorset, UK 
 
Protogel (30% solution at 37.5:1 ratio)                    Geneflow UK 
          Staffordshire, UK 
 
Protogel resolving buffer                                           Geneflow UK 
                                           Staffordshire, UK 
 
Protogel stacking buffer                                           Geneflow UK 
                                           Staffordshire, UK 
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2xqPCR Mastermix for iCycler 12.5ml                             Primerdesign Ltd 
plus SYBR Green        Southampton, UK 
 
RNaseZap® RNase Decontamination Solution                              Applied Biosystems,  
                                                                                                                Warrington, UK 
 
RNasin Ribonuclease Inhibitor                                    Promega UK, Southampton, UK                         
                               
RPMI 1640 without Glucose                                                       PAA Laboratories Ltd,  
                                    Yeovil, UK 
 
RPMI 1640 without L-Glutamine                                               PAA Laboratories Ltd,  
                       Yeovil, UK 
Recombinant human visfatin                               Axxora UK LTD 
 
SeeBlue® Plus2 Pre-Stained Standard                               Invitrogen Ltd., Paisley, UK 
 
Sodium bicarbonate                                                          Sigma-Aldrich Company Ltd,  
                       Dorset, UK  
 
Sodium pyruvate solution                                                 Sigma-Aldrich Company Ltd,  
                                        Dorset, UK                            
 
Sodium Chloride                                                              Sigma-Aldrich Company Ltd,  
           Dorset, UK 
 
Sodium phosphate monobasic dihydrate                            BDH Laboratories Supplies,   
                           Poole, England 
 
SV Total RNA Isolation System        Promega UK, Southampton, UK 
                             
TEMED                                                                            Sigma-Aldrich Company Ltd,  
                       Dorset, UK 
 
 197 
Tissue culture plasticware                                                                   Becton-Dickinson   
           Franklin Lakes, NJ 
 
Tris buffered saline                                 Sigma-Aldrich Company Ltd,  
                                        Dorset, UK 
 
Tris buffered saline (with tween)                                     Sigma-Aldrich Company Ltd,  
                                        Dorset, UK 
 
Tris/Glycine/SDS running buffer                                                              Geneflow Ltd,                  
             Staffordshire, UK                                                                                          
 
 
Tris/Glycine transfer buffer                                                                      Geneflow Ltd,   
                                                                                                             Staffordshire, UK 
 
Triton X            Sigma-Aldrich Company Ltd,   
                       Dorset, UK 
 
Trizma® hydrochloride solution                                      Sigma-Aldrich Company Ltd,   
                       Dorset, UK 
 
Trizma® HCL                                                                  Sigma-Aldrich Company Ltd,   
                       Dorset, UK 
 
Trizma® Base                                             Sigma-Aldrich Company Ltd,   
                                         Dorset, UK 
 
Trypsin/EDTA                                                                  Sigma-Aldrich Company Ltd,   
           Dorset, UK 
 
Tween–20                                                                                          Pharmacia Biotech, 
 
Urea                                                               Sigma-Aldrich Company Ltd, Dorset, UK 
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Appendix 2 
 
Appendix 2.1 Effects of resistin on gene expression profile in 
mouse βTC-6 cells 
 
RT-real time PCR array analysis of transcripts expressed in βTC-6 cells exposed to 
resistin resulted in altered patterns of expression. The table below represents the genes 
that were not significantly regulated by resistin (p>0.05). 
 
 
Description Fold Change p value 
Acly ATP citrate lyase -1.7817 0.084041219 
Adra R a1a Adrenergic receptor, alpha 1a -1.1755 0.677983311 
Adra R b3 Adrenergic receptor, beta 3 1.6624 0.117926367 
Agt angiotensinogen 1.9096 0.388713508 
Akt2  1.0717 0.090975081 
Aqp2 Aquaporin 2 1.9096 0.393317552 
Ccl5 
Chemokine (C-C motif) ligand 5; small 
inducible cytokine A5 4.8121 0.316747233 
Ccr2 Chemokine (C-C) receptor 2 2.0945 0.056861898 
CeaCam 
Carcinoembryonic antigen-related cell 
adhesion molecule pseudogene 1 1.4472 0.577056158 
Cebpa 
CCAAT/enhancer binding protein 
(C/EBP), alpha 2.4060 0.18613699 
DPPIV Dipeptidyl-peptidase 4 8 0.563424508 
Dusp4 Dual specificity phosphatase 4 1.9096 0.811762895 
Enpp1 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 1 1.3503 0.994929123 
Fbp1 Fructose bisphosphatase 1 2.8284 0.734777383 
Foxg1 Forkhead box G1 -1.4142 0.546800032 
Foxp3 Forkhead box P3 1.0092 0.179655246 
Gcg R Glucagon receptor 1.0968 0.109701782 
GLP-1 R Glucagon-like peptide 1 receptor 4.1891 0.833419789 
Gsk3b Musculus glycogen synthase kinase 3 beta 1.4810 0.316033459 
Hmox1 Musculus heme oxygenase (decycling) 1 -1.0472 0.109697203 
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ICAM-1 Intercellular adhesion molecule 1.8660 0.536402527 
Ide Insulin degrading enzyme 2.5198 0.799804479 
IfnG Interferon gamma 4.3872 0.744246832 
Igfbp5 
Insulin-like growth factor binding protein 
5 1.8234 0.568768424 
Ikbkb 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 2 0.371528346 
Il10 Interleukin 10 -1.4472 0.294852614 
Il12b Interleukin 12B 3.0314 0.773175579 
Il4 Ra Interleukin 4 receptor, alpha 2.9621 0.863078818 
Ipf1 
Insulin promoter factor 1, homeodomain 
transcription factor -3.7321 0.25693434 
IRS1 Insulin receptor substrate 1 1.3819 0.888963482 
Neurod1 Neurogenic differentiation 1 2.700699892 0.543960627 
Nfkb1 
Nuclear factor of kappa light chain gene 
enhancer in B-cells 1, p105 2.094588246 0.114422573 
Nos3 
Musculus nitric oxide synthase 3, 
endothelial cell -1.231144413 0.560528488 
NRF1 Nuclear respiratory factor 1 1.175547906 0.67802319 
Nsf N-ethylmaleimide sensitive fusion protein 1.274560627 0.176024388 
Parp1  28.50875898 0.452436054 
Pck1 
Phosphoenolpyruvate carboxykinase 1, 
cytosolic 2.193649959 0.134575435 
Pik3r1 
Phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) 2.193649959 0.659040069 
PPARa 
Peroxisome proliferator activated receptor 
alpha 1.447269237 0.164535421 
PPARg 
Peroxisome proliferator activated receptor 
gamma 3.646889954 0.380643637 
PPARg c1a  54.4426983 0.393620986 
Ptpn1 
Protein tyrosine phosphatase, non-
receptor type 1 1.25992105 0.685085441 
Pygl Liver glycogen phosphorylase -1.447269237 0.215295252 
Rab4a RAB4A, member RAS oncogene family -1.481097552 0.185240692 
Sell Selectin, lymphocyte -1.350349946 0.800747199 
Serpine1 Mouse plasminogen activator inhibitor, 1.289370308 0.06079973 
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Serine proteinase inhibitor 
Slc14a2 
Solute carrier family 14 (urea transporter), 
member 2 2.351095813 0.272247246 
Snap23 Synaptosomal-associated protein 23 -1.047294123 0.558413254 
Snap25 Synaptosomal-associated protein 25 -2.143546925 0.128924982 
Sod2 superoxide dismutase 2, mitochondrial 1.4142 0.935066398 
Srebf1 Sterol regulatory element binding factor 1 1.7211 0.954531541 
Stxbp1 Syntaxin binding protein 1 -11.0553 0.148731951 
Stxbp4 Syntaxin binding protein 4 2.9621 0.136042844 
Tgfb1 Transforming growth factor, beta 1 54.4426 0.152194079 
Tnf tumor necrosis factor 2.3510 0.163261352 
Tnfrsf1a 
Tumor necrosis factor receptor 
superfamily, member 1a 1.6624 0.548745715 
Tnfrsf1b 
Tumor necrosis factor receptor 
superfamily, member 1b 2.4060 0.174416588 
Trib3 Tribbles homolog 3 2.3510 2.97294E-05 
UCP2 Uncoupling protein 2, mitochondrial -1.2893 0.876142543 
Vamp2 Vesicle-associated membrane protein 2 1.2893 0.244660209 
Vapa 
Vesicle-associated membrane protein, 
associated protein A -30.5549 0.130899437 
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Appendix 2.2 Effects of visfatin on gene expression profile in 
mouse βTC-6 cells 
 
RT-real time PCR array analysis of 84 genes was performed to reveal genes regulated 
by visfatin. The table below represents the genes that were not significantly regulated 
by visfatin (p>0.05). 
             
 Description Fold Change p value 
Ace 1 Angiotensin-converting enzyme -3.7321 0.015655069 
Acly ATP citrate lyase 2.7006 0.471153199 
Adra R a1a Adrenergic receptor, alpha 1a 4.9245 0.517866023 
Adra R b3 Adrenergic receptor, beta 3 1.2311 0.334403221 
Agt angiotensinogen 1.8234 0.844951734 
Aqp2 Aquaporin 2 1.2599 0.337708525 
Ccl5 
Chemokine (C-C motif) ligand 5; small 
inducible cytokine A5 7.2937 0.051644769 
Ccr2 Chemokine (C-C) receptor 2 3.1748 0.329699176 
Cebpa 
CCAAT/enhancer binding protein 
(C/EBP), alpha 4.3872 0.407346191 
Ctla4 
Cytotoxic T-lymphocyte-associated 
protein 4 8.5741 0.166988611 
Dusp4 Dual specificity phosphatase 4 3.6468 0.419052334 
Enpp1 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 1 1.5157 0.663494285 
Fbp1 Fructose bisphosphatase 1 -2 0.158159302 
Foxc2 Forkhead box C2 1.7411 0.831267123 
Foxg1 Forkhead box G1 1.4142 0.800735881 
Foxp3 Forkhead box P3 -1.2893 0.087497875 
G6pc Glucose-6-phosphatase, catalytic 4.9245 0.074838271 
G6pd2 Glucose-6-phosphate dehydrogenase 2 1.9096 0.774508188 
Gcg Glucagon 1.7817 0.651687656 
Gcg R Glucagon receptor 2.2973 0.873211439 
GLP-1 R Glucagon-like peptide 1 receptor 1.0717 0.284345238 
Gpd1 
Glycerol-3-phosphate dehydrogenase 1 
(soluble) 2.9621 0.171942962 
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Gsk3b Musculus glycogen synthase kinase 3 beta -1.4472 0.265892181 
Hmox1 Musculus heme oxygenase (decycling) 1 3.6468 0.202419341 
ICAM-1 Intercellular adhesion molecule -1.2599 0.363088348 
Ide Insulin degrading enzyme 1.0968 0.396278215 
IfnG Interferon gamma 2.7638 0.586450912 
Igfbp5 
Insulin-like growth factor binding protein 
5 2.7638 0.844364914 
Ikbkb 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 1.5157 0.726549287 
Il10 Interleukin 10 7.1271 0.481530346 
Il12b Interleukin 12B 4.8121 0.663889265 
Il4 Ra Interleukin 4 receptor, alpha 12.4091 0.103260036 
Il6 Interleukin 6 2.3510 0.692378847 
Inppl1 Inositol polyphosphate phosphatase-like 1 2.4622 0.370523986 
Ipf1 
Insulin promoter factor 1, homeodomain 
transcription factor 2.0467 0.921952374 
IRS1 Insulin receptor substrate 1 4.2870 0.320091065 
Mapk14 Mitogen-activated protein kinase 14 2.6390 0.771075372 
Neurod1 Neurogenic differentiation 1 1.1224 0.118191636 
Nos3 Musculus nitric oxide synthase 3,  8.9796 0.35973144 
NRF1 Nuclear respiratory factor 1 1.5874 0.39052759 
Nsf N-ethylmaleimide sensitive fusion protein 2.2449 0.901014369 
Parp1  1.1755 0.168815644 
Pax4 Paired box gene 4 16 0.113507305 
Pck1 
Phosphoenolpyruvate carboxykinase 1, 
cytosolic 3.4822 0.108129377 
Pfkfb3 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 3.4822 0.451151128 
Pik3cd 
Phosphatidylinositol 3-kinase catalytic 
delta polypeptide 2.0945 0.966682432 
Pik3r1 
Phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) 2.2973 0.947380411 
PPARg 
Peroxisome proliferator activated receptor 
gamma 2.8945 0.761844161 
PPARg c1a  5.5276 0.404103527 
Ptpn1 Protein tyrosine phosphatase, non- 2.2973 0.904054495 
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receptor type 1 
Pygl Liver glycogen phosphorylase 2 0.776799629 
Rab4a RAB4A, member RAS oncogene family 1.1755 0.284139537 
Retn Resistin 3.5635 0.499490948 
Sell Selectin, lymphocyte 15.2774 0.119007467 
Serpine1 
Mouse plasminogen activator inhibitor, 
Serine proteinase inhibitor 1.2893 0.552680071 
Slc14a2 
Solute carrier family 14 (urea transporter), 
member 2 2.3510 0.874060481 
Slc2a4 
Solute carrier family 2 (facilitated glucose 
transporter),member 4 2.7006 0.624193569 
Snap23 Synaptosomal-associated protein 23 -1.0472 0.417365703 
Snap25 Synaptosomal-associated protein 25 -2.1435 0.12800747 
Sod2 superoxide dismutase 2, mitochondrial 1.4142 0.691779363 
Srebf1 Sterol regulatory element binding factor 1 1.7211 0.8131873 
Stxbp1 Syntaxin binding protein 1 -11.0553 0.318665471 
Stxbp4 Syntaxin binding protein 4 2.9621 0.405292492 
Tgfb1 Transforming growth factor, beta 1 54.4426 0.155133222 
Tnf tumor necrosis factor 2.3510 0.89080638 
Tnfrsf1a 
Tumor necrosis factor receptor 
superfamily, member 1a 1.6624 0.736695019 
Tnfrsf1b 
Tumor necrosis factor receptor 
superfamily, member 1b 2.4060 0.861448053 
Trib3 Tribbles homolog 3 2.3510 0.952761409 
Vamp2 Vesicle-associated membrane protein 2 1.2893 0.331494111 
Vamp3 Vesicle-associated membrane protein 3 -6.3496 0.307442214 
Vapa 
Vesicle-associated membrane protein, 
associated protein A -30.5549 0.254341088 
Vegfa Vascular endothelial growth factor A -4.7021 0.389972132 
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